var title_f37_33_38416="Fluocinolone: Patient drug information";
var content_f37_33_38416=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Fluocinolone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/12/1220?source=see_link\">",
"       Fluocinolone (otic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/16/5380?source=see_link\">",
"       Fluocinolone (topical): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12479 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-7AD06D259D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_33_38416=[""].join("\n");
var outline_f37_33_38416=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/12/1220?source=related_link\">",
"      Fluocinolone (otic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/16/5380?source=related_link\">",
"      Fluocinolone (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_33_38417="Lower extremity alignment";
var content_f37_33_38417=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Physiologic progression of lower-extremity alignment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 372px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF0AXkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiis/xDqaaJoGp6rLG0kdjbS3TIpwWCIWIH5UAM1vWrbSBAkyzT3VyxS2tYE3yzsBkhR0A9WYhRkZIFYUVh4r1ZBd3mtHQmcZSws4IZvKGeBLJIrb2x12bQOgJxuMskcmgWbalPG+qeIrwpCqedhTIxH7uLIxHEuCxwpbahZt7AksfxDrlnqcttfeFr2e2QFkvLCaKVHGRj5WZWBweRjqPl3daACbTvFthL5mla9a6pDlS1vrFqqOeeQs0AQICPWJ+fbitDQ/EQvNQl0rU7b+zdaiTzTatKsizR5x5sLjG9MjByFZeNyruXOReeKb3VbmDTvCdjdpdOxae71PTLiC3tY1GSSHCGR2OFCqe5Y8Lg1I7pPF0934c8U6a2j+IbJFvLeS3uVkYLuZFuraQfMMMpBDKCAwDAhsEA9AorD8GatLrGgRS3hi/tCCSS0vBH90TxOY3IHUKSpZc87WWtygAooooAKKKKACiiigAoNFFABmikFLQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVk+LrCbVfCetadbEC4u7Ke3jzjG542UdeOp71rUUAcZoms/wDCR6n4fuYoNtv/AGWdQmR8E28su1I1z13YFyp47HNdf0x3rxv9nKKM+FNZ0m8t5Zx9qeZ7i4UtHeRzFuRu4xlWDKON27PJNWLH4ZXPhjxlf+JtN1t/s+zFrpyWiRhpW2rtcoFUqegwoxkHPHIB631Fcv4ss5I/EHhjWYZNgtLprS4zgBobhdmOhOfNEGADjuemRzPxR8Ka742LWeka2umGynjPkupMc0LJlnYD7x3ZCjp8jA9cix450u28LfC26S3vJ7QWtxbXLXcFrFJKXW5iYN5fyIW+UA9B3welAHR/D2FV0rUbnZslu9WvpZD/AHttw8an/viNK6iuJ+C88lz8N9LmknkuFd7hop5F2tLF9ok8tyOeWTackknOSSea7agAoozSE0ALRSCloAKKKKACj8aKKAEPA4paTFL0oAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOLNjF4a8c2ctlJcxafrzTxTWnmboBeAGYSqp+4WRJ923AYhSRnknxJ13StJ02CPV9T1fTlkkWUSabC7PIEYEoXCMFBJGRlSRkA4yKj+KcBuR4UijuZ7WU65D5c0BAdG8qXHXII7Ed1JHeuonubaeSWwNyYrpkOFB2yYx95AeoGeoyM0Acb4W8Q6BceN72wt/FGpXurSQIH0+9wiqUHLLH5alHwfmAxnqRxxN8UbKXxDFo/hS3uzbLq1wzXjpCJHW0iQs7LuGFbzDAoc52lwcHGK0hLp3gzTit1fXl7c3MhaJJ5POurp+MRxjgtjjjoo5OBkivHokq/FK116W6u5PO0m4thbSMvlWwEls2ECjqTvJJJJwBnCgUAdRpWn2uk6XZ6dp8Xk2dnClvBHknZGihVGTycADrVqiigBp/yaMYIxxR360pz6UALiigUUAFFFFABRRQaAEpaSloAQ0tFAoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiis3X9c0/QLFbvVbjyYnkWGNVRpJJZGPyoiKCzseyqCeD6UAaVc9qXi3TbTUZNNtBPqmrR432VgglkjzjHmMSEi4OR5jLkDjPSsqZPEviqOMSB/DOkFw0kQk3X9xH3Qsh22+fVWdsHqhrptH0mw0bT4rHSLSCys4vuQwIFUZ5JwO5OST1NAGJNpmsa1qmh32prZ2Ntp9w139kjJmkZzDJGu6ThRjzSSApwUGGOeLurLDNqEVjq1rbXOl3ahYhNGHVZ1y21gR3XkH1QjqRnQ1C3vJjGbS9+zKoJIESvvbtnP8PXIGCeMMO8WqJFLYLbX8gVpdqLMEIVZeCrDOdp3AFcnrgZzigDOnsdL8ORvNo+k2FvqV2RbxCC3WMyuckBioztGCx9FUnmtHULS8mgtvsl4sF1A4fzHi3pJ8pVgygrkHOeCMEA9sGHy1XWbe8vWAuGgFvBCoLFCSGlIx1BxGCTwNg6buZ72HUmnDWd7awxDGUktTIT68hx+HHHv0oAyLnxadFbb4q0+XTYMgDUIiZ7PkgDc4AaLryZFVR/eNdJaXMF5aw3NnNFPbTIJI5YmDI6kZDKRwQR3py45PrXGXHhO60XUv7S8CtaWBkcve6VKGS0vCcDcNufJkwM71Q7v4g3BAB2xGaK5bQPGVtf6mmj6tZ3Oia8yllsbzGJwFBZoJVJSVRnnadwx8yrXU0AFFFFABRRRQAUUUnegBaKKKADvRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAMnljghkmnkSOKNS7u7YVVHJJJ6AVxfgm3bX5k8Y6orNNeITpcEoH+hWjfcwATiSVcO568qnROdL4iwm68J3FjuYR381vYzbcZMM08cUoGeh2O/PbrXQgcdPyoAU8DrQMDjNV7C8hvYXltnLxrJJCTjGGRyjD8GUirOKABuOeaZPEk8EkUqho5FKsPUHg089aOR0/KgCJbeNbppwCZWQRliewJP9T/AJAqRhnpzS4z04oA44NAARxS9KQH8KCTmgDH8V+HbDxRpLWGpJIFDCaC4hbZNbTL9yaJxyrqeQR9DkEg0fAesXd9Y3em61Ij67pE/wBjvWUKom4DRzhQTtEiMrY7Esv8Nb1ldwXsLTW0gdFkkiLAEYdHKMPwZSPwrmLoDT/irps4kdU1fS5raRSPlaS3kR4sccHbNcnryB7UAdjRRiigAooooAKKKKAAnBopCMkHPSloAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiud8Ta7c2twuk6BBDeeIJ4jLHHM+2G3jzjzpyOQmcgKPmcggYAZlzG8Df2ksj+K9c1jV5JF2tDDdSWNqoySVWKFlyOcfvGkbAHzGgDtaTnPQYrhU+F3hW1LvpVpe6TO6FDNpuo3Fs2PU7HAJ+oPvVQ6jrXgC8hTxHqZ1jwlM8cC6pdBUudPdsIouGUBXiLY/e4BUt82R8wAPRqKKKACiiigDi/ibc3EVvoMVngu+sWTSjGcQi4jDH82QfjXYjjngVk3UUd34liR1DpbWbGRHUFSZJEKH6gwN+YrWA4oA5rwlN9m1PXtElBEtpdteR5BzJBcs0of0/1hnTHX91k9a6fvXlviKHULL466Hqem4khu9MbTbqNshQMzTxkn1PlSAHt+NbNrHqF34stXu763to7a5muFjMzrcTo0ZQQmIgKEXIO5S4Zo1YYJJAB3HfBpeo5qNZI5HZEkUumNyg5Iz0yO1c6uq6hrdwbbSbO7sbFSVm1C8haFv92GJwGJ/22UKOo39KAOm5o7etYWrjVNNkS80eBtRgwqT2DShZCo43xM5xu9VYgN13KQd1/RtTi1ayW5ghu4VJwUu7aS3kUjqCrgH8RkHsTQBcOQeOagvbuCwsbi7u5VhtreNpZZG6IigksfoATWZ4pstSuotPl0mZBNaXQuGt5Lh4I7lAjrsZ0BIALK/3WBKAEYOR5j8XNV1Rvhxaaay/aI7y5W31G9hLMiwKHmcI2FMgEce1nwARu4ySFAPRfh3bXtv4Qs21WLyb67aa+nh2kGF55XmMZB5yvmbfwrN8Y3zW/j3wPblE+zNNdTSTMPuERCJB7bmnArtR0PcVzPxCjVPD/wBvESs9nc2s7Pj5lijuoZJMH/djz+AoA6kUUgpaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKADHOaKKiu7iGztZrm6kWK3hRpJJGOAqgZJP0AoA878B3r/2Ze+KEt2uW1rU7l7lyqrIkEcjQ24GONqxxLkMcZd23ZyD18HiTRJ1Ux6rYglS2x5lRsDqcEg8V538Jdbt7vWr1dKjvYNOeTUGkgubcxMGS4jlRlj6qdt2yHqSI4+mMV3Vsll4hkuF1Hw1LFGACkmo20JFwp7gbmYdB8rhSMjjrgA5nxd8TYLG70zTdBge6v9Tv49OguJIyIY2ZgGkCkhplQHcdny4wC65GXX3h5vDekajNqt5da7pN8kia215K5lELBg0iKH2KqqfmREX5cleVCHpYPD2h+HzNqGheGbFL7Ztxp9rBDNICR8u47R74LDpVPxldy33wz8SzJZ3VtOdMul+zzxjzAwiYY+UkH6qSD2JoAsfDK5vLnwLpI1RnfULVGsbmR33tJLA7Qu5buWaMtn3rp68/+C/iO213ww6x2d3Y3KzS3bwXKYJSeaWRZFYEhlJ3jI7q3A4rvye1AC0UgJxmg0AYtq5/4TXVFP3Rp9oR9TJc/wCFa+cc+tYfhZFnbVNSZpHlub2WLDfwLA7Qqq+3yM31dq3u1AHJeErqHVPEfi6ciOVrLVEsopCuSipaQsVHph5pv++m9a6m4hiuI2iuI0ljbqjqCD+Bryr4UwyaX4r1+VmZrXXtQ1GZcucJcW19NGwweMvG0eMdoW44r1jnP1oAbBDHbxLHBGkUajCoi7QPoKr3F3It/Da28HmsR5krs21Ykzgdjlic4HH3W5GOZby6gsrSW5u5BFBEpZ3bsKj02SSe1We4jMUk3z+W33kX+FT74xkeucUAGom9EG7TxA0ynPlzZAkH93I+6ffBx6Gl028S/s47iJXQNkMjgBo2BwytjPIIIOPSq+gXJu7GWQsW23VzFknsk7oP/Qao6oToWotqyZ/s+4KrqC9osDC3HsAAFf8A2QGyAhyAb/07VR1jTLPWNPns9QgSa3lR42DdcOjI2D2JVmGR2Jq8enr9K53x7JKfC91ZWbFb7U8afAVYhlaX5C4xydilpDjsh6daAK/ws8Rf8JX8PNB1pvM824tgJjIACZEJRzx6srEVZ+IpA+H3iZicAaZctn6RNWB8BjG3wt0loE2QyTXbxqOiobqUqB7YIrr/ABJpi614d1TS5XKR31rLbMw6gOhUn9aANOisvwrcveeGNIupZTNJPZwytIerlkBJ/HOa1KACiiigAooooAMUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFZ/iLTF1rQNT0qSVokvrWW2aRBkoHQrke4zWhRQBxXgG7TU3m1C4tbeHVnt4odR8pQNt3GzxzLnknBjUA5OVCdRiqKeDND8NePH8XSXur+feL9mMc12WtLf5OXbODz5eMszDc/TOCNvXbIaRrCeItO04Su4MOpLbRZmmiwNsgUcyMhVfl5YoWC5IVTOuqR+JdBe48JaxaPuyn2iPEmxsZ2kfwOMjIYEjutAFTxbp1h4ttZvD73eoweajM13p04QwNG8RKluQHO5eCD8u7p3pa7ZW/hH4YXGnpd3dxCkKWa3F9cNNIxlZYgzO3u4PGAOwA4roNAg1S2tiuq3UU5AG0KNzL1zl8KG7Y+Rcep61i6read4wvYNDsZI9QsYrhLnUJogJIU8lw6Ql+VMhkVMpyQgfO3K5AIvhRYtHo0+oNhorplis5NpQvaxLtR9vYSOZpgPSYDPFdvjnNLRQAAYqG9uIrSznubhgkMMbSOx6KoGSfyFTVznxJ3f8K78U7M7v7KusY9fJagBfh7HIngTw99oBFwdPgaXd94yGNSxPuWJJPrW/jniqulSR3GlWc1vjypIUdMdNpUEY/CrRyPTNAHknh2/C+F9YvB8kmgeLb13fGQkbXbtMxH/XC4kr1w84+teSMttbx/EfSIiB9s8Q2kMyDqEvIrON2/HfLj6GvWqAK9xZQ3FzDNOpkMJ3RqxO1W/vY6E+hPTtjmrOaU0hz+FAGdoVi2m2UsDkMXuricEekkzyAf8Aj9aB6YwMY71QsdWtL3UNSsrdpDPp7pFcZjZVVmRXADEYY7WBOCcZGe1X+aAKml2EWnW5t7UuLUMTFETlYV/uJ6KOcDtnAwAAOY8SalHa+I5ru6DGx8O6VLqky56vIHVGX3VIbgHP/PQV2R46mvJPjDqI0y38bLco4i1LwuIbZh0aRZJYmX65u4PzoA7H4U2X9n/DPwnatH5ciaXbb1PUOY1LZ/Emurx0psahECqAqqAAAOgp2O+eKAMDwGCnh42/RLW8u7aJc/cijuZEjX6BFUfhXQ1zfglt0GslT+7/ALVugn4Phv8Ax4NXSUAFFFFABRRRQAUHqOaKM+lABRRRQAUUUUAFFFFABRRRQAUUUUAFYGveLtH0O6WzuriWbUXTzEsbOCS5uGXn5vKjDMFyMbiAue9U/HmtXln/AGfpGiyxQarqbPi6lQsllbxrumuCMbTtBRVDYBeRM5Ga0vDWg6doNh5GlR/61vOmuHbzJblz1kkkPLsfUn2HAAoAy4vFupzRLLH4G8TFGGRuexQ491a5BH0IBpulfELRLzUbfTNQF7oerXBZYbPV7ZrZpSGC4jc/u5TllwEdjzXWZ5rgvHOteHtW83w5qWkNrtg+5dQkUJ9nsFGNzSSsyhHUMGwp3qMH5cqSAegUVwnw1vr+2udT8MavfSalJpqxXFhqMrKz3ljKG8pnYH5pFZJEZsDdtVv4s13dABRRRQAUUVhnUrjVL6e20V4lt7WQxXN467wJB1ijGRlh/Ex+VTgYYhgoBY8R67p/h3TWvtVnEUW4RxqBl5XPREXqzHBwB6E9Aa4/4f8Ahm0vPDNhq9/YGx1q6ea8W4iPl3MaSzSSojuvLAK65Rsrkcg4rbTwqIdSGppfS3eqliPtuoKJnhjIwUgQbUiyMchecfMGrdsreaBSst3LdL2aVFVge/KgDHTtn3PYAyZvC1hfMh1x7jWPLztW+KtF+MKhYyRzhipYZ61ifCvWNPj0S18PMRa6tZebDLDINv2l45XWWaLs6mRXJx90nBA4rs7d7p7Q+fHDBckMMI5lQHsckKT2yOPTPesi98Ow6xZG08RR2N5Csonh8iB7d4ZASfMRw5ZXySQ6lSMnnmgDoaK5y00zVdDsimn6hcatHGWZbfUnDSleyJMADxzzIHJ4BYda1tG1KDV9OjvLXeI3LKySLteN1Yq6MOzKwII9RQBdqO5gjubeWCdBJDKhR0PRlIwR+VSUUAcv8M2J+H3h6GTIntrKK0nVuqzRL5Uin3Dow/CulwB3rk/BE6W+s+LNEEhP2HUjcxIwwRFcos5Oe4Mz3AH+7jtXWccZoA8d8Y2HkeNfFFzZRGa5kfw3eCNWCl5FvpY8Ak4yVjA54r2FGVwSjhgCQcHPIOCPzryqaJr7xnr0sUqyNeeINO05OflSOzgW8bB9dxlU+4rqtfiv9A1KbX9KSS7spQp1PT1yWYKAPtEI7yKoAZP41UY+ZQGAOtA6YNIc460y1nhu7aG5tZUmt5kEkckbBldSMhgR1BHcVL2oAYFwTwMk8n1pc8807oOMUcdOlADOWPTNeU/FAJqPiCCOdQ1rbHSIkxysoutUi8wH2AtEx/vmuo1e+vte1qbQNEkktrS3IGqakuVMeQG+zwn/AJ6spBL/AMCsMfMRt5H4vLLoou7nTraNo4dOtL9IUXARNOvopWAA6DZMen92gD1wnnp2pQetAOfeue+IWpT6T4N1SewLjUZIxa2ewc/aJmEUPX/po6UAV/hlMbrwfBfEMsd/c3d/CHHPkz3MssZP/AHWusqno2nwaTpFjp1oCLazgS3iDHJCIoUZP0Aq5QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHC+M71tE8ZaVrMsZksodLvI5iW2iJPOtWdwcckIrPtHJEbYyeK17XQrrSkEOh38dtaAkrBcQGZU9lw64A/MkkkmuK8ZeGT4k8X37XupXkE9kYoreAOWh+x3UTQFggIG/wA0zZJzwgBGCpGhq3j6HQviHp/h7V9Vj36g5EFpDo0+8gkhP33mEHkckIRwc7etAF/xJofirVBHFFq+nxoGPzwi5tsA/wB5Y5tz46jDpz7ZB1Ph94XTwb4R0/Q4rlrv7OHZ52jWPzJHdpHIVeFG5zgdhgZPWuiOPwxXDReO9OuviF/wjNprES30YDS6fJpNz5oXYGyZchFGGU5IxyB1oAzfCNpbWvxT1K0soo4bfTobi1ijX/lnE62UwjA/uB5JSo6KH2qMDA9OrxOfS7K5+NdxqdnHKmpy3kFtHOsjqB5UavOeDyvlxmJh0DSR/wB7Ne2UAFFFFAGT4u1OXRPCetarbxrLNY2U90kbZw7JGzAHHYkUeGdL/sTQLDTjL58sEQWWYjDTSdXkb/adizEnOSxNUviGqy+FLm1kzsvZrexYqcFRPPHEWHuA+fwroM8cUALnsKPpWbc63ptqtkZ72BRfMq2p3g+eWIxsx977wPHbnoCa0CefSgBRmlpOM+pqnqGq2OmvbpqF3BbG4fZCZnCB24woJ6sc8DqecdDQBd6Vy1hu034j6jagMLbV7Jb9BuyPPhKxTHHbKPaj0+U9856cSI0jRhlMgAYrnkA5wSPwP5Vz2qskHj3w9PLuAls72zjIHBkYwSgH/gMDn8KAOlooooA461mEfxe1aDHzXGh2cg/7Z3F0D/6MFdTd3MFnaT3N3KsVvAjSyySHCoqjJJPYAAmuQvIDB8aNNuS6hbzQbmEL7xXEDfymP5Gp/iij3vhR9GglZJtbuItM+RdzGKRwJ8e4gEzZ7baAOb8DxTT2/gYXQSO6vft3iadQpXDzZzHzz8v27HP/ADzFZfxs+JeseFtetdC8Px2sU7Wq3k91cR+ZhWd0VUXIGcxsSTntx3rvrULc/Ee/ZmJFhpUEcYHRDNLKZB9SIIfwrk/j74U0zWNAt9TuEkj1K2mit4rmFtriOSRQynsw5yMg4PTGTWVfmVNuDsz0MqVGWMpxxEOaDeqva/b8TV+CXiyTxZ4MMk9nbWc+n3BsJI7ZdsJ2ojKUXnaNrqNuTggiu/OcEd6x/CfhrS/Cmix6Xolv5NqjFzuYs7ueS7MeST7+wHAArYAq4pqK5tzkrypyqSlSVotuy7Lohev0pO9GM0Z9OaoyILS1gs43jto1jRpHlIXoXdizH6lmJ/GuU8b6bFqGs6Ra3a5s9Utr7RpwDhgs0IkJH4W5H412IABrmvHavFb6LfxtiWy1a1KjHBEz/ZmB/wCATufqBQAnwx1OfVvAOi3N/wCb/aCQC1vPNGH+0RExTZ/7aI9V/iDb/bbzwfZNIyxTa5FI+0/e8mGa4UH/AIFCv5VD4HhbSvFnjLRjHIkBvI9Xti0m5fLuUO8Adv38Nw2P9qneMboHxz4B09EdpGvrq8YqMhY47OaMk+nzTxj8aAO1FFJS0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBheI9FkvZodR06VYdVto3jjZlDJKjFWMbj03IpDAgqQDyCytd0jULXVtPhvrF/MhlBxkYZSCQysDyrKQVKnkEEHkU/WNW0/RrI3erXkFnbA7fMmcKCx6KM9SewHJ7Vw9noseveLtW1nTf7V0SBobdI7uANavdTKZDI7QyLtkG141DSIT8pxjAJAJrV4HeTw3/wAI1rZ0ooYAXdjF5Zj2FSWYAIFyMBjyMgZxXbTtBbJJdTtFFGiEySuQoVBkkluwHJrKW28QJB5S6np8jBcC4lsmLH03KsgBPqRtHoB25fXvDUtlrWj6nqd3qev6fHO325b66jSC2QISk5hURwsEYAklSwyGH3aANH4eeH1txca/dm6N9qU1xPHHOwxbQSzGRUVQBtJURFs5OVAzhQB2tUtJ1XTtYtjcaTf2l/bhihltZllQMOoypIzyOKu0AFFFFAHH/EJHubzwfZrIUjuNciaQD+IQwzXAH/fUK1veIdSj0fQNS1OVS0dlbS3LAcZCIWP8qx/GQJ8QeByBnGsSfh/xL7yofHyf2v8A2b4YUEnVJfNusEgLZwsjTZx1DkxxYzn99nkKaANfwfFHD4T0WGKYTxpZQKsuCN4Ea4bB5561sVgeBZPN8GaMCSZIrSOCTIwVkjXY6n3DKwPuK3h0H+NABzR2oPFB6DNAHPWd0p+IWsWeQHXS7KYL3IMt0Cf/AB0fnVXxtcJa654IkkOEbWjGfq1ldKP/AB4isLX3bS/H8Pit2X7HbOmhXuQP3UMypIkpOR0maJT1wrse2a0Pigpkk8HIiFpT4htSuP4cCRmP/fAagDuqKKKAOL+ITQ2WseCdUmgLC31pbdpUXLRrcQTQAE9lMrw5+gPYUvifSjYavY+IY7lk06wne9vrXbuH+oliMyehCyEsozuC5A3DDVvjjO9p8NNRu4mKyWtxZ3KsOxju4XB/8drffxBaxx6s86Mq2F0lkQOTJI6RMiqPVjMigetAFLwiyya34wnUh0bVEVHHdVs7YYz7Nu/WqfxcG7whjHBvbUc/9dlp3wmsV07wibVCT5OoX0O4nJYJdSxj9EA/Cj4qjd4VjHc39oP/ACOlZVv4cvQ7ss/3ul/iX5nZEcday9Fu5JbnVraVy/2S78tGbqVaOOTB+hkKj2A6nJrUziuP1nU/+EU8RXWo6jBKNAv4ozLeRI0gtZ0DAtKoBKoybPn6Aod2MjOpwm34q1JtH8OalqCBWlt4GeJW6PJj5F/FsD8a0reMxQRxmR5CihS743NgdT7muI1HWtP8bfZtK8OTjUrVbuCe7v7f57WJYZUm2eb912baq7VJIDEnGMHu80AJ36VzHxPjD/D3xC7Eh7eykuo2BwRJEPMQj6MgNdP34rE8c2/2vwT4gtv+e2nXEf5xMKAMibTLnWfGlze29yYNJS2SyuSi4a6dJGbYGz91SxUnHUuvrgtFW9+LeozC4aT+y9HggWIEbY3uJpHf6MVghJ9tv4t8JeJ7dfh7FqV5u82ziVLpB95pSqsD9ZA6OPaQU/wHMlxr/jyZAP8AkOCLcP8AYsrVcfmDQB2dFA6CigAooooAKKKKACiik96AMfU9Sumvf7P0eKOS6ADTzTA+VbqemQMF3PZARxySuV3PTShJGDd3l/PLjBcXDQ/+OxlR39M+pNQ+F7+HVNCs9Rt2Vxexrcthg2C4DbSfbIH0ArTnnMKKRDLKM8+Xj5R64JBP4ZNAGVL4e8pxNpupanaXIGAWupLiNh/daOVmXGccrtbsGGTWlYXTytJb3OwXcIBcJ91lOdrgdQDg8HoQRzjJtGsa+do/FOj+WpYyRXEbgD7qfu23f99Ko/4FQBt0UUUAFFFFABVHXNTg0bSrm/uhI0cK5EcY3PIxOFRB3dmIVR3JAq9XL+J4ZdQ8T+GrAr/ocUk2pT5zhzCqrGhHT78yyDPeIUAW9C0u4jRL3W5Rc6tIfMYgkxWxIxshB6AA43YBbqfQbPfiqGoXyWeoaZFIz4vJXtkRQCN/ltJknqMLE44/vVejlSQyLG6s0bbXAOdpwDg+hwQce9ADuOccUE8YoPP3qSR1jUM7qqkgZJxkk4A/EmgDG1XQIJ7qTUtOKWGubNiXyRglgOiyrx5idtp5GTtKnDCbwtrI1vShcPF9nu4pHt7q23hzBMh2ume4yMg4GVKtjmrCXqvrM1ipbfBbxzSAjgiRnC4Oe3lP27isWxR7D4i6lGiP9l1Sxjuzgnas8TeW7EdiyNAB7RUAdTRRRQByPiYzXPjvwdZx7fKga81KQnr+7h8gAfjdfpWnq8y2+s6E4B8yeeS0z/smF5CPzhX8qq6kAfiNoX/YK1D/ANHWdTa4Fl1vw5GpHmxXUlyV7+WtvKhb6BpUH/AhQBR+GzF/Dt2Tz/xONVH4f2hcV1fH0ryI/EXRvAGjWdnqUV5fX2oy3Wqrb6equYobi5lmjLl2QDh8YznKnGRzXonhLxJpvivQrfVtIlZ7WXIw6lXjYHDKy9iDkfyyOalSTfKnqayoVI01VlFqL2dtH6M2elLn0qjp+mWmnzXUtrEUkuXMkpLs2SSTxknaMsxwMDLE9Sau9BzVGRw1pclvF/iXR5g0csl/Y38LHkPGYlGPzs5v0qz8TId2m6JdKxD2mu6c6/8AA7lIT/47K1ZmtN9i+Jw1J3AtwumW8ijJK72v4kP0Mk6D863viAqtoVru6f2tph/H7dBigDp6KKKAMDx/oLeKPBOt6LGyJNe2kkUTuSFSTHyMcc4DBT+FeX+HtavdUgvJdRtZIDq19YXBCwsVtNTgmhguLeQqzbVDQROu7G5XbBOK9vrzHxOreHvEXiSYAy2moWC69FFngXViYxIOnAdPs2OT9xzxQB03w+50K6z/ANBbU/8A0unqr8TRnSdLjP3JdWskYD085f8ACr/g2P7NDq1mTzBqdyxx/wBNX88fpMKpfEnmw0T/ALDVl/6NFZVvgZ3Zb/vVP1Ou6jikzj60YwfasbxteTad4O1y8tJAlzDZTPCx7SBDt/8AHsVqcJj/AAc1CPU/hb4XuYhgf2fFER6Mi7GH5qa7IfnXH/DGyi0fQbrQoFKDStQubfaecI8hnj/8hzR12AIzxQAMDisjxhOtp4T1q5fG2GxnkP4Rsa1/THSub+Jn/JOPFeDz/ZV3/wCiWoA84urmHT9Cn0ieVdrXdpe6mSGYWtlbWdtJK52gkBvJEY9Wk46Gu6+FOm3Vr4dudR1O2ltL/W76fVZbWU/NAJW/dxtwMMsaxgjs2awtSi/4SC/stHgjxbajrU15fo6hl+zWDJEV56h5o7cYwfldvQ16hQAYoo5ooAKKKKACsTxXrL6JYJNBALm4lkWGKEtt3MeT0BJIUMcAEnGO+a2653xXKVv/AA7AigSXGohFkxzHthmkYj6rGyfRzQBx9j8WSzRNf6HMsTBA62jSTSxOysSrI0aZ2lQCQTzJGADu49GsNStL/SbfU7adWsZ4FuY5jlQY2UMG5xgYOea5/XNMW9mt9OkuGkedzcrJIAzRBAAWUY25y64yMDJJB6VHLqWl2+mvoumWF5qNrbxiweGzTeqDGzyzIxCkgcEbiV6tgZNAHIeEvB+oeHdb07U7XV9Su7WXS0hh0u4m8uKJwFADFVJKhSMcHBye/HTeIfh3pnijxHouvavNqMd5pRYRQWt4yRSfMSrMAAQ3Q/KV54JYAVkSW1nqWh6faeP9LvVvdPARppI5JIJVBA84tESg34yVY5U9iAGO/wCGNW8JWNv9k0G9sktoRsbZcDagHI+82T16jPp6UAdcpzXLaT9qvfHN5dyNL9kt7MRwqwIH7x8kjtn91nudrJ0zina74r0H+xdREevWqSCBwDa3UfnBipx5ecjfnpwecVoeD9Ku9I0C1ttUvTf6lt3XVyVVfMkPXAUAYHQcDOMnkmgDaooooAKKKKACuYuLh5/iRa20QbyrHSZZbhjjAM80YiA7k/6PP9OPWunrjPA80WoeIvGuoLudhqi2Cs55EcFvENg9AJHmI/3ye9AFvxnG8z6BHazC31A6mhtpmXeqlYpGkDLnkNCJV6jBYEEEZroIIIYBJ9niji8xzI+xQNzHqxx1J9a57XC0vjjwxbn/AFMcd3d4H/PRUSNf/HZnrps4oAXH5VDdWtveW7Q3cEU8JIYxyoGUkEEHB9CAfwqQ07HHXmgDm9BjePxb4ja9nWW9f7OYgqbVjtMOIl6nJ8z7QSepz2GAE1K7+yfEHQ4mcrDf2V3COCQ0qNC6LnsdnnH6KaLMlfiPqqnGH0mzPXus1z/8VUXxBV4bXQ9QifZPZazZFOAQRNKLZwf+2dxJ+OKAOsAwKKKKAOY8bKbWXRNZQKP7PvkWYk7SYJswuM/3VZ45Dnj91WL45nlXVdReJmhnt9DkgtCBzLNdSqgC+6tDF9PNFb/j5kXw2fOQPCbyzWQMMgIbmIMT7AZP4VxvjDUP7R8daTYxRFLiC8+yLk5EirLp107dOMKCPwoA5P8AaD8BXAaTxdo8lqIoLaK3urSUsnCttRoyAf74BUgDC5Hv6X8KPCQ8F+Ff7Lku47u9aZri7kj4USsB8qg8gBQo55PXjOKtfFCH7R8PfECYJxaO/A/ujd/SptSYfYbXxBa3Bt3jiR5mWPzElgOCwdcjIUEsCDuXnGQWVsIwiq0pJatL9T1a2KrVMupUZSbjGUrLtpFr82dEOlVE1K2k1abTI3LXcMKXEihThEcsEyemSUfj/Z+ma+sal9mhtIrWSH7ZfyGCzMgLRl/LeTJ28kBUY9s4xkZzS6DpEWkWkqJJJPcTyGe5uZTl55SAC7dhwAABgAAAAAAVueUcP8T/ADrfVnktGHmy6U19s27jJLYXUE0KAdckyyDA65HpXW+IYP7T1TRtNJPkif8AtCcY4ZYCrIuex81oW9wjfQ8l8Y9ltqvw/vQD5p8QwWRPrHKrFgR3yY0/KtzR9Ut9X8SeHtRgh8p9Q0Oa5wwG9UL27KrH/gbY/GgDsaTBpaKACuS+I/hH/hLtNsoY5YoZ7W4Miu4flWjeNhlGU4w+7bnaxQK3BOOtooA53w98niLxVDI37xryK4VT18traFA30LRSD/gJqj8SP+PHQ+//ABOrL/0cKsMXs/iZltph1PSQo9Va2mJx/wACF3/44ag+I3/HloX/AGGrH/0cKyrfAzuy3/eoep1nY5Nc740X7RBpGmj717qduAT0Aib7QwPsVgZfqwrpK5u8/wBM8e6fCAXTTrKW6kGcBJZWWOJsdyVS5Htz6itThINFJtPH/iayVx5d1BaamAeDvZXgcD1AW2i+hb3FdTgfia5zVx9m8Z+Hb0jKzx3Wm4HUM6rOrH2AtnH1Ye9dGM5NADge2MVyfxRRrnwZdWSyeX9vubWwZsZwk9zHE3/jrmuqXleuDXK+LYhqPiTwlphjaRVvZNSmXOF8uCJgpPPOJpbcgeoz2oAi8HeEp9G8S6/q15LG/wBtlYWsayySCKNpZJWI3cIXMihkUY/dhsknA7KiigAopDxS0AFFFFABXOa2BN4v8PwvkRwx3N4D/tqqxAf98zufwro6p6lZC6EEiMVuLeTzYmyQM4KkH1BVmHQ4zkcgUAYmv2Vze63pn2KaSACKaO5lXgrA2zIRu0hZEAPZd56haqa9qNh4YstO06OM2lszxrbiI43FZFJi5/iYdOfm+bPvo6rr8OkxRm9sdVeZwcR2mnz3XIA43RIwHXjJH6GsO+uLrXPEGhwXumS2NlbF9SljunVpWMQCxgrGWCgvIHBLZJiPyjHIB1thHNFaoLp/MnwWkI6bickD2GcD2Aq6gBX1qpatI8f7yNo8cKHYFiPU4/z/ACq2uFWgAZQfvAFemKwrv+zJtSFldWiLdMwSJ0GHw0bsGDjBX/VyDg5+XPetuZ/LTftZlHXaMmsDXLW6u9V0C5sriFI1nYyyAbi0ZjYgJ1GTjGT0BbHWgDR0l7qKa4srx3mMO14p2UDzI2zgHGBuUqQcDoVPUml8QXV1a2KNYmFZpJ4ot8yF0QM4UkqGUnrgc9SO1ZOsz3Wn+KtNuLaG5v47iGaGS0iZN0Z+RhKN5UBfl2t83VkwM5zqrDJfmCfUIfJWNhJHbFg2G7M5HBYegJAPOWIBAB5rfXvj/RvNub3WdPaGKVp5lngjZYrcNJgfJtdiVUY4XJA5ySo9G8Jaymv+HLHUk2BpkIkVG3KsikrIqkZDAOrAEEggZBIOaoOZ/EE91Fp13Np+nwSmKW5gjQyXMq/K6qXVgEXG0tgksCAV2/NvafZwafZx21pH5cKZwCSxJJyWYnlmJJJYkkkkkkmgCxXH+DoYNOh1TVJJoIbXXtSF9bJ90ASRxRoDn+Jym/HrJir/AMQrg23gnWSrskktu1ujg42PJ+7VvwLg/hWxLaQTWwt5YI3gG3CMoKjBBXA9iAR6YoA5/Q7me58aeJ45X3Q2ZtooRkHZuj3uPbJKn8B6V0vtXA+B0uovH3iy9vFEcWryB7aNW3bfsrNbOT6EgQt/wPHY12Nnq+m391NbWOoWdzcQcSxQzq7x9vmAORz60AXNw3bcguBnGecetO7YzWFp2jLbeLdX1aGeTF5FDFNDJG2FeMHDIxOMFWAIAIyOoORW72FAGB4kuZbbVvDiW52PeXxtZH64j8mSZhj3MCj8TVfxxFLqWkGPTmhmewvra7uolO6TEEiXHlqB/G2xAAccPn0zkfE2W5Gp+F/sO4S2OoR6g5XktHvS2aPHqy3Tkf7hrt7W1gtVdbeNY1eRpWx/EzElifck0AT280VxBHNbyJLDIodJEYMrKRkEEdQRT65r4dbk8KQ2pYsllcXVjESBnyoLiSGMH32IvNdLQBleLNJOveFtY0hZfJN/ZzWokxnYZEK7vwzmvEfBGsTan4x8EPrAf+3TNc214C3+rnhsyJSw/vOhtcj+FoXAAyc/QdcF4z0bSLHxf4W8SLp1tHqZ1JbSa9WMCRklgljVWYdRvaMc+1AHReMoGuPCOuQLjMtjOg+pjYVF4DZn8EeHmc5ZtOtyfr5S1r3sIns54WxiRGT5unIxXLfCO7N98N9ClJOVg8n1+4xT/wBlrJ6VF6HdHXBS8pL8U/8AIZ4H0zTBf6te21vtmtr2ezizIzJAgK7liQnbGCRkhQM4Gc4rssmuP+GnOn643JLa5qGe/S4Yf0FdhzWpwnmfxyiae18GRRSPFcP4igEEqYJil8mbY+CCCFbDEEcgGmfBJp9Uk1vX/mTSJRb6ZpETDpaW6ttfPcsZW3dwysvbA0viLodl4t8Q+FvD2r2Ud5pnmXGqXEbuVyIYxGo4IP37hD+Hpmu7tLaCztYrazhigt4lCRxRIFVFHQADgCgCWiiigAooooA5Xx75lvJ4b1GIKTZ6xAGB7rMHtjj6eeG/4DVX4iXEbR6Nbg/vY9Y092XHQNNgc/8AAT+VN+JrP9o8GxICwl8QW4ZR/EFjlf8AQoD+FeD/ALSxuf8AhP8A/ioM/wBkfZ4/7O87PkdP3m3Py+Zuzn+Lbt7VhiZctNu1z1cloe3xsIcyj5t2WiPqsNn6VgeGj9s1jX9SyWR7kWcD9AY4VwQB7TNcD/62K474Br4rXwdA/iaYHTsN9iS5jYXSxZ+QuxP3dvQMNwGMnoB13w9Ly+D9Ou5du+/D6gVA+79odptv4eZj8K2Turnm1Ick3C97PdbfId43iP8AY8d7Gdr6fdwXpcHlI0cedj1zCZVx33V0AHX9arapZi/0y8s2YqLiF4t3XG5SM/rWJFqOtapovh6/0aKzWO6FvPeLPuLrE4UsIxkDdgnknjHQk8Mg35riKCWBJG2tO/lxjB+ZtpbHtwpP4VgaZNHe/EHXDyzafZ21su7/AJZtIZJH2+m4eTn12D0roJ5hE0SlHYyPsG1c44JJPoMA8n6dSBXJeHGX/haPjBFXafsWnO3+0T9oGfyUD8KAO0ooooAKKKKACiiigAooooAK5vSG+0+KvEdw20GB7ewAH91IhNk++blh9AK6Sua0ICLxF4ojfIkkvYrgKRjKG1hQMPYtG4z6qfSgDd70kt1bWyj7RPFFnpvcLnt3paZc2VrfQrHe28NwgO4LKgYA4I7+xI+hNAFhjWLrl4LG+0KNYi32q9aLCYyP3Ezk/wDjh9/rW0eeBXPeLV3T+H3jz9qj1SIwgD72UdZP/ITSn8KANW4nsLPzr24nggAVY5ZpHCgAEkAk9OWP51m3ct1rn+i6a0ttp5/198Mozr/dg78j/lp0APyknldx7aCS4juJIImnjBCSFAWXPXB6ipaAIrW3htLWG2tYkit4UEccaDCooGAAOwAFS0UUAc/8QtOm1fwH4i0+0jEt3c6fPHAnrKYzs/Hdir2halFrOiadqlsGEF7bx3MYbrtdQwz+Bp3iHUl0bQdS1N4zKtlbSXBjBwX2KW2g+pxiud1GK78JfDS20/S5I2vrW1ttMtZ5cKiysUgSRuvyhmDEc8AigDnha6hrvws8Wjw/dOuoXd7qYtXifbuK3EsYVT0+YIQD23Z7Zrwj4V6ZfwfEjRRZ2N1pr6ddJ9ukmgaBbaIg5jkJAA3j5Qp6kgj1r6Y+FWn22j+EV0ayLmDTLu5s1LnLELM+Cfcgg/jWdpUV1D8RfHL28ENwJYrBzFI+3ePKkU4OCM/L0I59q561NSnCT6P9P+Aexl2MnRw2JpRSalFXurv4ktO3xX67I9B7daT2rktNttEvdIkv7OK8s4Ig261gvnthEVGSrRpIqI3qDgjvjmpNO06/leFIbWPRdNWYXEkaS+ZdXTAggSsPlXJUbjucuOCRznoPHF+JF0th4VN7ISsFtfWM8zYJ2RJdws7H2Chj9BXSvIkSNJIwVEBZmY4AA7mue+JUazfDnxTE/wB19KulOPQwsKpeH7a98QfDKTS9XuCuotbXGk3N0p375Iy9u0w6feKl8cYzg9KANH4dbn8E6TdSH97fRf2hIMYw9wxmYY9A0hH4V0dZvhm+XU/D2nXixxxedAjNFGciJsfMn/ATlfwrSoAK4/4sXEdj4Na/nB8my1CwupCBkqkd5Czn8FDV2FYvjbSpNd8G69pMBUTX1hPbRlugZ42UH8yKANcfrXG/CKNbfwJaWyk5guLqNgeoIuJOD+GK3PCWq/254V0bVjH5Rv7OG62DnbvQNj8M1ynw8vBp2k+M5J8iDT9avWA7hAFf+prKX8SPo/0O6lrhKq/vRf8A6Uv1G/BW4uLjRNaa8AEzatNOcdCJ0juAR7ETA16HiuL+HWlXGjRvC64t7ixsLglvvCcQCGRfoFghP1JrtGrU4Tk7RhffFW/Pm5Gk6RDEiLj5XuZXZ8++LaHj0PvXX1x/w+U3N34r1doljF9rEscZzliluiWpyf8AfgkIH+1712FABRRRQAUUUhOPegDk9dxe/EXwxYtLhLS2vNUKLjPmKI4EJ9ttxN+I9qq+OLqK+0bwzdW5Jhn1bT5YyRg7WkUj9DV2ziV/ijq8zDMkWjWSL7B57ot+exfyrM+I8Edlp3hG1tQY4YtdsIkUE8KHwB79KyrfAzuy3/eoP+tjT8b3sbf2b4f4abXpmtmGSuIFQvMc467AVHfLg9jXUAALgcAenauK+IlsLC2j8RiSQPp11ZzMVGRHCsrJOxHp5M8ufoDXa+mcVqcIHp71yfh2+jsvFes+GnTYY1Gp2vOd8Mztv7cFZQ/4MvpXV4z3rifC1uus+Kdf10+avkakbG3dlxvhghMbKP8AZ8+S457lR6CgDtj65/CuNtJ0PxK0++s5w9nrmgs2CuM/Z5kaMjPPK3kmR7Cuy2iuJ17T49P8XfD0WnyQW81zYqucnYbR2A9/9Sv5UAdzRRRQAmeeKWiigAooooAKKKKACvJfjl4lu/BaQ61omz7dND9hm3jcihmJikZc/wAH79h2xvB7V61WHqsVkY9Wn1KGKW1+z+VOki7laJVZiGB4Iw7fhSexdP4lpfy7ngfwg+IXiWf4gadpOr6rJqdnqZlVxcKgaJljaQOhVRgEqF29PmGMd/pVfuivM/gv4M0nQ/COn6hHp1sup31v5ktxgszRu29UBOcLjZ8owOK7C+1ttNmuI7i1u7oJ5bqbaMN8sjFQGyRjBViWOFAHJzWOHUlTXO7s9HOalGeMn7CmoRTtZO600b6bmrd3UFpGHuJFiUttUHqxPRQO59hya5zxVLNHrPhK9j8xrcagYXgZMZMkMirJnqCuTx3DnIzjG7Z2apO95cR5vJVAJLbvKXA+RT2XIz7nn0wurwPPpV0kaB5zE/l5/vbTjnt161ueWX6KAQQCDkGigAooooA57x/YXmpeEdQg0tBLfqEnghJAEzxOsgjJJAAYptyePmrzfXfF9/4lh07wtPp09nqGsxG3kilj8h4JMRyCXbIQ3lqEuwCudzRDHUGvaagltLaa5guJbeF7iDd5MrIC0e4YbaeoyODjrQBzfhJo49f8X2q4Vk1NJQnfa9rAd30LiT8Qag04+T8Utaj+6bjTbWbGfvbXlXP64ov5X0v4pafI7N9l1zT2sslCQs9szSxru6AtHLcHB/55VX+dfjV32P4f/Mrc/wD2VZVN4vzO7Baxqx7xf4NP9BNW0LTrr4p6dPdWNrctc6XM7maFX2vBND5bDI64uH/JfQV2dvKJkLqsigMyYdCp+ViCcHtxwe4wRwa5OS8af4w29lgBLPQpZs/3jNcRj9PI/WuyNanCcr8Sju8Li0Mmxb6+s7J8HBZJbmJJFH1Rn/DNcXaeNrjw9J4i0GKxmuNV0+eWaKFYzM07TTzzZ2xknaUaAZwMPOgOM113ij/T/HXg/SxGjpBJc6vMWPRYovJUY9d90jA/9MzXVQWVrBdXNzBbQR3NyVM8qRgPLtGF3EctgcDPQUAZPgaG5i8M2730LW9xcyz3jQOCGiE0zyhGHZlDgEeoNb1FFABRRRQB5Rc2ur6Z8G/EOkeHvtY1TTJLu1t1QN5ywiYtGIz1LfZ3TaR3x3FfOnghrpL/AFR/DW7aunXh1Py87PJ+zyZ87/a3bcZ53fjX1/o9z9qh1+8E7Q20l7Mkcqgbk8pFhc4IIyJIpCMgjGPpXDaZHcL8CkguWBvNbH2VpT/fvbjylc/Tzgce1c9SHNVi7vS/6HsYPE+wwNePJF8zirtaq/M7p/L8j1FJojevbqR5scSOVxyFYsB/6CfyqaRykbMFLEDO1ep+lcx4tvItA1zSddu2EenMr6feS4OIvMKtFI5A+6HQpz0M2c9a6K3ikieZpLiWYSNuVXCgRj+6u0Dj65PvXQeOc58J7ZbP4c6DAFdZ0tx9qVySwuiSZwxP8XmmTPvmutrk/DkxsPGniHRGZBDIsWrWq7uVEu5JVA9pIjISO89dZQAUUUUAFIRS0UActp4P/CzNf6/8gjTv/R17Wd8VTiLwrk/8zDY/+hmrkUz2/wAWruF0IjvtEheN8cEwTyhx/wCTKfnVL4rY8rwn/wBjFZf+hGsq3wM7su/3mPz/ACZrfEkZ+HXikeulXX/olq6MdOa534gtnwnc2udq38sGnMcZwtxMkLHHsJCa6PJ/GtThE9u9cx8Nzu8NSsRgtqeolh/tG9nz+ua6fOa5b4fOF0/V7NkZJrPWL5ZFP/TSd50P0KTIfxoA6r+Vcr4tdR4o8EJkbjqkzAewsbnP8xXU9/51x/iC3a5+Jvg9N+1LW11C9Ix94gQwj9JzQB2VB4FFI3SgBaKSkHJoAdRRRQAUUUUAFee/EfVTB4N8Y+XuaRHWzC45zLFCMD8JM16FXz78QfH+iWPii504TTyiPxDb3l+0MBkWGKGKJGVu5bdHnCg8Y9ayrO0Gd+WQc8VBpXs7vrotX+R7lp1pHp+nW1lbjENvEsKD0VQAP0FZFjbDXtO8Qs0myO+kmsYpFHzpHGDCR+EgmYezUuu62o8MLe6LPFPPqCxxaa4+ZZJJcCNsd1Gd7YzhVY9q29IsItK0my0+2LtBaQpAhc5YqqhQSe54rXY4W3J3ZBoGoHU9GsryRPLlmiUyxf8APOTo6HuCrAqQeQRg1fY4BOeBzXN6Ix0zxPq2juNsFwTqdl1wVc4nQZ6lZfnP/XworV161mv9C1GztJBDcXFtJFFIcgIzKQDx6E0CLOmTC4020mUECSJHAPXkA1Zqno1zBeaRY3NoCttNAkkQPZCoI/QirlABRRRQAUUUUAcz42Foz+Hkuoi9w2rQ/ZHDlfLkCuzHI9Y1lXHfdivlfxh4w8RjxvrGsS6vfafqdjcTW0cUcpVLeNJDtiMf3XU7VJ3A7uvpX1F8TbNZfDH9o5Al0W4i1dCWI4gbfIvH96PzE/4FWH4t0nSn+LPgu6n0yxkvJkvAbh7dDJlI0ZDuIzlcHHpniufEwcoq0rao9fJcRToVpupTU7wlo+lk3f8AC36owdB1G/ufiPbeINReO3eeeDw/Nb44jJsDdsCfUTPs+vFex57d68ytrC3XSbvwy5Z7+bxC3m3AOxi7Ob4S7lwQwiAAOMB0AwVFemqAMY7V0HkHJeHYXvPiH4q1SdYcWa22kW+3JYKsYuHY+m43CDA/55iuwrlvh7A76bf6xLKJW1u9fUUI6CEqscGPrDFETnuTXU0AFFFFABWT4t1f+wPC+rasEWRrK1knSNmwJGVSVTPucD8a1q5n4iBW8Owo67kfU9ORlPQg3sAI/I0AZXiaBPCvwgvrR5vMe2002zTAbTJKy7DIfdnbcfc1Y1fR7e08LeHLGaMyvp93pywqXI+dJY13YB+bC7jg56Z7A1H8VWWbR9J02RC8Wp6taWsigdU8ze36JWteuL7xnptkBldPhfUJCOCjuGhiB9Qym56d0H45LWo32S/r8juqe7g4R7yk/kkkvx5hPiLFHN8P/Esc8ayRnTbglWGQcRsRW6mdgz1xzWR45t5rvwT4gtrVDJcTadcRxoOrMY2AA/E1c0e+i1TSbK/tz+4uoEnTP91lDD9DWpwmLexr/wALP0OUAbjo2oKx7kCezI/mfzNdVXM3hH/CxtDHf+yb/wD9HWddNQAUUUUAFFFFAHJeJjLZ+PPB18mwx3BvNKdTnI8yIXAYfjZ4/wCBVR+Kp/d+Eh/1MVl/6E1S/F0QweF7XVbjeF0jVLK/Lp1RFuEWU/TynkqH4qgbfCP/AGMVl/NqyrfAzuy3/eY/P8maXigG+8V+FNNCb1SebU5tx+Xy4Yyg47kSzwsP93PauqrltGAvvHuv3pUmOwgt9MjLHlZCDPLt9Ayy2+fUp7V1NanCIelcjocn2H4jeJdOaVSt7BbarGhGG3FTbyAHuAIIT7F66+uQ8VGSy8deDdQWRBFPJdaVKrDqJYfPUg+u60Uf8DoA60flXJacUv8A4p6zN5jyf2XpltaIOdsckzySSj6lUtj9MV1v61yXw6aS6j8RapIyEahrNyVCjhVgK2g+uRbbv+BUAdfQenNFFACd6WkpaACiiigAooooAK+WPip8P9Vs/iFdHTJLOW11m+ieNpnZDBLcs/DgKcrujc5HPIGO9fU9eZ/GQyJb7rRU+1JZSXqEnvbT27/oryfrWGJpxnTfMr21PVyXF1sLjIOjLlcvdvps/X7yXw9oh8MX/hHTL6dJdOsbQ2NmzZ3S3pQs0hHQDy0lC+m5x3Fej1y3ix47jRLGZCGRtR090YehuoeR+B/Wuprc8t3vqcl4289tY8NrpaI+rRXMlwAeCbVYyJgT6EvEoGcbzGxyFrY16eW30i4+zyrDcybYIJGG4JLIwRGI7gMyk1VgcP441GNlB8nTbVkJ6rvluN2PTPlrn12j0qPxb5kkuhWUfH2rU4tx7ARBp/18nH40CNvTbOHTtPtbK1BWC2iWGME5IVQAP0FWKKKACiiigAooooA5n4oHb8NPFp9NIuz/AOQXrN8Vxg/EHwLPn7st4n/fVuT/AOy12GpWUGpaddWN4nmWt1E8MqH+JGBDD8ia+Y7/AOK15aR+GtLTTRdat4XkNvqUtzckCW4iV4HVSFOc/f3f7QGDzWNeSjC8n1X5npZTRqV8R7OlFtuM1p5xa/U9Xk8v/hoNIWO1G0JbpVzgNMsskYb3Ox2H0r0qvFtH1Ftdm0X4ji1mjjudahsVikkBeC1aN7PZgcH/AEuVm9xg8V6R4/v5tO8G6pLZb/t0sQtbTbjP2iZhFD16fvHTmtk7nnSTi7PcZ8LiT8M/CJPU6Raf+iUrp6q6TYQaVpVnp1oCttaQpbxAnJCIoUZP0Aq1QIKKKKACuZ+Ief8AhH7bH/QW0z/0ugrpq5L4qyvbeCLu6jGWtbi1uvwjuYnP6KaAK/iUyXXxE8IWceGjgF1ezr6AR+Wh/wC+nq74LP26717Wzz9rvntocsSVhtiYQvpgyrO4x2krm4tc0+f4ieJNat76C5ttC0VYpUhkV+Wd5WPB6gRgV1Hw2szp/wAPfDVs6BJU06DzQO8hjBcn3LEk+5rKn9p93/wP0O7GtJUqa+zFfi3L/wBuOkriPhxPLbeHrfRninmk0i6m0mSTaq+XHDnyXcEgnfF5J+UHlx2yR29cdpdxFY/FPXtMR3H2/T7bVAh5HmKzwSN7fJHbjHsa1OEfI7SfFazj/ht9FnY/WSeH/wCNV11ccVaL4uox+5c6EwQ+8dwuf/Rq12NABRRRQAUUUUAc58SLZ734d+KLWIFpJ9Luo1A7kwsB/OuW8aagur+H/h9qSqFW81nTrgAdt6lv613niG/j0vQNT1CaPzYrS2lnePON4RCxH44rz/xXpp0fw18OdML+YbPVtOtt2MbtiMuf0rKt8DO7Lf8AeY/P8mdL4CIkuPFMxbM0msyiQf3dkcUaj/vhEP411dcn4OBj8S+N49hCnVIpQ3Y7rK2BH1ypP411lanCFch8S7aObTdElZgs1vrmnyQ88ljcIjAf8Ad/wzXX1y/jIK+s+DYpFDI+rsSD0ytndOp/BlB/CgDoppkt4JJpWCRxqXZj0AAyTXKfCaCOx+FvhfA2B9NhuZSx/jkQSOxPuzMfxroddsTqmh6jYJL5LXdvJAJNudhdSM474zmuUsIzrXgnw/HbwGz0z7Da3AkkKupzGNkYjHL4O04O0ZC/fGVoA6m11iG51CK2ihuCksTyx3BUCNwjKCBzn+MEHGCOQTV+OWOR5FjkRmibY4U5KNgHB9Dgg/QivC/EXgDxvrviaO6jvJEtbYrPFJqd6H8yYKWjzFGPLVEcKGUINxzywwy7MPwu1i5tntbvXDYQNLFcSNaSu8lxJHjZubCbQu3PGdzOzfKVTaAetSzRxKGldUUsEBY4GSQAPqSQB7mpK8yT4URXV9Dfa3rVzd3UN3DeIkMQihZolKxI4Yu7ooJ4L5+ZsnmvRre3aKaeV7iaUykEK5G2MAfdUADjOTk5PPXAAABPRRRQAUUUUAFee/HCSzsvBR1W+8zZZTou2IAvIk+baRQD1OyZiBkfMq9hXoVeP+OBb/FCzutIGof2RaWV4yWxPzzXN0jbQWjH/LIZPy53MGVjsAG5SV07GlFqNSLk7K623M34UePLXxZe+G/Dd9aXFncabamfErqyXMkSqiAYJzgMzkEAhkUgnBr3LoOa8C+Cvw21LS/G9zrWq3VnNa6Z5tpbm234lnIUO4JHKqC6H/bDD+Hn32sqHP7NKorM7M1eGeKnLBycoPW70eu/br5HPa7Gtp4h0XU0GGkZ9Om945BuU8ckiSNAOwEjn3oRPtfjx2kxt07TlMQ65aeRgxP0FuoH++1M8bJdRW+m6raQNdLpN017Pbof3ksXkSxsEGDuceYGC8Z24yM1Q1/UbawvrbxBpc9tcOLZUuIBOF+12zEtG0bZ2s6kOUydpDyAlc7hseednRVTSNQg1bSrPUbMsba7hSeIsu0lGUMMjtwat0AFFFFABRRR3oAzdf1q00Ox+0XjMzu3lwW8YzLcSHpHGv8AEx/TknABI8a8SfBGK9tLnWP7ZXTNYuPPvNQwge2aV3eUkFsFQu7ZuP8ACgJGc12euaZ4hs/G19rOk6eL4zQLFC/mIfLVV+4d7qQC4PyrwdwbORg69pp19rjWS67bTxWNm3mPDd+UzXs2DhnSNmQRrncBnJcKfl2AvM4RmuWSujbD4mrhpqrRk4yXVaHIahokmn/s5Wtloe6K5gsLa9SSRSpWYSJO8rDnB37nI6D6V2Pjiwn1vQLGbSrgypa3tpqZjh2v9rihlWXy1J4ywUFSCMsFyQCa6uuJvtJ1vRobyDw5Ektm8jXNlEkgjNtM2SyOG4eBmLE4O5d5CjhStGTbbuzqtJ1Oy1a0Fzp1zHcQ52kqeUYdVYHlWHdSAQeCBVyuC8HeFNasPGepa/q+oKVurUWxto3LCRhISsjcAAqvAAzjzGGcACu9oEFFFFABXE/GuG4n+FHilbVgrrYvI/OMxr80i59SgYfjXbV5jrOuWmv6tLHqcc0uj6dLK8dhbkO93NbzeVunHAC+dgRx5+Yjc2AMKPUadnc8M+FfhLVdS8bWcFvpd/YWqRzQX80to8KxwPEytG24DJJK4X1APavqXwPcy3nhDSJrgR+abdFLRHKSbRgOh/uMBuHswqjp3jLTtQ15dMgO2QQ3c0hkYKUFvcfZycf3WYOQfReevFr4fJs8EaIQGRJLVJUiJz5KONyxg9wgIUey9qyo0VRjyJ3O7MsxnmNd16kVF2SslZaHQVyF7pxT4raZqUM0ambSLi3nR1yXWOaJk2cjGDK2TzxgY7119c7ftGnj7SPM5eTTrxY8kADEluWHuTx/3zWpwEGvbrXx14VvcKUnW70sgnBDSIs4YfhaEf8AAq6mvO5vEnh7xtotvbSrdiOf7NNHcQEZtZnllSJ1kB4ZZbdlBxjJUHIYitnwH4kk1qGW1uj5tzbwxTi6RQqXMUhdVfZ1jfMTq6EDaynGRQB1dFFFABRRVLWdUs9F0u51HU51t7O3TfJIQTgdgAOSScAAAkkgAEmgCh44ntovCeppeo0sVzCbRYUO1pnl/dpGpwcFmdVBPAzk8V4l8VvH9zpOraJ4ct7ZdSvvD1xaXd7eTyeSJ5li3bFAU4yHDFu2cYNet6ZBdeJbyw1rWLNrG0tSZtPsJHDSb2Ur58207Q21iFQEhdxJJYgJxnxX+F+jarf3nim41qfRgI1a/ZYRMsgRQoYL1D7Qq8ZzhRtJ6414zlC1PfzPSymrhqOJU8Xfk1231VjpPhD4gtfFena5rtkskaXuogvDIMNDIltBGyZ74KHnvXe1w3wh8L/8Ir4evLZLWWztrm7+0wW88geZV8qJC0pHy+Y7Rs5AyBvx2rua1V7annz5eZ8uwVz/AIpgEuqeFnEgR4dTLqCud3+i3CkdePlZjn2roK5zxpHdxrpOp2drLerpd4bqa2g5lkjMEsR8sfxMPNDbcgkKQMnALJNq9SeSyuI7OVYblo2WOVk3hGxwxXjIB5xkVm+CEtofCGkWtn5nk2lslptkOXRoh5bK3+0GQg47g1f0rULXVtMtdQ0+ZZ7O6jWaGVcgMjDIPPI47Hmuc1L+0vDes3Gp6dZPqOi3f72+tLcZuIJQuPOiX/loCqqGjHzZUMoZiQQDr6KqaTqNnq+mWuo6ZOlxZXUaywyp0dSMg/8A1jVugAooooAKKKKACiiigArkz8PfDY1EX0Nnc290pZla2vriELuLE4VHAAy7cAY5rrKKAILG0t7C0itbKGOC2iXakcahVUewqc9aKKACuSu/h74dupIzJbXSxRbvLgjvZkijDMGZVjD7VU7RlQMegHNdbRQBW0yxttM0+3sbGIRWtugjjTJOFHueSfc8nvVmiigAooooAKKKKACiiigAooooAKKKKACiiigAqlPpOm3Fybi40+zluDnMrwqzcgA8kZ6AD8B6VdooAx5/C+gTxyJPoelypLKZ3V7SNg8h4LkEctjv1rYoooAKp6rpWn6vAkGrWFpfQI+9Y7mFZVDYIyAwIzgkZ9zVyigDKg8OaJbmYwaPp0Zm2+ZstkG/aMLnA5xk49M1Y0zSdO0pZF0vT7SyWQguLeFY92BgZ2gZxV2igAooooAK4b4padcXdrYT+UbnT4Jf9IgEhjxllKyFudqhlAZ8EojOy8gEdzRQB5Xp+tvfagNGsdbt/Mv5ZY2vUZUkYxE/aXjTPByY4owclVjL5YAbt6N7bxLqWn6fo0iy+H9KkSe4niO+KaWIgwwI+fm2sA7EZwY0U/eYDq9T0yw1W1Ntqdla3tuSGMVxEsiEjocMCM1Yghit4I4beNIoY1CJGihVVRwAAOgoAfRRRQAUUUUAcXpSf2Dquo6DqDeXpWozyXOmz79g3SktNb7gBhw5d15yVfC/6tsYfifWdRtGaw1CeG3a0ZUN9OhMEhkIFu8wBwscgE8MnHDFWAA2kelXdtBeW0lveQRXFvINrxSoGVh6EHg1S0/w/o2m7P7O0jTrTy3MieRbJHtYjBYYHBI4z6UAch8G7e7j0a4uPMkOj3DeZaJLL5jly8jSuW5BBLKu4EiQxmX/AJaEn0KiigAooooAKKKKACiiigAooooAKK8HHxH1/wD4WDdG+kki0GHxKnh2KztXiEu4r8ssiPCzujdcpIhAHQ13HxB+IFz4W8QWOk2WjxahNdWF1f75bwwKqwLuK8RvkkZx7/nQB6BRXibfHeO3sp7q+8OvHGdEg1u1EN35hkSWZYQj5QCMh265YY568Vqz/FXU4jrllH4RnvNa0e9trW5hsLiS5gVJkLibzEh8wqoHzAREgkcGgD1eisHwN4ih8V+FrHWbdrRo7kPj7LK8kY2uVwGeONs8cgouDkc9TvUAFFFFABRRRQAUV4/p3i/xFaL8WBrGr2csnh9FaylFl5cMJNuZBlAWcjdjOWY9cY6VV+CPjLxNrPiefS/FlzN5kmj22pwwXMcJdt5AaSN4FVPKORhWy4zz0OQD2qivItU+L91Z6/dWEXh2GWCHXofD4mbUCjNNKpZH2eUQF4IPzZHYGobH40T6ibOzsvDsX9sSy38csM+oGO3jFoMuVl8olyRjA2D3wOaAPY6K8em+NJ+waHqaeHpbXRdStUnbUtRkmjt4pGk8vyd8UEo3ZBIL7ARg55r2GgAooooAKKKKACivFf2ifH/iPwtpNxF4WjvLF7aJLibU2015oWLSKiwo5Row3JYlyOgUZZuO58deNT4V8G2viRNNmvbEywfag+63kt4JCAZSjJuyuVyhCnk5IxQB2NFeNzfGPVLg+H10Dwa2pya/Nfrp0f8AaSQGaG2xiUl02rvG44zwFGC2cV0Gg/Ea41Dx9J4a1LRf7HkaSdbX7ZLMs12kQyZI18jymU+0xOBnFAHolFFFABRRRQAUUUjgsjAMVJGAwxke/NAC0V4X4Y8T+Oj491XQNe1FG03wost5qN7DBF52pQuu+3TYFwh2hs7MdMZB5M0vx2e20r7dd+G0VLnSH1mxWHUPMMkSybCsv7oeU3fjeO2c0Ae3UV45rXxrOmy6+ieHxMdLXTSP9N2+d9sVW/55nbt3e+fapT8Ybr+1m0MeHI/7f/to6OsR1A/ZiQm/zDN5W4DH8Pl5oA9eorh/BXj6PxH8PbrxRdWtvpkdubgOkt0WiXymYFjJsBCnbnO049DXDj49okWpLN4eLXUK2rWnk3Eqw3QuGCo2+aCN1XnO7YQR0zQB7hRXgfgr4iarpXinV7HXYmvJdS8WnSUT+0HkisQYwcRlkG5QRwMJ17VWv/iXq/iTWPBep6PHLpgf+3YnsvtjGKd7e3BjaTCYOG5AKnBoA+haK4b4J65rPiT4baPqviIwSXtzHu86JwTMufvMoRQjZyNoyOAc84Hc0AFFFFABRRRQAUUUUAFFFFAGY3h/Rn1oaw2k6e2rgBRfG2QzgYxjzMbunHWpb3R9MvrqO5vtOs7m4jjeFJZoFd1jcYdQSMhWHBHQ96vUUAZEfhnQYhiPRNLQfZfsPy2kY/0fOfJ6f6vPO3pntVZvBPhVtNXTm8M6GdPWXzltTYReUJMY3hNuN2OM4zXQUUAQWFna6fZxWlhbQ2trEu2OGGMIiD0CjgCp6KKACiiigAooooAwtN8H+GdLuZbjTPDujWc8yNFJJb2MUbOjfeUlVBIOOR3qzonh3RdBEo0PR9O00TEGT7HapDvx03bQM/jWpRQBlSeHNDkmaWTRtNaVrlb1na1QsbheFmJx98dm6j1qC68IeGru0NpdeHtHntTM1x5MllEyea33pNpXG49z1NblFAGHceEfDdzfQXtx4f0eW8gVUinkso2kjVeFCsVyAOwHStyiigAooooAKKKKAKuqadZatYy2Wq2dte2UuPMt7mJZI3wQRlWBBwQD9RVHxdoFt4n8M6hod5NcQWt9EYZHtyocKeoUspAyOOnetiigDJ07w5pGnwaRHBp9qW0iH7PYyvErSW6bQhCNjK5AAOMZ703TPC/h/Sr+S+0vQtKsr2TO+4trOOOR88nLKATmtiigAooooAKKKKACiiigCrBptjBqFzfwWdtHfXQVZ7hIlWSUKMKGYDLYHTPSs+z8J+HbL7aLPQNJtxeqUuvKs4089T1D4X5gfQ5raooAwIPBfhaCCWGDw1okUM2wyRpYRKr7DlMgLztPTPTtVTxR4F0fX7Ga2MEFl9ouBdXEkFjaytPIFIBcTRSKTz97G7jrjIPVUUAc/wCEPCOleFfCsXh7T4mm09A4cXJEjTFyS5fgA5JORjHbGKLbwT4Vtra4t7bwzocNvcoI5oo7CJVlQNuCsAuCM84PfmugooAwR4N8MDT3sR4c0UWLyLM1uLGLy2kUYDlduNwHAPXFWLLw1oVi1o1loumW7WjSPbmG0jQwtIMSFMD5Sw4OOvetaigCho2jaXolvJBoum2WnQSSGV47SBYVZyACxCgAnAHPsKv0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Between birth and 18 months, varus alignment is normal. Between approximately 18 and 24 months, alignment is neutral. Between approximately 2 and 5 years, valgus alignment is normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Skaggs DL, Flynn JM. Knees Bow Out, Feet Turn In, Who Cares. In: Staying Out of Trouble in Pediatric Orthopaedics, Skaggs DL, Flynn JM, Philadelphia, 2006, Lippincott Williams &amp; Wilkins. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_33_38417=[""].join("\n");
var outline_f37_33_38417=null;
var title_f37_33_38418="Patient information: Ulcerative colitis in children (The Basics)";
var content_f37_33_38418=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86458\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/60/13250\">",
"         Diagram of the colon and rectum",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/46/4834\">",
"          Colonoscopy",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/39/37490\">",
"           Upper endoscopy",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/7/6256\">",
"            Colostomy",
"           </a>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?41/29/42450\">",
"         Patient information: Bloody stools (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/38/11875\">",
"         Patient information: Colostomy care (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?33/34/34338\">",
"         Patient information: Diarrhea in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?25/24/25986\">",
"         Patient information: Stomach ache and stomach upset (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?41/17/42258\">",
"         Patient information: Ulcerative colitis in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?10/11/10418\">",
"         Patient information: Bloody stools in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?28/40/29315\">",
"         Patient information: Chronic abdominal pain in children and adolescents (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?10/39/10869\">",
"         Patient information: Ulcerative colitis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Ulcerative colitis in children (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H95343652\">",
"      <span class=\"h1\">",
"       What is ulcerative colitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Ulcerative colitis is a condition that causes diarrhea, belly pain, and bloody bowel movements. These symptoms happen because the large intestine becomes inflamed and gets sores called &ldquo;ulcers.&rdquo; The large intestine is part of the digestive system. It is also called the colon (",
"      <a class=\"graphic graphic_figure graphicRef58531 \" href=\"mobipreview.htm?12/60/13250\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H95343686\">",
"      <span class=\"h1\">",
"       What are the symptoms of ulcerative colitis in children?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms can be mild or severe. They can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Diarrhea that often has blood in it",
"       </li>",
"       <li>",
"        Belly pain",
"       </li>",
"       <li>",
"        Weight loss",
"       </li>",
"       <li>",
"        Tiredness",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Joint pain, eye irritation, or skin rashes",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H95343703\">",
"      <span class=\"h1\">",
"       Is there a test for ulcerative colitis in children?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Doctors can do the following tests:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Imaging tests &ndash; Such as X-rays, CT scans or MRI scans. Imaging tests create pictures of the inside of the body.",
"       </li>",
"       <li>",
"        A test called a &ldquo;colonoscopy&rdquo; &ndash; This test looks at the lining of the colon. During this test, a doctor puts a thin tube into the rectum (the lower part of the large intestine) and moves it up into the colon (",
"        <a class=\"graphic graphic_figure graphicRef52258 \" href=\"mobipreview.htm?4/46/4834\">",
"         figure 2",
"        </a>",
"        ). The tube has a camera on it. It also has tools attached so the doctor can take samples of tissue to look at under a microscope. Sometimes doctors do a test called an &ldquo;upper endoscopy&rdquo; at the same time. During this test, the doctor looks at the upper part of the digestive system (",
"        <a class=\"graphic graphic_figure graphicRef75392 \" href=\"mobipreview.htm?36/39/37490\">",
"         figure 3",
"        </a>",
"        ).",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H95343781\">",
"      <span class=\"h1\">",
"       How is ulcerative colitis in children treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on each child&rsquo;s symptoms and other factors. Treatments can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines that go directly into the rectum &ndash; Doctors give these medicines to children with ulcerative colitis that affects only the rectum.",
"       </li>",
"       <li>",
"        Medicines the child takes by mouth &ndash; A common type is called &ldquo;5-ASA.&rdquo; (If your child has trouble swallowing pills, the doctor can give your child liquid medicines or powders you put in foods or drinks.)",
"       </li>",
"       <li>",
"        Steroid medicines &ndash; If other medicines do not work, doctors can give steroid medicines to reduce swelling. These are not the same steroids athletes use to build muscle. Steroid medicines are usually taken for a few weeks or months at a time.",
"       </li>",
"       <li>",
"        Stronger medicines for severe cases &ndash; These medicines work on the immune system to protect the colon from damage. Common ones are &ldquo;6-mercaptopurine&rdquo;&nbsp;and &ldquo;",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?27/31/28149?source=see_link\">",
"         azathioprine",
"        </a>",
"        .&rdquo;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some children with severe symptoms need treatment in the hospital until the symptoms get better.",
"     </p>",
"     <p>",
"      Ulcerative colitis and some of the medicines that treat it can affect your child&rsquo;s growth. During treatment, the doctor will check your child&rsquo;s height and weight often to make sure he or she is growing as normally as possible.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H95343798\">",
"      <span class=\"h1\">",
"       Will my child need surgery?",
"      </span>",
"      &nbsp;&mdash;&nbsp;When medicines do not work, doctors can do surgery to remove the colon. After the colon is removed, ulcerative colitis does not come back.",
"     </p>",
"     <p>",
"      When doctors do surgery for ulcerative colitis in children, they can remove the colon and rectum. After this, they can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Connect the rest of the intestine to the anus right away. Children who have this surgery can have bowel movements the normal way.",
"       </li>",
"       <li>",
"        Wait until later to connect the intestine to the anus. This helps the intestine heal. Children who have this surgery can no longer have bowel movements in the normal way. Instead, their bowel movements come out through a hole in the belly (",
"        <a class=\"graphic graphic_figure graphicRef57774 \" href=\"mobipreview.htm?6/7/6256\">",
"         figure 4",
"        </a>",
"        ). A plastic bag catches the waste.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H95343844\">",
"      <span class=\"h1\">",
"       Is my child at risk for colon cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your child has ulcerative colitis, he or she can have an increased risk of colon cancer. The risk for colon cancer starts about 10 years after ulcerative colitis is found. After that, your child should have a colonoscopy every 1 or 2 years. Doctors can look for colon cancer and treat it if they find it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H95343861\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/29/42450?source=see_link\">",
"       Patient information: Bloody stools (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/38/11875?source=see_link\">",
"       Patient information: Colostomy care (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/34/34338?source=see_link\">",
"       Patient information: Diarrhea in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/24/25986?source=see_link\">",
"       Patient information: Stomach ache and stomach upset (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/17/42258?source=see_link\">",
"       Patient information: Ulcerative colitis in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/11/10418?source=see_link\">",
"       Patient information: Bloody stools in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/40/29315?source=see_link\">",
"       Patient information: Chronic abdominal pain in children and adolescents (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/39/10869?source=see_link\">",
"       Patient information: Ulcerative colitis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?37/33/38418?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86458 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-543E46505B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_33_38418=[""].join("\n");
var outline_f37_33_38418=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95343652\">",
"      What is ulcerative colitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95343686\">",
"      What are the symptoms of ulcerative colitis in children?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95343703\">",
"      Is there a test for ulcerative colitis in children?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95343781\">",
"      How is ulcerative colitis in children treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95343798\">",
"      Will my child need surgery?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95343844\">",
"      Is my child at risk for colon cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95343861\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86458\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/60/13250\">",
"      Diagram of the colon and rectum",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/46/4834\">",
"       Colonoscopy",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/39/37490\">",
"        Upper endoscopy",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/7/6256\">",
"         Colostomy",
"        </a>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/29/42450?source=related_link\">",
"      Patient information: Bloody stools (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/11/10418?source=related_link\">",
"      Patient information: Bloody stools in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/40/29315?source=related_link\">",
"      Patient information: Chronic abdominal pain in children and adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/38/11875?source=related_link\">",
"      Patient information: Colostomy care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/34/34338?source=related_link\">",
"      Patient information: Diarrhea in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/24/25986?source=related_link\">",
"      Patient information: Stomach ache and stomach upset (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/39/10869?source=related_link\">",
"      Patient information: Ulcerative colitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/17/42258?source=related_link\">",
"      Patient information: Ulcerative colitis in adults (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_33_38419="Anterior wall MI four chamber echo 2";
var content_f37_33_38419=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/50724/4chanmi2_conv.mp4?title=Anterior+wall+MI+four+chamber+echo+2\" style=\"width:328px;height:248px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anterior wall myocardial infarction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 264px; height: 449px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Four chamber view from a 2-D echocardiogram shows a large area of hypokinesis and akinesis of the anterior wall and apex of the left ventricle. The left ventricular wall and interventricular septum are thin and fail to thicken during systole.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_33_38419=[""].join("\n");
var outline_f37_33_38419=null;
var title_f37_33_38420="Prescription and technique of therapeutic plasma exchange";
var content_f37_33_38420=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prescription and technique of therapeutic plasma exchange",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/33/38420/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/33/38420/contributors\">",
"     Joy L Fridey, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/33/38420/contributors\">",
"     Andre A Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/33/38420/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/33/38420/contributors\">",
"     Arthur J Silvergleid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/33/38420/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/33/38420/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/33/38420/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic plasma exchange (TPE, plasmapheresis) is an extracorporeal blood purification technique designed for the removal of large molecular weight substances from the plasma. This topic will review the basic elements of the plasma exchange prescription and technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38420/abstract/1\">",
"     1",
"    </a>",
"    ]. Indications for and complications of TPE are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/19/12597?source=see_link\">",
"     \"Indications for therapeutic plasma exchange\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/31/6646?source=see_link\">",
"     \"Complications of therapeutic plasma exchange\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRESCRIPTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, large molecular weight compounds equilibrate slowly between the vascular space and the interstitium. Thus, calculations of the rate of removal by TPE can be simplified to first order kinetics. A single plasma volume exchange will lower plasma macromolecule levels by 60 percent and an exchange equal to 1.4 times the plasma volume will lower plasma levels by 75 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38420/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following formula can be used to estimate the plasma volume in an adult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38420/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;Estimated plasma volume (in liters) &nbsp;= &nbsp;0.07 &nbsp;x &nbsp;weight (kg) &nbsp;x &nbsp;(1 &nbsp;- &nbsp;hematocrit)",
"   </p>",
"   <p>",
"    Performing more than one plasma volume exchange increases procedure time, challenges patient tolerance, and increases the cost. As an example, currently available cell separators can perform one complete volume exchange in 1.5 to 2 hours; exchanges equaling two to three plasma exchanges will double or triple the time required to perform the procedure. For most conditions in which plasmapheresis is used, it is considered acceptable to perform 1 to 1.5 plasma volume exchanges per procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma exchange is most commonly performed with centrifugation devices used in blood banking procedures. These devices offer the advantage of allowing selective cell removal (cytapheresis).",
"   </p>",
"   <p>",
"    The use of a highly permeable filter with standard hemodialysis equipment is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/33/28179?source=see_link\">",
"     \"Plasmapheresis with hemodialysis equipment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Venous access",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful execution of a TPE procedure requires reliable venous access, which may be either two large, durable peripheral veins, or a central line using a catheter which has a dual lumen and is rigid enough to withstand significant flow and pressures. Examples of products that would meet these requirements include, but not are limited to: the Quinton-Mahurkar catheter (Quinton Instrument Company), MedComp apheresis catheters, and Hickman",
"    <span class=\"nowrap\">",
"     apheresis/dialysis",
"    </span>",
"    catheters. Radiographic confirmation of catheter placement is critical, especially for apheresis procedures, to prevent perforation of vital structures and because cardiac arrhythmias may result if citrate anticoagulant (which binds ionized calcium) is infused close to the sinoatrial node.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Apheresis schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;The plasma exchange regimen should be determined according to what pathological substance is being removed and by the desired endpoint, eg, clinical improvement or a reduction in the level of a specific measurable pathogenic moiety. In immunologically-mediated, paraproteinemic, or hyperviscosity conditions, immunoglobulin compartmental shifts, especially those of IgG and IgM, must be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38420/abstract/5\">",
"     5",
"    </a>",
"    ]. In most cases, TPE only serves an adjunctive role as the patients are receiving concomitant chemotherapy or immunosuppressive therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 75 percent of IgM is intravascular. As a result, only one or two procedures are usually required to rapidly reduce IgM levels.",
"     </li>",
"     <li>",
"      In comparison, only 45 percent of IgG is intravascular, and within 48 hours of a procedure, the plasma IgG production returns to 40 percent of the pre-apheresis level. IgG production is also characterized by a \"rebound\" phenomenon, and cessation of TPE after several procedures can result in pretreatment or even higher levels of IgG, especially if the patient is not on immunosuppressive therapy. As a result, a more rigorous regimen involving several TPE procedures and the institution of immunosuppressive therapy is required to significantly reduce IgG levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38420/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If one assumes a negligible production rate of new immunoglobulin (due in part to concurrent immunosuppressive therapy) and that the rate of extravascular to intravascular equilibration is approximately 1 to 2 percent per hour, then five separate exchanges over 7 to 10 days is required to remove 90 percent of the total initial body immunoglobulin burden [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38420/abstract/7\">",
"     7",
"    </a>",
"    ]. Additional treatments may be required if new antibody production occurs.",
"   </p>",
"   <p>",
"    The AABB (formerly the American Association of Blood Banks) general recommendation for conditions requiring plasmapheresis is that one exchange be performed every second or third day, each exchange consisting of 1 to 1.5 plasma volumes, for a total of three to five procedures. In some conditions, such as acute Guillain-Barr&eacute; syndrome, it may be necessary after the initial exchanges to perform TPE one to two times a week until improvement occurs. Another exception is thrombotic thrombocytopenic purpura (TTP); in this disorder, plasma exchanges should be performed daily until the platelet count is normal for two to three consecutive days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38420/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42490?source=see_link\">",
"     \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\"",
"    </a>",
"    .) In general, treatment for Goodpasture's syndrome (anti-GBM mediated disease) is also performed on a daily basis for at least two weeks. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/16/7432?source=see_link\">",
"     \"Treatment of anti-GBM antibody (Goodpasture's) disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Replacement fluids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fluid volume removed by TPE must be replaced to prevent marked volume depletion. Albumin, saline, or a combination of albumin and saline, are the replacement fluids of choice for most conditions. It is generally recommended that FFP only be used as the replacement fluids for TTP,",
"    <span class=\"nowrap\">",
"     TTP/HUS,",
"    </span>",
"    or thrombotic microangiopathy (TMA). Each has advantages and disadvantages, and the optimal choice often varies with the clinical setting. Albumin is used for most conditions, saline for hyperviscosity, some combination of albumin and saline if cost is a consideration, and fresh frozen plasma for TTP,",
"    <span class=\"nowrap\">",
"     TTP/HUS,",
"    </span>",
"    or TMA.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Albumin &mdash; Albumin solutions have the advantages of lack of viral transmission [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38420/abstract/8\">",
"       8",
"      </a>",
"      ] and minimal risk of anaphylactoid reactions. There is, however, a postpheresis depletion coagulopathy and a net loss of immunoglobulins (see below).",
"     </li>",
"     <li>",
"      Albumin-saline combination &mdash; When colloid and crystalloid solutions are used in combination, the amount of colloid should not be less than 50 percent of the total infused. An appropriate replacement solution would consist of 60 to 80 percent colloid and 20 to 40 percent saline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38420/abstract/5,9\">",
"       5,9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fresh frozen plasma &mdash; Fresh frozen plasma (FFP) replaces the normal proteins that have been removed. As a result, there is no depletion of coagulation factors or immunoglobulins. However, complications are more common than with albumin. These include transfusion-related acute lung injury (TRALI), infectious disease transmission, citrate-induced paresthesias (due to binding of free (ionized) calcium to citrate), muscle cramps, urticaria, and, less often, severe anaphylactoid reactions. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/31/6646?source=see_link\">",
"       \"Complications of therapeutic plasma exchange\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Either FFP or cryosupernatant (also called cryoprecipitate-reduced or cryo-poor plasma) is used as the replacement fluid for thrombotic thrombocytopenic purpura and",
"    <span class=\"nowrap\">",
"     TTP/HUS",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38420/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=see_link\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42490?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\", section on 'Available plasma products'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is not strong evidence to support the use of TPE in treating transplant-associated thrombotic microangiopathy, so recommendations regarding replacement fluid are not made in this article [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38420/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cytapheresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to routine TPE, cytapheresis usually aims to lower the leukocyte, platelet, or erythrocyte count. A complete blood count can determine if cytapheresis has been successful.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The post-procedure target white blood cell count in hyperleukocytosis is less than",
"      <span class=\"nowrap\">",
"       100,000/microL.",
"      </span>",
"     </li>",
"     <li>",
"      For thrombocytosis, the goal is fewer than one million platelet per microL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38420/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cytapheresis can also be performed prophylactically to prevent the complications of sickle cell disease or for sickle cell crisis. In the latter setting, the goal is the removal of more than 50 percent of hemoglobin S, and replacement with normal allogeneic red cells that are negative for sickle cell trait [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38420/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory assessment is based upon the desired endpoint of therapy and the number of procedures that will be performed. For plasmapheresis, baseline CBC, serum protein electrophoresis, and coagulation and electrolyte studies should be performed. If a large number of closely spaced procedures are planned, subsequent laboratory evaluation should occur more frequently than would be necessary for a less aggressive course. If a patient is undergoing cytapheresis, obtaining the appropriate cell count determines the adequacy of response.",
"   </p>",
"   <p>",
"    A comprehensive review of indications for therapeutic apheresis, as well as information about replacement fluids, apheresis schedules, and other technical information has also been published by the American Society for Apheresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38420/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3915389\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3915412\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic plasma exchange (TPE, plasmapheresis) is an extracorporeal blood purification technique designed for the removal of large molecular weight substances (eg, antibodies, paraproteins) from the plasma. In general, an exchange equal to the patient&rsquo;s estimated plasma volume will lower plasma macromolecule levels by 60 percent and an exchange equal to 1.4 times the plasma volume will lower plasma levels by 75 percent. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Prescription'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Successful execution of a TPE procedure requires reliable venous access, which may be either two large, durable peripheral veins, or a central line using a catheter which has a dual lumen and is rigid enough to withstand significant flow and pressures. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Venous access'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3915419\">",
"    <span class=\"h2\">",
"     Treatment regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The plasma exchange regimen should be determined according to the characteristics of the pathological substance that is being removed and by the desired endpoint (eg, clinical improvement or a reduction in the level of a specific measurable pathogenic moiety).",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Approximately 75 percent of IgM is intravascular. As a result, only one or two procedures are usually required to rapidly reduce IgM levels.",
"     </li>",
"     <li>",
"      Only 45 percent of IgG is intravascular. Within 48 hours of a procedure, the plasma IgG production returns to 40 percent of the pre-apheresis level.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3915463\">",
"    <span class=\"h2\">",
"     Fluids used for replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fluid volume removed by TPE must be replaced to prevent marked volume depletion. Albumin, saline, or a combination of albumin and saline, are the replacement fluids of choice for most conditions. Thrombotic thrombocytopenic purpura (TTP) and",
"    <span class=\"nowrap\">",
"     TTP/hemolytic",
"    </span>",
"    uremic syndrome are the only conditions for which FFP (or cryosupernatant) is the appropriate replacement fluid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3915471\">",
"    <span class=\"h2\">",
"     Removal of white cells, platelets, and red cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytapheresis (eg, removal of white blood cells, platelets, or red blood cells) can be performed in order to reduce excessive numbers of these cells, and includes the following. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Cytapheresis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Leukapheresis: removal of white blood cells to prevent or treat hyperleukocytosis",
"     </li>",
"     <li>",
"      Platelet pheresis: removal of platelets in patients with excessively high platelet counts",
"     </li>",
"     <li>",
"      Phlebotomy: removal of red cells in patients with polycythemia, iron overload, or to reduce the percent of sickle hemoglobin",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38420/abstract/1\">",
"      Kaplan AA. Therapeutic plasma exchange: core curriculum 2008. Am J Kidney Dis 2008; 52:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38420/abstract/2\">",
"      Kaplan AA, Halley SE. Plasma exchange with a rotating filter. Kidney Int 1990; 38:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38420/abstract/3\">",
"      Kaplan AA. Towards a rational prescription of plasma exchange: The kinetics of immunoglobulin removal. Semin Dial 1992; 5:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38420/abstract/4\">",
"      Kaplan AA. A simple and accurate method for prescribing plasma exchange. ASAIO Trans 1990; 36:M597.",
"     </a>",
"    </li>",
"    <li>",
"     Leitman SF, Ciaverella D, McLeod B, et al. Guidelines for Therapeutic Hemapheresis, American Association of Blood Banks, Bethesda 1994.",
"    </li>",
"    <li>",
"     Therapeutic Apheresis, Kolins J, Jones JM (Eds), American Association of Blood Banks, Arlington 1983. p.2.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38420/abstract/7\">",
"      Keller AJ, Urbaniak SJ. Intensive plasma exchange on the cell separator: effects on serum immunoglobulins and complement components. Br J Haematol 1978; 38:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38420/abstract/8\">",
"      Tabor E. The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 1999; 39:1160.",
"     </a>",
"    </li>",
"    <li>",
"     Technical Manual, 11th ed, Walker RH (Ed), American Association of Blood Banks, Bethesda 1993. p.37.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38420/abstract/10\">",
"      Obrador GT, Zeigler ZR, Shadduck RK, et al. Effectiveness of cryosupernatant therapy in refractory and chronic relapsing thrombotic thrombocytopenic purpura. Am J Hematol 1993; 42:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38420/abstract/11\">",
"      Rock G, Shumak KH, Sutton DM, et al. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group. Br J Haematol 1996; 94:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38420/abstract/12\">",
"      Szczepiorkowski ZM, Winters JL, Bandarenko N, et al. Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2010; 25:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38420/abstract/13\">",
"      Laskin BL, Goebel J, Davies SM, Jodele S. Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Blood 2011; 118:1452.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7941 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-C801F8800B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_33_38420=[""].join("\n");
var outline_f37_33_38420=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3915389\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRESCRIPTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Venous access",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Apheresis schedule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Replacement fluids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cytapheresis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3915389\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3915412\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3915419\">",
"      Treatment regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3915463\">",
"      Fluids used for replacement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3915471\">",
"      Removal of white cells, platelets, and red cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/31/6646?source=related_link\">",
"      Complications of therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/19/12597?source=related_link\">",
"      Indications for therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/33/28179?source=related_link\">",
"      Plasmapheresis with hemodialysis equipment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42490?source=related_link\">",
"      Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/16/7432?source=related_link\">",
"      Treatment of anti-GBM antibody (Goodpasture's) disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_33_38421="Magnesium carbonate, calcium carbonate, and folic acid: Drug information";
var content_f37_33_38421=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Magnesium carbonate, calcium carbonate, and folic acid: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/13/2260?source=see_link\">",
"    see \"Magnesium carbonate, calcium carbonate, and folic acid: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10118994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      MagneBind&reg; 400 Rx",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F10118998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Calcium Salt;",
"     </li>",
"     <li>",
"      Electrolyte Supplement, Oral;",
"     </li>",
"     <li>",
"      Magnesium Salt;",
"     </li>",
"     <li>",
"      Vitamin;",
"     </li>",
"     <li>",
"      Vitamin, Water Soluble",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F10119005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention or treatment of nutritional deficiencies: Oral: 1-3 tablets 3 times/day with meals",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F10119006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F10119007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended for use in renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F10119008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     MagneBind&reg; 400 Rx: Magnesium carbonate 400 mg [equivalent to elemental magnesium 114 mg], calcium carbonate 200 mg [equivalent to elemental calcium 80 mg], and folic acid 1 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F10118996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10118999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention or treatment of nutritional deficiencies",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10119000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypermagnesemia, renal dysfunction",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10119001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Pernicious anemia: Folic acid may obscure pernicious anemia or produce remission while neurological progression occurs.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F10149391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Antacids may decrease the serum concentration of ACE Inhibitors.  Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Enalaprilat; Ramipril.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Antacids may decrease the absorption of Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Antacids may decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antacids may decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): Antacids may decrease the serum concentration of Anticonvulsants (Hydantoin).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antacids may decrease the absorption of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Antacids may decrease the absorption of Atazanavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisacodyl: Antacids may diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine.  Gastric irritation and/or cramps may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral calcium supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Antacids may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of antacids containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: Antacids may decrease the serum concentration of Bosutinib.  Management: Administer antacids more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Acetate: Calcium Salts may enhance the adverse/toxic effect of Calcium Acetate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: Antacids may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis and/or loss of efficacy of the cation exchange resin.  Management: To minimize this interaction, consider: a)separating doses by 2 or more hours; b)rectal administration of the exchange resin; or c)alternatives to antacids. Monitor for metabolic alkalosis and attenuation of CPS effects. Avoid magnesium hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: Antacids may decrease the serum concentration of Cefditoren.  Management: Concomitant use of cefditoren with antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy. If antacid therapy can not be avoided, separate dosing by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefpodoxime: Antacids may decrease the serum concentration of Cefpodoxime.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefuroxime: Antacids may decrease the serum concentration of Cefuroxime.  Management:  Consider administering antacids and cefuroxime at least 2 hours apart.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloroquine: Antacids may decrease the serum concentration of Chloroquine.  Management: Separate administration of antacids and chloroquine by at least 4 hours to minimize any potential negative impact of antacids on chloroquine bioavailability.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Oral): Antacids may decrease the bioavailability of Corticosteroids (Oral).  Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Antacids may decrease the serum concentration of Dabigatran Etexilate.  Management: Dabigatran etexilate Canadian product labeling recommends avoiding concomitant use with antacids for 24 hours after surgery. In other situations, administer dabigatran etexilate 2 hours prior to antacids. Monitor clinical response to dabigatran therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Antacids may decrease the absorption of Dasatinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Antacids may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Calcium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: Antacids may decrease the serum concentration of Delavirdine.  Management: Separate doses of delavirdine and antacids by at least 1 hour. Monitor for decreased delavirdine therapeutic effects with this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: Antacids may increase the absorption of Dexmethylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOBUTamine: Calcium Salts may diminish the therapeutic effect of DOBUTamine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Calcium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., calcium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Antacids may decrease the serum concentration of Elvitegravir.  Management: Separate administration of antacids and the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product by at least 2 hours in order to minimize the risk for an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Antacids may decrease the serum concentration of Erlotinib.  Management: Separate the administration of erlotinib and any antacid by several hours in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estramustine: Calcium Salts may decrease the absorption of Estramustine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fexofenadine: Antacids may decrease the serum concentration of Fexofenadine.  Management: No specific recommendations concerning the time required between their administration are provided. Separate administration of each agent by as much time as possible to decrease the risk of an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Folic Acid may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gabapentin: Antacids may decrease the serum concentration of Gabapentin.  Management: Administer gabapentin at least 2 hours after antacid administration.  Monitor patients closely for evidence of reduced response to gabapentin therapy when both of these drugs are being used.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Green Tea: May decrease the serum concentration of Folic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Antacids may decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: Antacids may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Antacids may decrease the absorption of Isoniazid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Antacids may decrease the serum concentration of Itraconazole.  Management: Administer itraconazole at least 1 hour after and 2 hours before administration of any antacids.  Itraconazole oral suspension may be less sensitive to the effects of decreased gastric acidity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Antacids may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer oral ketoconazole at least 2 hours prior to use of any antacid product.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: Antacids may diminish the therapeutic effect of Mesalamine. Antacid-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Avoid concurrent administration of antacids with sustained-release mesalamine products.  Separating antacid and mesalamine administration, and/or using lower antacid doses may be adequate means of avoiding this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: Antacids may diminish the therapeutic effect of Methenamine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antacids may increase the absorption of Methylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Misoprostol: Antacids may enhance the adverse/toxic effect of Misoprostol. More specifically, concomitant use with magnesium-containing antacids may increase the risk of diarrhea.  Management: Avoid concomitant use of misoprostol and magnesium-containing antacids. In patients requiring antacid therapy, employ magnesium-free preparations. Monitor for increased adverse effects (e.g., diarrhea, dehydration).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Antacids may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, antacids may decrease the absorption of orally administered iron.  Management: Separate dosing of oral iron-containing multivitamin preparations and antacids by as much time as possible in order to minimize impact on therapeutic efficacy of the iron preparation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Calcium Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Antacids may decrease the absorption of Mycophenolate.  Management: Separate doses of mycophenolate and antacids by at least 2 hours. Monitor for reduced effects of mycophenolate if taken concomitant with antacids.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: Antacids may decrease the serum concentration of Nilotinib.  Management: Separate the administration of nilotinib and any antacid by several hours whenever possible in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PenicillAMINE: Antacids may decrease the serum concentration of PenicillAMINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: Folic Acid may decrease the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Folic Acid may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Antacids may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Calcium Salts may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: Antacids may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: Folic Acid may decrease the serum concentration of Primidone. Additionally, folic acid may decrease concentrations of active metabolites of primidone (e.g., phenobarbital).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: Antacids may decrease the absorption of Protease Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Darunavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Antacids may decrease the excretion of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Antacids may decrease the serum concentration of QuiNINE.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Antacids may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of quinolones.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Calcium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Moxifloxacin (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltitrexed: Folic Acid may diminish the therapeutic effect of Raltitrexed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Antacids may decrease the serum concentration of Rilpivirine.  Management: Administer antacids at least 2 hours before or 4 hours after rilpivirine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: Antacids may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis and/or loss of efficacy of the exchange resin.  Management: To minimize this interaction, consider: a)separating doses by 2 or more hours; b)rectal administration of the exchange resin; or c)alternatives to antacids. Monitor for metabolic alkalosis and attenuation of SPS effects. Avoid magnesium hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: Calcium Salts may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and oral calcium salts by at least 2 hours in order to minimize this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Antacids may decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Calcium Salts may decrease the serum concentration of Tetracycline Derivatives.  Management: If coadministration of oral calcium with oral tetracyclines can not be avoided, consider separating administration of each agent by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Calcium Salts may diminish the therapeutic effect of Thyroid Products.  Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Antacids may decrease the absorption of Trientine.  Management: Separate trientine dosing from other oral drugs (eg, antacids) by at least 1 hour. Monitor for decreased therapeutic effects of trientine if an antacid is initiated/dose increased, or increased effects if an antacid is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Calcium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Calcium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: Antacids may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Calcium Salts may enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14287013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9553 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-558F5CFEDC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_33_38421=[""].join("\n");
var outline_f37_33_38421=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10118994\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10118998\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10119005\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10119006\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10119007\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10119008\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10118996\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10118999\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10119000\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10119001\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299629\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10149391\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287012\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287013\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9553\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9553|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/13/2260?source=related_link\">",
"      Magnesium carbonate, calcium carbonate, and folic acid: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_33_38422="Myocardial action potential and action of antiarrhythmic drugs";
var content_f37_33_38422=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Myocardial action potential and action of antiarrhythmic drugs",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/33/38422/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/33/38422/contributors\">",
"     Jonathan C Makielski, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/33/38422/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/33/38422/contributors\">",
"     Samuel L&eacute;vy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/33/38422/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/33/38422/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/33/38422/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     CARDIAC EXCITABILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac excitability refers to the ease with which cardiac cells undergo a series of events characterized by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sequential depolarization and repolarization",
"     </li>",
"     <li>",
"      Communication with adjacent cells",
"     </li>",
"     <li>",
"      Propagation of the electrical activity in a normal or abnormal manner",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The heartbeat arises from organized flow of ionic currents through ion-specific channels in the cell membrane, through the myoplasm and gap junctions that connect cells, and through the extracellular space (",
"    <a class=\"graphic graphic_figure graphicRef70771 \" href=\"mobipreview.htm?19/59/20401\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38422/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Mutations in genes encoding the subunits and associated proteins of these channels have been associated with familial arrhythmic syndromes and sudden cardiac death. Examples include the congenital long QT syndrome (sodium and potassium current), the Brugada syndrome (mainly sodium current), and congenital heart block (sodium current). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/0/28681?source=see_link\">",
"     \"Genetics of congenital and acquired long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28250?source=see_link\">",
"     \"Brugada syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32007?source=see_link&amp;anchor=H8#H8\">",
"     \"Etiology of atrioventricular block\", section on 'Familial disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Cardiac ion channels and currents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ions (sodium, potassium, chloride and calcium) flow through the cardiac membrane in channels with pores formed by proteins encoded by specific genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38422/abstract/3\">",
"     3",
"    </a>",
"    ]. The pore-forming protein is called the alpha subunit, which also contains the voltage dependent sensors and gates. The currents carry specific names based upon the permeant ion and distinguishing kinetics or pharmacology. In most cases, the gene and protein underlying each current has been described and each has a distinct name (",
"    <a class=\"graphic graphic_figure graphicRef70771 \" href=\"mobipreview.htm?19/59/20401\">",
"     figure 1",
"    </a>",
"    ). For example, the voltage dependent sodium current (INa) flows through the protein NaV1.5 encoded by the gene SCN5A and similarly for other ion channels. Ion channels also consist of multiple subunits (usually named beta, delta, gamma, and so on) and other accessory proteins forming a macromolecular complex that regulates the current. The sodium-potassium pump and the sodium-calcium exchanger are not considered channels because they require energy to drive ions across the membrane against their gradients, but they do generate currents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     The resting potential",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal resting potential in most myocardial cells is between 80 and 95 mV, with the cell interior negative relative to the extracellular space. The resting potential of the cell is set by the balance of inward (sodium and calcium) and outward (potassium) currents and the corresponding equilibrium potentials of these currents. In turn, the equilibrium potential for a given ion is determined by the concentrations of that ion inside and outside the cell. Using these concentrations, the equilibrium potential is calculated by the Nernst equation. As an example, potassium ion concentrations are higher inside than outside the cell, and the potassium equilibrium potential is between -80 and -95 mV. When potassium channels open, potassium ions flow down their gradient as an outward current, carrying positive ions outside the cell and taking the cell toward more negative potentials.",
"   </p>",
"   <p>",
"    In the heart, the resting potential is generated by the inward rectifier current IK1, which is the predominant open channel at rest. Potassium current flow through this channel continues until the interior negative potential is at the same magnitude as the equilibrium potential for potassium. Only small amounts of actual potassium flow is required to maintain this potential. The equilibrium potentials for sodium and calcium are positive (~+40 mV and ~+80 mV, respectively) so that when these channels are open, they tend to depolarize the membrane. Voltage-sensitive sodium, calcium, and potassium channels play only a small role in the resting state, since most of these channels are closed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38422/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The Na-K-ATPase pump maintains the potassium and sodium gradients by pumping potassium into and sodium out of the cells. The Na-Ca exchanger uses the power of the Na gradient to pump calcium out of the cell. These and other pumps maintain the ion channel gradient that is important for both excitability and contraction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Action potential in fast response tissues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissues that depend upon the opening of voltage-sensitive, kinetically rapid (opening in less than a millisecond) sodium channels to initiate depolarization are called fast response tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38422/abstract/6\">",
"     6",
"    </a>",
"    ]. Fast response tissues include the atria, the specialized infranodal conducting system (bundle of His, fascicles and bundle branches, terminal Purkinje fibers), the ventricles, and atrioventricular bypass tracts.",
"   </p>",
"   <p>",
"    The following is a simplified description of the steps involved in the generation of an action potential in the heart (",
"    <a class=\"graphic graphic_figure graphicRef70771 \" href=\"mobipreview.htm?19/59/20401\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef71390 \" href=\"mobipreview.htm?15/55/16253\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef61058 \" href=\"mobipreview.htm?31/46/32481\">",
"     movie 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38422/abstract/7\">",
"     7",
"    </a>",
"    ]. The particular shape and duration of the individual action potential varies for atria, nodal tissue, specialized conduction tissue, and ventricle (",
"    <a class=\"graphic graphic_figure graphicRef61989 \" href=\"mobipreview.htm?34/63/35827\">",
"     figure 3",
"    </a>",
"    ), depending upon differences in the density of ion channels in these tissues. The shape and duration of the action potentials also vary in right and left ventricle, and transmurally across the wall of the heart [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38422/abstract/8\">",
"     8",
"    </a>",
"    ], again depending upon differences in ion channel and current densities.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapid depolarization (phase 0) occurs when the resting cell is brought to threshold, leading sequentially to activation or opening of voltage-dependent sodium channels, rapid sodium entry into the cells down a favorable concentration gradient, and a cell interior positive potential that can approach +45 mV. The marked depolarization initiates voltage-dependent inactivation of the sodium channels. Calcium channels also open during depolarization but the inward calcium flux is much slower.",
"     </li>",
"     <li>",
"      Phase 1 repolarization often inscribes a \"notch\" and is primarily caused by activation of the transient outward potassium currents (Ito) combined with a corresponding rapid decay of the sodium current.",
"     </li>",
"     <li>",
"      This is followed by a plateau in phase 2 in which continued \"late\" calcium and to a lesser extent, \"late\" sodium current into the cell balances the effect of potassium currents, thus maintaining a stable membrane potential.",
"     </li>",
"     <li>",
"      The decay of the calcium current and increases in delayed rectifier potassium currents initiate repolarization and the inward rectifier current dominates the terminal repolarization with return to the resting potential (phase 3).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During one cycle of depolarization and repolarization, the voltage-dependent channels cycle through three different kinetic or gating states:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Resting.",
"     </li>",
"     <li>",
"      Open, as the channels open during phase 0 depolarization.",
"     </li>",
"     <li>",
"      Inactivated, which occurs at positive potentials (end of phase 0) and during sustained depolarization (as during the phase 2 plateau). During recovery in diastole, the channel returns to the resting state.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The resting and inactivated states are different physiologically, even though the channel is effectively nonconducting in both settings. In the resting state, the channels can be opened positive to the threshold potential. In comparison, the inactivated channel cannot be activated until it cycles to the resting state. These different states are important clinically, since, for example, some antiarrhythmic drugs (such as the class I antiarrhythmic drugs) preferentially bind to open and inactivated sodium channels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Impulse propagation",
"    </span>",
"    &nbsp;&mdash;&nbsp;When an action potential forms in a patch of membrane (the source), current flows from this patch to neighboring patches (the sink). Gap junctions are the low resistance structures that allow ions to flow from one cell to another and, if the current flow is sufficient, to cause sequential depolarization from cell to cell. The gap junctions are actually active, opening and closing in response to changes in pH, calcium, and, at times, voltage. In addition to ion flow and gap junction resistance, impulse propagation can also be affected by the orientation of fibers and of the collagen matrix in which the fibers reside.",
"   </p>",
"   <p>",
"    \"Fast\" tissues may conduct very slowly - declining from",
"    <span class=\"nowrap\">",
"     meters/sec",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     millimeters/sec",
"    </span>",
"    - in a number of circumstances, resulting in prolongation of the QRS and QT intervals on the surface ECG. These include inactivation of sodium channels induced by hyperkalemia or ischemia-induced acidosis, direct damage to the cells, or the effect of drugs, particularly antiarrhythmic drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Action potential in slow response tissues",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sinoatrial (SA) and atrioventricular (AV) nodes represent slow response tissues, which have different properties from the fast response tissues (",
"    <a class=\"graphic graphic_table graphicRef71831 \" href=\"mobipreview.htm?22/41/23196\">",
"     table 1",
"    </a>",
"    ). Phase 0 depolarization depends on an inward calcium (not sodium) current via L-type calcium channels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38422/abstract/9\">",
"     9",
"    </a>",
"    ]. These channels are selective for calcium, have a slower conduction velocity than the sodium channels, and take longer to reactivate.",
"   </p>",
"   <p>",
"    In some cases, as with tissue damage or changes in the extracellular milieu, fast response tissues can be converted to slow response tissues. In this setting, sodium channels become inactivated and depolarization is dependent upon the slow calcium channels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF ANTIARRHYTHMIC DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The different antiarrhythmic drugs often have several effects on action potential generation and propagation and may also affect the autonomic nervous system. Those drugs that act on ion channels may preferentially influence the activated (open) or inactivated state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38422/abstract/10\">",
"     10",
"    </a>",
"    ]. The classification of antiarrhythmic drugs according to the Harrison modification of the Vaughan-Williams classification assumes that individual drugs have a predominant mechanism of action (",
"    <a class=\"graphic graphic_table graphicRef56600 \" href=\"mobipreview.htm?2/52/2892\">",
"     table 2",
"    </a>",
"    ). This distinction remains clinically useful even though it does not account for complicated electrophysiologic and autonomic interactions that may be present or for the action of certain antiarrhythmic drugs such as digitalis and adenosine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38422/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The modified Vaughan-Williams classification has proven surprisingly useful even though it represents an oversimplification of the electrophysiologic events that occur. The classification appears to work because the multiple factors that influence cardiac excitability are sufficiently coordinated to produce predictable outcomes, rather than unpredictably complex behavior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38422/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. This paradox, called Arnsdorf's paradox, can be explained by the fact that the electrophysiologic universe often seems to move as a single system. Reviewed briefly:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is an electrophysiologic matrix of interacting active (ion channels) and passive (lipid bilayer of the cell membrane, myoplasm, and gap junctions) cellular properties that determine normal cardiac excitability.",
"     </li>",
"     <li>",
"      The normal matrix is altered by arrhythmogenic influences that affect one or more determinants of excitability. The ensuing proarrhythmic state can result in reentrant, automatic, or triggered arrhythmias.",
"     </li>",
"     <li>",
"      The matrix that is deformed by arrhythmogenic factors interacts with antiarrhythmic drugs. Depending upon the matrix encountered, the resulting matrix may be antiarrhythmic, antifibrillatory, or proarrhythmic.",
"     </li>",
"     <li>",
"      Certain arrhythmogenic matrices are common, such as those induced by ischemia or infarction. In this setting, a certain effect of a drug becomes predominant and predictable, as with class I activity in ischemia, and a drug classification appears accurate. However, the major drug effect may be quite different if a different proarrhythmic matrix exists. Consider, for example, the differences in digitalis action in hypokalemia and hyperkalemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Class I",
"    </span>",
"    &nbsp;&mdash;&nbsp;The class I drugs act by modulating or blocking the sodium channels, thereby inhibiting phase 0 depolarization. They are all positively charged and presumably interact with specific amino acid residues in the internal pore of the sodium channel. Three different subgroups have been identified because their mechanism or duration of action is somewhat different due to variable rates of drug binding to and dissociation from the channel receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38422/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The class IC agents have the slowest binding and dissociation from the receptor.",
"     </li>",
"     <li>",
"      The class IB agents have the most rapid binding and dissociation from the receptor.",
"     </li>",
"     <li>",
"      The class IA agents are intermediate in terms of the speed of binding and dissociation from the receptor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During faster heart rates, less time exists for the drug to dissociate from the receptor, resulting in an increased number of blocked channels and enhanced blockade. These pharmacologic effects may cause a progressive decrease in impulse conduction velocity and a widening of the QRS complex. This property is known as \"use-dependence\" and is seen most frequently with the class IC agents, less frequently with the class IA drugs, and rarely with the class IB agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38422/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Class IA drugs (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/49/35607?source=see_link\">",
"       disopyramide",
"      </a>",
"      ) depress phase 0 (sodium-dependent) depolarization, thereby slowing conduction. They also have moderate potassium channel blocking activity (which tends to slow the rate of repolarization and prolong action potential duration [APD]), anticholinergic activity, and tend to depress myocardial contractility. At slower heart rates, when use-dependent blockade of the sodium current is not significant, potassium channel blockade may become predominant (reverse use-dependence), leading to prolongation of the APD and QT interval and increased automaticity.",
"      <br/>",
"      <br/>",
"      One difference between the drugs is that quinidine and procainamide generally decrease vascular resistance, whereas disopyramide increases vascular resistance. In addition, N-acetyl-procainamide (NAPA), a metabolite of procainamide, has little sodium current blocking activity, while retaining potassium current blocking activity. Thus, NAPA behaves like a class III drug. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Class III'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The class IB drugs (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/9/10389?source=see_link\">",
"       mexiletine",
"      </a>",
"      ) have less prominent sodium channel blocking activity at rest, but effectively block the sodium channel in depolarized tissues. They tend to bind in the inactivated state (which is induced by depolarization) and dissociate from the sodium channel more rapidly than other class I drugs. As a result, they are more effective with tachyarrhythmias than with slow arrhythmias.",
"     </li>",
"     <li>",
"      Class IC drugs (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"       flecainide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"       propafenone",
"      </a>",
"      ) primarily block open sodium channels and slow conduction. They dissociate slowly from the sodium channels during diastole, resulting in increased effect at more rapid rate (use-dependence). This characteristic is the basis for their antiarrhythmic efficacy, especially against supraventricular arrhythmias. Use-dependence may also contribute to the proarrhythmic activity of these drugs, especially in the diseased myocardium, resulting in incessant ventricular tachycardia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     Flecainide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    also have potassium channel blocking activity and can increase the APD in ventricular myocytes. Propafenone has significant beta blocking activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Class II",
"    </span>",
"    &nbsp;&mdash;&nbsp;The class II drugs act by inhibiting sympathetic activity, primarily by causing beta blockade. They may also have a mild inhibitory effect on the sodium channels. Sympathetic stimulation has the following potential proarrhythmic actions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38422/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increase in automaticity due to enhancement of phase 4 spontaneous depolarization (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/5/42070?source=see_link\">",
"       \"Enhanced cardiac automaticity\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      An increase in membrane excitability due to shortening in refractoriness (phases 2 and 3 of the action potential)",
"     </li>",
"     <li>",
"      An increase in the rate of impulse conduction through the myocardial membrane resulting from acceleration of phase 0 upstroke velocity or the rate of membrane depolarization",
"     </li>",
"     <li>",
"      An increase in delayed afterpotentials, especially when the cell is calcium loaded",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By blocking catecholamine and sympathetically mediated actions, beta blockers slow the rate of discharge of the sinus and ectopic pacemakers and increase the effective refractory period of the atrioventricular node. They also slow both antegrade and retrograde conduction in anomalous pathways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38422/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     Carvedilol",
"    </a>",
"    is a beta-blocker with unique additional properties. In addition to beta- and alpha-adrenergic blockade, carvedilol can also block potassium (HERG), calcium, and sodium currents and modestly prolong APD. However, when administered chronically, carvedilol increases the number of these channels, which is probably a favorable effect in diseased hearts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38422/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Class III",
"    </span>",
"    &nbsp;&mdash;&nbsp;The class III drugs (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , vernakalant, and azimilide) block the potassium channels to inhibit I(KR), I(KS), I(K1), and I(KUR), thereby prolonging repolarization, the APD, and the refractory period. The relative potency of these drugs for specific potassium currents may account for atrial selectivity, for example I(KUR) predominates in atria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38422/abstract/16\">",
"     16",
"    </a>",
"    ]. Block of ventricular potassium currents is manifested on the surface ECG by prolongation of the QT interval, providing the substrate for torsades de pointes, a polymorphic ventricular tachycardia. Amiodarone and dronedarone are exceptions with very little proarrhythmic activity, perhaps because of a balance of offsetting actions, and vernakalant blocks, primarily atrial I(KUR).",
"   </p>",
"   <p>",
"    These drugs also have other antiarrhythmic effects.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"       Sotalol",
"      </a>",
"      has beta blocking activity. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/10/28841?source=see_link\">",
"       \"Therapeutic use and major side effects of sotalol\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/3/5176?source=see_link\">",
"       dronedarone",
"      </a>",
"      block sodium channels in depolarized tissues (a Class Ib effect) and also block calcium channels, potassium channels, and adrenergic receptors. Amiodarone also has thyroid effects that dronedarone, an amiodarone derivative without the iodine moiety, lacks. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38857?source=see_link\">",
"       \"Clinical uses of amiodarone\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/28/12745?source=see_link\">",
"       \"Clinical uses of dronedarone\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25065?source=see_link\">",
"       \"Amiodarone and thyroid dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"       Ibutilide",
"      </a>",
"      , which is approved for the acute termination of atrial flutter and atrial fibrillation, prolongs the QT interval by enhancing the slow, delayed inward sodium current as well as blocking potassium channels during repolarization. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/11/40118?source=see_link\">",
"       \"Therapeutic use of ibutilide\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some of the class III agents, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    , exhibit",
"    <strong>",
"     reverse",
"    </strong>",
"    use-dependent effects on repolarization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38422/abstract/17\">",
"     17",
"    </a>",
"    ]. This pharmacologic property is characterized by prolongation of repolarization and the refractory period during slower heart rates, effects that are less obvious at higher heart rates. Thus, the QT interval is longer at slower heart rates and decreases as the heart rate increases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Class IV",
"    </span>",
"    &nbsp;&mdash;&nbsp;The class IV drugs are calcium channel blockers.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     Verapamil",
"    </a>",
"    has a more pronounced inhibitory effect on the slow response SA and AV nodes than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    . In comparison, the dihydropyridines, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    , have little electrophysiologic effect on the heart. Verapamil and diltiazem can slow the sinus rate (usually in the presence of the sick sinus syndrome or beta blockade), increase the refractoriness of and prolong conduction through the AV node, occasionally prolong the PR interval, and depress left ventricular function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1761920864\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antiarrhythmic drugs target ion channels and receptors in the heart, generally blocking or inhibiting function. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Cardiac excitability'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although antiarrhythmic drugs are generally classified in the Vaughan Williams scheme (",
"      <a class=\"graphic graphic_table graphicRef56600 \" href=\"mobipreview.htm?2/52/2892\">",
"       table 2",
"      </a>",
"      ) by their predominant action and target, all clinically used drugs act on multiple targets. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Classification of antiarrhythmic drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The multiple electrophysiologic actions of antiarrhythmic drugs interacting with the variable underlying substrate present in each patient determine whether the clinical effect will be proarrhythmic or antiarrhythmic. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Classification of antiarrhythmic drugs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38422/abstract/1\">",
"      Arnsdorf MF. The cellular basis of cardiac arrhythmias. A matrical perspective. Ann N Y Acad Sci 1990; 601:263.",
"     </a>",
"    </li>",
"    <li>",
"     Fozzard HA, Arnsdor MF. Cardiac electrophysiology. In: The Heart and Cardiovascular System, Fozzard HA, Haber E, Jennings A, et al (Eds), Raven Press, New York 1991. p.63.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38422/abstract/3\">",
"      Grant AO. Cardiac Ion Channels. Circ Arrythm Electrophysiol 2009; 2:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38422/abstract/4\">",
"      Catterall WA. Structure and function of voltage-sensitive ion channels. Science 1988; 242:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38422/abstract/5\">",
"      St&uuml;hmer W, Conti F, Suzuki H, et al. Structural parts involved in activation and inactivation of the sodium channel. Nature 1989; 339:597.",
"     </a>",
"    </li>",
"    <li>",
"     Fozzard HA, Danck DA. Sodium channels. In: The Heart and Cardiovascular System, Fozzard HA, Haber E, Jennings A, et al (Eds), Raven Press, New York 1991. p.1091.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38422/abstract/7\">",
"      The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. Circulation 1991; 84:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38422/abstract/8\">",
"      Liu DW, Gintant GA, Antzelevitch C. Ionic bases for electrophysiological distinctions among epicardial, midmyocardial, and endocardial myocytes from the free wall of the canine left ventricle. Circ Res 1993; 72:671.",
"     </a>",
"    </li>",
"    <li>",
"     Pelzer D, Pelzer S, McDonald TF. Calcium channels in heart. In: The Heart and Cardiovascular System,, Fozzard HA, Haber E, Jennings A, et al (Eds), Raven Press, New York1 991. p.1049.",
"    </li>",
"    <li>",
"     Snyders DJ, Hondeghem LM, Bennett PB. Mechanisms of drug-channel interaction. In: The Heart and Cardiovascular System, Fozzard HA, Haber E, Jennings A, et al (Eds), Raven Press, New York 1991. p.2165.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38422/abstract/11\">",
"      Arnsdorf MF. Arnsdorf's paradox. J Cardiovasc Electrophysiol 1990; 1:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38422/abstract/12\">",
"      Arnsdorf MF. Cardiac excitability, the electrophysiologic matrix and electrically induced ventricular arrhythmias: order and reproducibility in seeming electrophysiologic chaos. J Am Coll Cardiol 1991; 17:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38422/abstract/13\">",
"      Hondeghem LM, Katzung BG. Antiarrhythmic agents: the modulated receptor mechanism of action of sodium and calcium channel-blocking drugs. Annu Rev Pharmacol Toxicol 1984; 24:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38422/abstract/14\">",
"      Podrid PJ, Fuchs T, Candinas R. Role of the sympathetic nervous system in the genesis of ventricular arrhythmia. Circulation 1990; 82:I103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38422/abstract/15\">",
"      Frishman W, Silverman R. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 2. Physiologic and metabolic effects. Am Heart J 1979; 97:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38422/abstract/16\">",
"      Naccarelli GV, Lukas MA. Carvedilol's antiarrhythmic properties: therapeutic implications in patients with left ventricular dysfunction. Clin Cardiol 2005; 28:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38422/abstract/17\">",
"      Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation 1990; 81:686.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 895 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-1.234.2.38-35693F307E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_33_38422=[""].join("\n");
var outline_f37_33_38422=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1761920864\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      CARDIAC EXCITABILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Cardiac ion channels and currents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      The resting potential",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Action potential in fast response tissues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Impulse propagation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Action potential in slow response tissues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLASSIFICATION OF ANTIARRHYTHMIC DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Class I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Class II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Class III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Class IV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1761920864\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/895\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/895|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/59/20401\" title=\"figure 1\">",
"      Action potential currents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/55/16253\" title=\"figure 2\">",
"      Myocardial action potential",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/63/35827\" title=\"figure 3\">",
"      Conduction system action potentials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/895|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?31/46/32481\" title=\"movie 1\">",
"      Generation of the myocardial action potential",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/895|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/41/23196\" title=\"table 1\">",
"      Fast v slow conduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/52/2892\" title=\"table 2\">",
"      Vaughan Williams classification of antiarrhythmic drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25065?source=related_link\">",
"      Amiodarone and thyroid dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28250?source=related_link\">",
"      Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38857?source=related_link\">",
"      Clinical uses of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/28/12745?source=related_link\">",
"      Clinical uses of dronedarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/5/42070?source=related_link\">",
"      Enhanced cardiac automaticity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32007?source=related_link\">",
"      Etiology of atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/0/28681?source=related_link\">",
"      Genetics of congenital and acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/10/28841?source=related_link\">",
"      Therapeutic use and major side effects of sotalol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/11/40118?source=related_link\">",
"      Therapeutic use of ibutilide",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_33_38423="Miliary tuberculosis - low power";
var content_f37_33_38423=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66594&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66594&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Miliary tuberculosis involving the liver in a 63-year-old man (low power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There are two noncaseating granulomas in the parenchyma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_33_38423=[""].join("\n");
var outline_f37_33_38423=null;
var title_f37_33_38424="Normal reference ranges in pregnant women";
var content_f37_33_38424=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81137&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81137&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Normal reference ranges in pregnant women",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Nonpregnant adult*",
"       </td>",
"       <td class=\"subtitle1\">",
"        First trimester",
"       </td>",
"       <td class=\"subtitle1\">",
"        Second trimester",
"       </td>",
"       <td class=\"subtitle1\">",
"        Third trimester",
"       </td>",
"       <td class=\"subtitle1\">",
"        References",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Hematology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Erythropoietin",
"        <sup>",
"         &bull;",
"        </sup>",
"        (U/L)",
"       </td>",
"       <td>",
"        4-27",
"       </td>",
"       <td>",
"        12-25",
"       </td>",
"       <td>",
"        8-67",
"       </td>",
"       <td>",
"        14-222",
"       </td>",
"       <td>",
"        1-3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ferritin",
"        <sup>",
"         &bull;",
"        </sup>",
"        (ng/mL)",
"       </td>",
"       <td>",
"        10-150",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        6-130",
"       </td>",
"       <td>",
"        2-230",
"       </td>",
"       <td>",
"        0-116",
"       </td>",
"       <td>",
"        1-8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Folate, red blood cell (ng/mL)",
"       </td>",
"       <td>",
"        150-450",
"       </td>",
"       <td>",
"        137-589",
"       </td>",
"       <td>",
"        94-828",
"       </td>",
"       <td>",
"        109-663",
"       </td>",
"       <td>",
"        6, 9, 10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Folate, serum (ng/mL)",
"       </td>",
"       <td>",
"        5.4-18.0",
"       </td>",
"       <td>",
"        2.6-15.0",
"       </td>",
"       <td>",
"        0.8-24.0",
"       </td>",
"       <td>",
"        1.4-20.7",
"       </td>",
"       <td>",
"        1, 6, 9-13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hemoglobin",
"        <sup>",
"         &bull;",
"        </sup>",
"        (g/dL)",
"       </td>",
"       <td>",
"        12-15.8",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        11.6-13.9",
"       </td>",
"       <td>",
"        9.7-14.8",
"       </td>",
"       <td>",
"        9.5-15.0",
"       </td>",
"       <td>",
"        2, 3, 6, 7, 13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hematocrit",
"        <sup>",
"         &bull;",
"        </sup>",
"        (percent)",
"       </td>",
"       <td>",
"        35.4-44.4",
"       </td>",
"       <td>",
"        31.0-41.0",
"       </td>",
"       <td>",
"        30.0-39.0",
"       </td>",
"       <td>",
"        28.0-40.0",
"       </td>",
"       <td>",
"        1, 2, 5, 6, 13-15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Iron, total binding capacity",
"        <sup>",
"         &bull;",
"        </sup>",
"        (&micro;g/dL)",
"       </td>",
"       <td>",
"        251-406",
"       </td>",
"       <td>",
"        278-403",
"       </td>",
"       <td>",
"        Not reported",
"       </td>",
"       <td>",
"        359-609",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Iron, serum",
"        <sup>",
"         &bull;",
"        </sup>",
"        (&micro;g/dL)",
"       </td>",
"       <td>",
"        41-141",
"       </td>",
"       <td>",
"        72-143",
"       </td>",
"       <td>",
"        44-178",
"       </td>",
"       <td>",
"        30-193",
"       </td>",
"       <td>",
"        2, 7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mean corpuscular hemoglobin (pg/cell)",
"       </td>",
"       <td>",
"        27-32",
"       </td>",
"       <td>",
"        30-32",
"       </td>",
"       <td>",
"        30-33",
"       </td>",
"       <td>",
"        29-32",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mean corpuscular volume (xm",
"        <sup>",
"         3",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        79-93",
"       </td>",
"       <td>",
"        81-96",
"       </td>",
"       <td>",
"        82-97",
"       </td>",
"       <td>",
"        81-99",
"       </td>",
"       <td>",
"        5, 6, 13, 14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Platelet (x10",
"        <sup>",
"         9",
"        </sup>",
"        /L)",
"       </td>",
"       <td>",
"        165-415",
"       </td>",
"       <td>",
"        174-391",
"       </td>",
"       <td>",
"        155-409",
"       </td>",
"       <td>",
"        146-429",
"       </td>",
"       <td>",
"        5, 6, 14, 16, 17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mean platelet volume (&micro;m",
"        <sup>",
"         3",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        6.4-11.0",
"       </td>",
"       <td>",
"        7.7-10.3",
"       </td>",
"       <td>",
"        7.8-10.2",
"       </td>",
"       <td>",
"        8.2-10.4",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Red blood cell count (x10",
"        <sup>",
"         6",
"        </sup>",
"        /mm",
"        <sup>",
"         3",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        4.00-5.20",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        3.42-4.55",
"       </td>",
"       <td>",
"        2.81-4.49",
"       </td>",
"       <td>",
"        2.71-4.43",
"       </td>",
"       <td>",
"        5, 6, 13, 14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Red cell distribution width (percent)",
"       </td>",
"       <td>",
"        &lt;14.5",
"       </td>",
"       <td>",
"        12.5-14.1",
"       </td>",
"       <td>",
"        13.4-13.6",
"       </td>",
"       <td>",
"        12.7-15.3",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        White blood cell count (x10",
"        <sup>",
"         3",
"        </sup>",
"        /mm",
"        <sup>",
"         3",
"        </sup>",
"        )",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        3.5-9.1",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        5.7-13.6",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        5.6-14.8",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        5.9-16.9",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        5, 6, 13, 14, 18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Neutrophils (x10",
"        <sup>",
"         3",
"        </sup>",
"        /mm",
"        <sup>",
"         3",
"        </sup>",
"        )",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.4-4.6",
"       </td>",
"       <td class=\"sublist_other\">",
"        3.6-10.1",
"       </td>",
"       <td class=\"sublist_other\">",
"        3.8-12.3",
"       </td>",
"       <td class=\"sublist_other\">",
"        3.9-13.1",
"       </td>",
"       <td class=\"sublist_other\">",
"        5, 14, 16, 18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Lymphocytes (x10",
"        <sup>",
"         3",
"        </sup>",
"        /mm",
"        <sup>",
"         3",
"        </sup>",
"        )",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.7-4.6",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.1-3.6",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.9-3.9",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.0-3.6",
"       </td>",
"       <td class=\"sublist_other\">",
"        5, 14, 16, 18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Monocytes (x10",
"        <sup>",
"         3",
"        </sup>",
"        /mm",
"        <sup>",
"         3",
"        </sup>",
"        )",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.1-0.7",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.1-1.1",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.1-1.1",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.1-1.4",
"       </td>",
"       <td class=\"sublist_other\">",
"        5, 14, 18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Eosinophils (x10",
"        <sup>",
"         3",
"        </sup>",
"        /mm",
"        <sup>",
"         3",
"        </sup>",
"        )",
"       </td>",
"       <td class=\"sublist_other\">",
"        0-0.6",
"       </td>",
"       <td class=\"sublist_other\">",
"        0-0.6",
"       </td>",
"       <td class=\"sublist_other\">",
"        0-0.6",
"       </td>",
"       <td class=\"sublist_other\">",
"        0-0.6",
"       </td>",
"       <td class=\"sublist_other\">",
"        14, 18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Basophils (x10",
"        <sup>",
"         3",
"        </sup>",
"        /mm",
"        <sup>",
"         3",
"        </sup>",
"        )",
"       </td>",
"       <td class=\"sublist_other\">",
"        0-0.2",
"       </td>",
"       <td class=\"sublist_other\">",
"        0-0.1",
"       </td>",
"       <td class=\"sublist_other\">",
"        0-0.1",
"       </td>",
"       <td class=\"sublist_other\">",
"        0-0.1",
"       </td>",
"       <td class=\"sublist_other\">",
"        14, 18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Transferrin (mg/dL)",
"       </td>",
"       <td>",
"        200-400",
"       </td>",
"       <td>",
"        254-344",
"       </td>",
"       <td>",
"        220-441",
"       </td>",
"       <td>",
"        288-530",
"       </td>",
"       <td>",
"        4, 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Transferrin, saturation without iron (percent)",
"       </td>",
"       <td>",
"        22-46",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Not reported",
"       </td>",
"       <td>",
"        10-44",
"       </td>",
"       <td>",
"        5-37",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Transferrin, saturation with iron (percent)",
"       </td>",
"       <td>",
"        22-46",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Not reported",
"       </td>",
"       <td>",
"        18-92",
"       </td>",
"       <td>",
"        9-98",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Coagulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Antithrombin III, functional (percent)",
"       </td>",
"       <td>",
"        70-130",
"       </td>",
"       <td>",
"        89-114",
"       </td>",
"       <td>",
"        78-126",
"       </td>",
"       <td>",
"        82-116",
"       </td>",
"       <td>",
"        17, 19, 20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        D-dimer (&micro;g/mL)",
"       </td>",
"       <td>",
"        0.22-0.74",
"       </td>",
"       <td>",
"        0.05-0.95",
"       </td>",
"       <td>",
"        0.32-1.29",
"       </td>",
"       <td>",
"        0.13-1.7",
"       </td>",
"       <td>",
"        17, 20-24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Factor V (percent)",
"       </td>",
"       <td>",
"        50-150",
"       </td>",
"       <td>",
"        75-95",
"       </td>",
"       <td>",
"        72-96",
"       </td>",
"       <td>",
"        60-88",
"       </td>",
"       <td>",
"        25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Factor VII (percent)",
"       </td>",
"       <td>",
"        50-150",
"       </td>",
"       <td>",
"        100-146",
"       </td>",
"       <td>",
"        95-153",
"       </td>",
"       <td>",
"        149-211",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Factor VIII (percent)",
"       </td>",
"       <td>",
"        50-150",
"       </td>",
"       <td>",
"        90-210",
"       </td>",
"       <td>",
"        97-312",
"       </td>",
"       <td>",
"        143-353",
"       </td>",
"       <td>",
"        17, 25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Factor IX (percent)",
"       </td>",
"       <td>",
"        50-150",
"       </td>",
"       <td>",
"        103-172",
"       </td>",
"       <td>",
"        154-217",
"       </td>",
"       <td>",
"        164-235",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Factor XI (percent)",
"       </td>",
"       <td>",
"        50-150",
"       </td>",
"       <td>",
"        80-127",
"       </td>",
"       <td>",
"        82-144",
"       </td>",
"       <td>",
"        65-123",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Factor XII (percent)",
"       </td>",
"       <td>",
"        50-150",
"       </td>",
"       <td>",
"        78-124",
"       </td>",
"       <td>",
"        90-151",
"       </td>",
"       <td>",
"        129-194",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fibrinogen (mg/dL)",
"       </td>",
"       <td>",
"        233-496",
"       </td>",
"       <td>",
"        244-510",
"       </td>",
"       <td>",
"        291-538",
"       </td>",
"       <td>",
"        301-696",
"       </td>",
"       <td>",
"        5, 17, 20, 21, 23, 24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Homocysteine (&micro;mol/L)",
"       </td>",
"       <td>",
"        4.4-10.8",
"       </td>",
"       <td>",
"        3.34-11",
"       </td>",
"       <td>",
"        2.0-26.9",
"       </td>",
"       <td>",
"        3.2-21.4",
"       </td>",
"       <td>",
"        6, 9, 10-12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        International Normalized Ratio",
"       </td>",
"       <td>",
"        0.9-1.04",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        0.86-1.08",
"       </td>",
"       <td>",
"        0.83-1.02",
"       </td>",
"       <td>",
"        0.80-1.09",
"       </td>",
"       <td>",
"        19, 24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Partial thromboplastin time, activated (sec)",
"       </td>",
"       <td>",
"        26.3-39.4",
"       </td>",
"       <td>",
"        23.0-38.9",
"       </td>",
"       <td>",
"        22.9-38.1",
"       </td>",
"       <td>",
"        22.6-35.0",
"       </td>",
"       <td>",
"        5, 17, 19, 24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prothrombin time (sec)",
"       </td>",
"       <td>",
"        12.7-15.4",
"       </td>",
"       <td>",
"        9.7-13.5",
"       </td>",
"       <td>",
"        9.5-13.4",
"       </td>",
"       <td>",
"        9.6-12.9",
"       </td>",
"       <td>",
"        5, 17, 24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Protein C, functional (percent)",
"       </td>",
"       <td>",
"        70-130",
"       </td>",
"       <td>",
"        78-121",
"       </td>",
"       <td>",
"        83-133",
"       </td>",
"       <td>",
"        67-135",
"       </td>",
"       <td>",
"        19, 25, 26",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Protein S, total (percent)",
"       </td>",
"       <td>",
"        70-140",
"       </td>",
"       <td>",
"        39-105",
"       </td>",
"       <td>",
"        27-101",
"       </td>",
"       <td>",
"        33-101",
"       </td>",
"       <td>",
"        17, 25, 26",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Protein S, free (percent)",
"       </td>",
"       <td>",
"        70-140",
"       </td>",
"       <td>",
"        34-133",
"       </td>",
"       <td>",
"        19-113",
"       </td>",
"       <td>",
"        20-65",
"       </td>",
"       <td>",
"        25, 26",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Protein S, functional activity (percent)",
"       </td>",
"       <td>",
"        65-140",
"       </td>",
"       <td>",
"        57-95",
"       </td>",
"       <td>",
"        42-68",
"       </td>",
"       <td>",
"        16-42",
"       </td>",
"       <td>",
"        25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tissue plasminogen activator (ng/mL)",
"       </td>",
"       <td>",
"        1.6-13",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        1.8-6.0",
"       </td>",
"       <td>",
"        2.36-6.6",
"       </td>",
"       <td>",
"        3.34-9.20",
"       </td>",
"       <td>",
"        17, 19",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Tissue plasminogen activator inhibitor-1 (ng/mL)",
"       </td>",
"       <td>",
"        4-43",
"       </td>",
"       <td>",
"        16-33",
"       </td>",
"       <td>",
"        36-55",
"       </td>",
"       <td>",
"        67-92",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        von Willebrand measurements",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        von Willebrand factor antigen (percent)",
"       </td>",
"       <td>",
"        75-125",
"       </td>",
"       <td>",
"        62-318",
"       </td>",
"       <td>",
"        90-247",
"       </td>",
"       <td>",
"        84-422",
"       </td>",
"       <td>",
"        20, 27, 28",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        ADAMTS-13, von Willebrand cleaving protease",
"       </td>",
"       <td>",
"        40-170",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        40-160",
"       </td>",
"       <td>",
"        22-135",
"       </td>",
"       <td>",
"        38-105",
"       </td>",
"       <td>",
"        20, 28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Blood chemical constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alanine transaminase (U/L)",
"       </td>",
"       <td>",
"        7-41",
"       </td>",
"       <td>",
"        3-30",
"       </td>",
"       <td>",
"        2-33",
"       </td>",
"       <td>",
"        2-25",
"       </td>",
"       <td>",
"        4, 5, 8, 29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Albumin (g/dL)",
"       </td>",
"       <td>",
"        4.1-5.3",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        3.1-5.1",
"       </td>",
"       <td>",
"        2.6-4.5",
"       </td>",
"       <td>",
"        2.3-4.2",
"       </td>",
"       <td>",
"        29-32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alkaline phosphatase (U/L)",
"       </td>",
"       <td>",
"        33-96",
"       </td>",
"       <td>",
"        17-88",
"       </td>",
"       <td>",
"        25-126",
"       </td>",
"       <td>",
"        38-229",
"       </td>",
"       <td>",
"        4, 5, 8, 29, 30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alpha-1 antitrypsin (mg/dL)",
"       </td>",
"       <td>",
"        100-200",
"       </td>",
"       <td>",
"        225-323",
"       </td>",
"       <td>",
"        273-391",
"       </td>",
"       <td>",
"        327-487",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amylase (U/L)",
"       </td>",
"       <td>",
"        20-96",
"       </td>",
"       <td>",
"        24-83",
"       </td>",
"       <td>",
"        16-73",
"       </td>",
"       <td>",
"        15-81",
"       </td>",
"       <td>",
"        4, 5, 33, 34",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anion gap (mmol/L)",
"       </td>",
"       <td>",
"        7-16",
"       </td>",
"       <td>",
"        13-17",
"       </td>",
"       <td>",
"        12-16",
"       </td>",
"       <td>",
"        12-16",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aspartate transaminase (U/L)",
"       </td>",
"       <td>",
"        12-38",
"       </td>",
"       <td>",
"        3-23",
"       </td>",
"       <td>",
"        3-33",
"       </td>",
"       <td>",
"        4-32",
"       </td>",
"       <td>",
"        4, 5, 8, 29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bicarbonate (mmol/L)",
"       </td>",
"       <td>",
"        22-30",
"       </td>",
"       <td>",
"        20-24",
"       </td>",
"       <td>",
"        20-24",
"       </td>",
"       <td>",
"        20-24",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bilirubin, total (mg/dL)",
"       </td>",
"       <td>",
"        0.3-1.3",
"       </td>",
"       <td>",
"        0.1-0.4",
"       </td>",
"       <td>",
"        0.1-0.8",
"       </td>",
"       <td>",
"        0.1-1.1",
"       </td>",
"       <td>",
"        4, 29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bilirubin, unconjugated (mg/dL)",
"       </td>",
"       <td>",
"        0.2-0.9",
"       </td>",
"       <td>",
"        0.1-0.5",
"       </td>",
"       <td>",
"        0.1-0.4",
"       </td>",
"       <td>",
"        0.1-0.5",
"       </td>",
"       <td>",
"        5, 29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bilirubin, conjugated (mg/dL)",
"       </td>",
"       <td>",
"        0.1-0.4",
"       </td>",
"       <td>",
"        0-0.1",
"       </td>",
"       <td>",
"        0-0.1",
"       </td>",
"       <td>",
"        0-0.1",
"       </td>",
"       <td>",
"        29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bile acids (&micro;mol/L)",
"       </td>",
"       <td>",
"        0.3-4.8",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        0-4.9",
"       </td>",
"       <td>",
"        0-9.1",
"       </td>",
"       <td>",
"        0-11.3",
"       </td>",
"       <td>",
"        29, 35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Calcium, ionized (mg/dL)",
"       </td>",
"       <td>",
"        4.5-5.3",
"       </td>",
"       <td>",
"        4.5-5.1",
"       </td>",
"       <td>",
"        4.4-5.0",
"       </td>",
"       <td>",
"        4.4-5.3",
"       </td>",
"       <td>",
"        5, 31, 36, 37",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Calcium, total (mg/dL)",
"       </td>",
"       <td>",
"        8.7-10.2",
"       </td>",
"       <td>",
"        8.8-10.6",
"       </td>",
"       <td>",
"        8.2-9.0",
"       </td>",
"       <td>",
"        8.2-9.7",
"       </td>",
"       <td>",
"        4, 5, 30, 32, 36-38",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ceruloplasmin (mg/dL)",
"       </td>",
"       <td>",
"        25-63",
"       </td>",
"       <td>",
"        30-49",
"       </td>",
"       <td>",
"        40-53",
"       </td>",
"       <td>",
"        43-78",
"       </td>",
"       <td>",
"        5, 39",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chloride (mEq/L)",
"       </td>",
"       <td>",
"        102-109",
"       </td>",
"       <td>",
"        101-105",
"       </td>",
"       <td>",
"        97-109",
"       </td>",
"       <td>",
"        97-109",
"       </td>",
"       <td>",
"        4, 5, 40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Creatinine (mg/dL)",
"       </td>",
"       <td>",
"        0.5-0.9",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.4-0.7",
"       </td>",
"       <td>",
"        0.4-0.8",
"       </td>",
"       <td>",
"        0.4-0.9",
"       </td>",
"       <td>",
"        4, 5, 46",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gamma-glutamyl transpeptidase (U/L)",
"       </td>",
"       <td>",
"        9-58",
"       </td>",
"       <td>",
"        2-23",
"       </td>",
"       <td>",
"        4-22",
"       </td>",
"       <td>",
"        3-26",
"       </td>",
"       <td>",
"        4, 5, 8, 29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lactate dehydrogenase (U/L)",
"       </td>",
"       <td>",
"        115-221",
"       </td>",
"       <td>",
"        78-433",
"       </td>",
"       <td>",
"        80-447",
"       </td>",
"       <td>",
"        82-524",
"       </td>",
"       <td>",
"        4, 5, 32, 8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lipase (U/L)",
"       </td>",
"       <td>",
"        3-43",
"       </td>",
"       <td>",
"        21-76",
"       </td>",
"       <td>",
"        26-100",
"       </td>",
"       <td>",
"        41-112",
"       </td>",
"       <td>",
"        33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Magnesium (mg/dL)",
"       </td>",
"       <td>",
"        1.5-2.3",
"       </td>",
"       <td>",
"        1.6-2.2",
"       </td>",
"       <td>",
"        1.5-2.2",
"       </td>",
"       <td>",
"        1.1-2.2",
"       </td>",
"       <td>",
"        4, 5, 30-32, 36, 38",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Osmolality (mOsm/kg H20)",
"       </td>",
"       <td>",
"        275-295",
"       </td>",
"       <td>",
"        275-280",
"       </td>",
"       <td>",
"        276-289",
"       </td>",
"       <td>",
"        278-280",
"       </td>",
"       <td>",
"        38, 41",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Phosphate (mg/dL)",
"       </td>",
"       <td>",
"        2.5-4.3",
"       </td>",
"       <td>",
"        3.1-4.6",
"       </td>",
"       <td>",
"        2.5-4.6",
"       </td>",
"       <td>",
"        2.8-4.6",
"       </td>",
"       <td>",
"        4, 5, 30, 31, 42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Potassium (mEq/L)",
"       </td>",
"       <td>",
"        3.5-5.0",
"       </td>",
"       <td>",
"        3.6-5.0",
"       </td>",
"       <td>",
"        3.3-5.0",
"       </td>",
"       <td>",
"        3.3-5.1",
"       </td>",
"       <td>",
"        4, 5, 15, 31, 32, 38, 40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prealbumin (mg/dL)",
"       </td>",
"       <td>",
"        17-34",
"       </td>",
"       <td>",
"        15-27",
"       </td>",
"       <td>",
"        20-27",
"       </td>",
"       <td>",
"        14-23",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Protein, total (g/dL)",
"       </td>",
"       <td>",
"        6.7-8.6",
"       </td>",
"       <td>",
"        6.2-7.6",
"       </td>",
"       <td>",
"        5.7-6.9",
"       </td>",
"       <td>",
"        5.6-6.7",
"       </td>",
"       <td>",
"        5, 31, 32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sodium (mEq/L)",
"       </td>",
"       <td>",
"        136-146",
"       </td>",
"       <td>",
"        133-148",
"       </td>",
"       <td>",
"        129-148",
"       </td>",
"       <td>",
"        130-148",
"       </td>",
"       <td>",
"        4, 5, 15, 31, 32, 38, 41",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Urea nitrogen (mg/dL)",
"       </td>",
"       <td>",
"        7-20",
"       </td>",
"       <td>",
"        7-12",
"       </td>",
"       <td>",
"        3-13",
"       </td>",
"       <td>",
"        3-11",
"       </td>",
"       <td>",
"        4, 5, 40",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Uric acid (mg/dL)",
"       </td>",
"       <td>",
"        2.5-5.6",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        2.0-4.2",
"       </td>",
"       <td>",
"        2.4-4.9",
"       </td>",
"       <td>",
"        3.1-6.3",
"       </td>",
"       <td>",
"        4, 5, 41",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Metabolic and endocrine tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aldosterone (ng/dL)",
"       </td>",
"       <td>",
"        2-9",
"       </td>",
"       <td>",
"        6-104",
"       </td>",
"       <td>",
"        9-104",
"       </td>",
"       <td>",
"        15-101",
"       </td>",
"       <td>",
"        43, 44, 45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Angiotensin converting enzyme (U/L)",
"       </td>",
"       <td>",
"        9-67",
"       </td>",
"       <td>",
"        1-38",
"       </td>",
"       <td>",
"        1-36",
"       </td>",
"       <td>",
"        1-39",
"       </td>",
"       <td>",
"        39, 46",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alpha-fetoprotein (ng/mL)",
"       </td>",
"       <td>",
"        0-8.5",
"       </td>",
"       <td>",
"        Not reported",
"       </td>",
"       <td>",
"        50-425",
"       </td>",
"       <td>",
"        50-590",
"       </td>",
"       <td>",
"        84, 86",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cortisol (&micro;g/dL)",
"       </td>",
"       <td>",
"        0-25",
"       </td>",
"       <td>",
"        7-19",
"       </td>",
"       <td>",
"        10-42",
"       </td>",
"       <td>",
"        12-50",
"       </td>",
"       <td>",
"        5, 45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hemoglobin A",
"        <sub>",
"         1C",
"        </sub>",
"        (percent)",
"       </td>",
"       <td>",
"        4-6",
"       </td>",
"       <td>",
"        4-6",
"       </td>",
"       <td>",
"        4-6",
"       </td>",
"       <td>",
"        4-7",
"       </td>",
"       <td>",
"        36, 47, 48",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Parathyroid hormone (pg/mL)",
"       </td>",
"       <td>",
"        8-51",
"       </td>",
"       <td>",
"        10-15",
"       </td>",
"       <td>",
"        18-25",
"       </td>",
"       <td>",
"        9-26",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Parathyroid hormone-related protein (pmol/L)",
"       </td>",
"       <td>",
"        &lt;1.3",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        0.7-0.9",
"       </td>",
"       <td>",
"        1.8-2.2",
"       </td>",
"       <td>",
"        2.5-2.8",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Renin, plasma activity (ng/mL/h)",
"       </td>",
"       <td>",
"        0.3-9.0",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        Not reported",
"       </td>",
"       <td>",
"        7.5-54.0",
"       </td>",
"       <td>",
"        5.9-58.8",
"       </td>",
"       <td>",
"        40, 44",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        <p>",
"         Thyroid-stimulating hormone (&micro;IU/mL)",
"        </p>",
"        <p>",
"         [American Thyroid Association recommendation]**",
"        </p>",
"       </td>",
"       <td rowspan=\"2\">",
"        0.34-4.25",
"       </td>",
"       <td>",
"        0.60-3.40",
"       </td>",
"       <td>",
"        0.37-3.60",
"       </td>",
"       <td>",
"        0.38-4.04",
"       </td>",
"       <td>",
"        4, 5, 49",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.1-2.5",
"       </td>",
"       <td>",
"        0.2-3.0",
"       </td>",
"       <td>",
"        0.3-3.0",
"       </td>",
"       <td>",
"        85",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Thyroxine-binding globulin (mg/dL)",
"       </td>",
"       <td>",
"        1.3-3.0",
"       </td>",
"       <td>",
"        1.8-3.2",
"       </td>",
"       <td>",
"        2.8-4.0",
"       </td>",
"       <td>",
"        2.6-4.2",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Thyroxine, free (ng/dL)",
"       </td>",
"       <td>",
"        0.8-1.7",
"       </td>",
"       <td>",
"        0.8-1.2",
"       </td>",
"       <td>",
"        0.6-1.0",
"       </td>",
"       <td>",
"        0.5-0.8",
"       </td>",
"       <td>",
"        5, 49",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Thyroxine, total (&micro;g/dL)",
"       </td>",
"       <td>",
"        5.4-11.7",
"       </td>",
"       <td>",
"        6.5-10.1",
"       </td>",
"       <td>",
"        7.5-10.3",
"       </td>",
"       <td>",
"        6.3-9.7",
"       </td>",
"       <td>",
"        5, 32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Triiodothyronine, free (pg/mL)",
"       </td>",
"       <td>",
"        2.4-4.2",
"       </td>",
"       <td>",
"        4.1-4.4",
"       </td>",
"       <td>",
"        4.0-4.2",
"       </td>",
"       <td>",
"        Not reported",
"       </td>",
"       <td>",
"        49",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Triiodothyronine, total (ng/dL)",
"       </td>",
"       <td>",
"        77-135",
"       </td>",
"       <td>",
"        97-149",
"       </td>",
"       <td>",
"        117-169",
"       </td>",
"       <td>",
"        123-162",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Vitamins and minerals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Copper (&micro;g/dL)",
"       </td>",
"       <td>",
"        70-140",
"       </td>",
"       <td>",
"        112-199",
"       </td>",
"       <td>",
"        165-221",
"       </td>",
"       <td>",
"        130-240",
"       </td>",
"       <td>",
"        50, 51, 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Selenium (&micro;g/L)",
"       </td>",
"       <td>",
"        63-160",
"       </td>",
"       <td>",
"        116-146",
"       </td>",
"       <td>",
"        75-145",
"       </td>",
"       <td>",
"        71-133",
"       </td>",
"       <td>",
"        5, 50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin A (retinol) (&micro;g/dL)",
"       </td>",
"       <td>",
"        20-100",
"       </td>",
"       <td>",
"        32-47",
"       </td>",
"       <td>",
"        35-44",
"       </td>",
"       <td>",
"        29-42",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin B12 (pg/mL)",
"       </td>",
"       <td>",
"        279-966",
"       </td>",
"       <td>",
"        118-438",
"       </td>",
"       <td>",
"        130-656",
"       </td>",
"       <td>",
"        99-526",
"       </td>",
"       <td>",
"        6, 10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin C (ascorbic acid) (mg/dL)",
"       </td>",
"       <td>",
"        0.4-1.0",
"       </td>",
"       <td>",
"        Not reported",
"       </td>",
"       <td>",
"        Not reported",
"       </td>",
"       <td>",
"        0.9-1.3",
"       </td>",
"       <td>",
"        52",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin D, 1,25-dihydroxy (pg/mL)",
"       </td>",
"       <td>",
"        25-45",
"       </td>",
"       <td>",
"        20-65",
"       </td>",
"       <td>",
"        72-160",
"       </td>",
"       <td>",
"        60-119",
"       </td>",
"       <td>",
"        30, 36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin D, 24,25-dihydroxy (ng/mL)",
"       </td>",
"       <td>",
"        0.5-5.0",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        1.2-1.8",
"       </td>",
"       <td>",
"        1.1-1.5",
"       </td>",
"       <td>",
"        0.7-0.9",
"       </td>",
"       <td>",
"        53",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin D, 25-hydroxy (ng/mL)",
"       </td>",
"       <td>",
"        14-80",
"       </td>",
"       <td>",
"        18-27",
"       </td>",
"       <td>",
"        10-22",
"       </td>",
"       <td>",
"        10-18",
"       </td>",
"       <td>",
"        30, 53",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin E (&alpha;-tocopherol) (&micro;g/mL)",
"       </td>",
"       <td>",
"        5-18",
"       </td>",
"       <td>",
"        7-13",
"       </td>",
"       <td>",
"        10-16",
"       </td>",
"       <td>",
"        13-23",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Zinc (&micro;g/dL)",
"       </td>",
"       <td>",
"        75-120",
"       </td>",
"       <td>",
"        57-88",
"       </td>",
"       <td>",
"        51-80",
"       </td>",
"       <td>",
"        50-77",
"       </td>",
"       <td>",
"        5, 13, 50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Autoimmune and inflammatory mediators",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        C3 complement (mg/dL)",
"       </td>",
"       <td>",
"        83-177",
"       </td>",
"       <td>",
"        62-98",
"       </td>",
"       <td>",
"        73-103",
"       </td>",
"       <td>",
"        77-111",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        C4 complement (mg/dL)",
"       </td>",
"       <td>",
"        16-47",
"       </td>",
"       <td>",
"        18-36",
"       </td>",
"       <td>",
"        18-34",
"       </td>",
"       <td>",
"        22-32",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        C-reactive protein (mg/L)",
"       </td>",
"       <td>",
"        0.2-3.0",
"       </td>",
"       <td>",
"        Not reported",
"       </td>",
"       <td>",
"        0.4-20.3",
"       </td>",
"       <td>",
"        0.4-8.1",
"       </td>",
"       <td>",
"        54",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Erythrocyte sedimentation rate (mm/h)",
"       </td>",
"       <td>",
"        0-20",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        4-57",
"       </td>",
"       <td>",
"        7-47",
"       </td>",
"       <td>",
"        13-70",
"       </td>",
"       <td>",
"        55",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Immunoglobulin A (mg/dL)",
"       </td>",
"       <td>",
"        70-350",
"       </td>",
"       <td>",
"        95-243",
"       </td>",
"       <td>",
"        99-237",
"       </td>",
"       <td>",
"        112-250",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Immunoglobulin G (mg/dL)",
"       </td>",
"       <td>",
"        700-1700",
"       </td>",
"       <td>",
"        981-1267",
"       </td>",
"       <td>",
"        813-1131",
"       </td>",
"       <td>",
"        678-990",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Immunoglobulin M (mg/dL)",
"       </td>",
"       <td>",
"        50-300",
"       </td>",
"       <td>",
"        78-232",
"       </td>",
"       <td>",
"        74-218",
"       </td>",
"       <td>",
"        85-269",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Sex hormones",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dehydroepiandrosterone sulfate (&micro;mol/L)",
"       </td>",
"       <td>",
"        1.3-6.8",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        2.0-16.5",
"       </td>",
"       <td>",
"        0.9-7.8",
"       </td>",
"       <td>",
"        0.8-6.5",
"       </td>",
"       <td>",
"        56",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Estradiol (pg/mL)",
"       </td>",
"       <td>",
"        &lt;20-443",
"        <sup>",
"         &Delta;,&bull;&bull;",
"        </sup>",
"       </td>",
"       <td>",
"        188-2497",
"       </td>",
"       <td>",
"        1278-7192",
"       </td>",
"       <td>",
"        6137-3460",
"       </td>",
"       <td>",
"        56, 57",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Progesterone (ng/mL)",
"       </td>",
"       <td>",
"        &lt;1-20",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        8-48",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        99-342",
"       </td>",
"       <td>",
"        56, 57",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prolactin (ng/mL)",
"       </td>",
"       <td>",
"        0-20",
"       </td>",
"       <td>",
"        36-213",
"       </td>",
"       <td>",
"        110-330",
"       </td>",
"       <td>",
"        137-372",
"       </td>",
"       <td>",
"        30, 47, 57, 58",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sex hormone binding globulin (nmol/L)",
"       </td>",
"       <td>",
"        18-114",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        39-131",
"       </td>",
"       <td>",
"        214-717",
"       </td>",
"       <td>",
"        216-724",
"       </td>",
"       <td>",
"        56, 59",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Testosterone (ng/dL)",
"       </td>",
"       <td>",
"        6-86",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        25.7-211.4",
"       </td>",
"       <td>",
"        34.3-242.9",
"       </td>",
"       <td>",
"        62.9-308.6",
"       </td>",
"       <td>",
"        56",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        17-hydroxyprogesterone (nmol/L)",
"       </td>",
"       <td>",
"        0.6-10.6",
"        <sup>",
"         &Delta;,",
"        </sup>",
"       </td>",
"       <td>",
"        5.2-28.5",
"       </td>",
"       <td>",
"        5.2-28.5",
"       </td>",
"       <td>",
"        15.5-84",
"       </td>",
"       <td>",
"        56",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Lipids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Cholesterol, total (mg/dL)",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        &lt;200",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        141-210",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        176-299",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        219-349",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        5, 60-62",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        High-density lipoprotein cholesterol (mg/dL)",
"       </td>",
"       <td class=\"sublist_other\">",
"        40-60",
"       </td>",
"       <td class=\"sublist_other\">",
"        40-78",
"       </td>",
"       <td class=\"sublist_other\">",
"        52-87",
"       </td>",
"       <td class=\"sublist_other\">",
"        48-87",
"       </td>",
"       <td class=\"sublist_other\">",
"        5, 60-63",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Low-density lipoprotein cholesterol (mg/dL)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &lt;100",
"       </td>",
"       <td class=\"sublist_other\">",
"        60-153",
"       </td>",
"       <td class=\"sublist_other\">",
"        77-184",
"       </td>",
"       <td class=\"sublist_other\">",
"        101-224",
"       </td>",
"       <td class=\"sublist_other\">",
"        5, 60-63",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Very-low-density lipoprotein cholesterol (mg/dL)",
"       </td>",
"       <td class=\"sublist_other\">",
"        6-40",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        10-18",
"       </td>",
"       <td class=\"sublist_other\">",
"        13-23",
"       </td>",
"       <td class=\"sublist_other\">",
"        21-36",
"       </td>",
"       <td class=\"sublist_other\">",
"        62",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Triglycerides (mg/dL)",
"       </td>",
"       <td>",
"        &lt;150",
"       </td>",
"       <td>",
"        40-159",
"       </td>",
"       <td>",
"        75-382",
"       </td>",
"       <td>",
"        131-453",
"       </td>",
"       <td>",
"        4, 5, 60-63",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Apolipoprotein A-I (mg/dL)",
"       </td>",
"       <td>",
"        119-240",
"       </td>",
"       <td>",
"        111-150",
"       </td>",
"       <td>",
"        142-253",
"       </td>",
"       <td>",
"        145-262",
"       </td>",
"       <td>",
"        4, 47, 61",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Apolipoprotein B (mg/dL)",
"       </td>",
"       <td>",
"        52-163",
"       </td>",
"       <td>",
"        58-81",
"       </td>",
"       <td>",
"        66-188",
"       </td>",
"       <td>",
"        85-238",
"       </td>",
"       <td>",
"        4, 47, 61",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Cardiac function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cardiac output (L/min)",
"       </td>",
"       <td>",
"        4.8-6.8",
"       </td>",
"       <td>",
"        5.6-9.7",
"       </td>",
"       <td>",
"        5.5-9.9",
"       </td>",
"       <td>",
"        4.8-8.7",
"       </td>",
"       <td>",
"        64, 65, 66, 67, 68",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cardiac index (L/min/m",
"        <sup>",
"         2",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        2.6-4.2",
"       </td>",
"       <td>",
"        3.2-4.6",
"       </td>",
"       <td>",
"        3.1-4.7",
"       </td>",
"       <td>",
"        2.5-4.4",
"       </td>",
"       <td>",
"        65, 68",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Stroke volume (mL)",
"       </td>",
"       <td>",
"        79-90",
"       </td>",
"       <td>",
"        77.5-107.6",
"       </td>",
"       <td>",
"        70.3-107.6",
"       </td>",
"       <td>",
"        54-99",
"       </td>",
"       <td>",
"        65, 68, 69",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Stroke index (mL/m",
"        <sup>",
"         2",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        46-62",
"       </td>",
"       <td>",
"        39-62",
"       </td>",
"       <td>",
"        30-42",
"       </td>",
"       <td>",
"        65",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Systemic vascular resistance (dyns/cm",
"        <sup>",
"         5",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        700-1600",
"       </td>",
"       <td>",
"        747-1485",
"       </td>",
"       <td>",
"        692-1201",
"       </td>",
"       <td>",
"        1034-1201",
"       </td>",
"       <td>",
"        65, 67, 70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Echocardiography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intraventricular septal diameter (cm)",
"       </td>",
"       <td>",
"        0.7-0.9",
"       </td>",
"       <td>",
"        0.7-0.8",
"       </td>",
"       <td>",
"        0.7-0.8",
"       </td>",
"       <td>",
"        0.7-0.9",
"       </td>",
"       <td>",
"        68, 69, 70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Posterior ventricular wall diameter (cm)",
"       </td>",
"       <td>",
"        0.75-0.9",
"       </td>",
"       <td>",
"        0.7-0.8",
"       </td>",
"       <td>",
"        0.7-0.9",
"       </td>",
"       <td>",
"        0.75-0.9",
"       </td>",
"       <td>",
"        68, 69, 70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Left ventricular mass (g)",
"       </td>",
"       <td>",
"        116-143",
"       </td>",
"       <td>",
"        108-167",
"       </td>",
"       <td>",
"        115-150",
"       </td>",
"       <td>",
"        128-162",
"       </td>",
"       <td>",
"        68, 70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Left ventricular mass index",
"       </td>",
"       <td>",
"        40-69",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        45-72",
"       </td>",
"       <td>",
"        68, 70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        E/A ratio",
"       </td>",
"       <td>",
"        1.4-1.75",
"       </td>",
"       <td>",
"        1.6",
"       </td>",
"       <td>",
"        1.4",
"       </td>",
"       <td>",
"        1.3",
"       </td>",
"       <td>",
"        68, 70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Left ventricular diastolic diameter (cm)",
"       </td>",
"       <td>",
"        4.3-4.8",
"       </td>",
"       <td>",
"        4.3-4.6",
"       </td>",
"       <td>",
"        4.4-4.9",
"       </td>",
"       <td>",
"        5.1",
"       </td>",
"       <td>",
"        69, 70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Left ventricular systolic diameter (cm)",
"       </td>",
"       <td>",
"        2.8-3.1",
"       </td>",
"       <td>",
"        2.8-2.9",
"       </td>",
"       <td>",
"        2.8-3.4",
"       </td>",
"       <td>",
"        2.8-3.3",
"       </td>",
"       <td>",
"        69, 70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Left vent, fractional shortening (percent)",
"       </td>",
"       <td>",
"        35-36",
"       </td>",
"       <td>",
"        35-37",
"       </td>",
"       <td>",
"        3.5",
"       </td>",
"       <td>",
"        35-36",
"       </td>",
"       <td>",
"        69, 70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Left vent ejection fraction (percent)",
"       </td>",
"       <td>",
"        60-73",
"       </td>",
"       <td>",
"        61-75",
"       </td>",
"       <td>",
"        61-63",
"       </td>",
"       <td>",
"        60-73",
"       </td>",
"       <td>",
"        69, 70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atrial natriuretic peptide (pg/mL)",
"       </td>",
"       <td>",
"        Not reported",
"       </td>",
"       <td>",
"        Not reported",
"       </td>",
"       <td>",
"        28.1-70.1",
"       </td>",
"       <td>",
"        Not reported",
"       </td>",
"       <td>",
"        73",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        B-type natriuretic peptide (pg/mL)",
"       </td>",
"       <td>",
"        &lt;167 (age- and gender-specific)",
"       </td>",
"       <td>",
"        18.4",
"       </td>",
"       <td>",
"        13.5-29.5",
"       </td>",
"       <td>",
"        15.5-46",
"       </td>",
"       <td>",
"        71, 72, 73",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Creatine kinase (U/L)",
"       </td>",
"       <td>",
"        39-238",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        27-83",
"       </td>",
"       <td>",
"        25-75",
"       </td>",
"       <td>",
"        13-101",
"       </td>",
"       <td>",
"        5, 74",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Creatine kinase-MB (U/L)",
"       </td>",
"       <td>",
"        &lt;6",
"        <sup>",
"         &Delta;&Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Not reported",
"       </td>",
"       <td>",
"        Not reported",
"       </td>",
"       <td>",
"        1.8-2.4",
"       </td>",
"       <td>",
"        74",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Troponin I (ng/mL)",
"       </td>",
"       <td>",
"        0-0.08",
"       </td>",
"       <td>",
"        Not reported",
"       </td>",
"       <td>",
"        Not reported",
"       </td>",
"       <td>",
"        0-0.064 (intrapartum)",
"       </td>",
"       <td>",
"        75, 76",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Blood gas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        pH",
"       </td>",
"       <td rowspan=\"2\">",
"        7.38-7.42 (arterial)",
"       </td>",
"       <td rowspan=\"2\">",
"        7.36-7.52 (venous)",
"       </td>",
"       <td rowspan=\"2\">",
"        7.40-7.52 (venous)",
"       </td>",
"       <td>",
"        7.41-7.53 (venous)",
"       </td>",
"       <td rowspan=\"2\">",
"        31, 77",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7.39-7.45 (arterial)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PO",
"        <sub>",
"         2",
"        </sub>",
"        (mmHg)",
"       </td>",
"       <td>",
"        90-100",
"       </td>",
"       <td>",
"        93-100",
"       </td>",
"       <td>",
"        90-98",
"       </td>",
"       <td>",
"        92-107",
"       </td>",
"       <td>",
"        77, 78",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PCO",
"        <sub>",
"         2",
"        </sub>",
"        (mmHg)",
"       </td>",
"       <td>",
"        38-42",
"       </td>",
"       <td>",
"        Not reported",
"       </td>",
"       <td>",
"        Not reported",
"       </td>",
"       <td>",
"        25-33",
"       </td>",
"       <td>",
"        77",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Bicarbonate (HCO",
"        <sub>",
"         3",
"        </sub>",
"        <sup>",
"         -",
"        </sup>",
"        ) (mEq/L)",
"       </td>",
"       <td>",
"        22-26",
"       </td>",
"       <td>",
"        Not reported",
"       </td>",
"       <td>",
"        Not reported",
"       </td>",
"       <td>",
"        16-22",
"       </td>",
"       <td>",
"        77",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Renal function tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Effective renal plasma flow (mL/min)",
"       </td>",
"       <td>",
"        492-696",
"        <sup>",
"         &Delta;,",
"        </sup>",
"       </td>",
"       <td>",
"        696-985",
"       </td>",
"       <td>",
"        612-1170",
"       </td>",
"       <td>",
"        595-945",
"       </td>",
"       <td>",
"        79, 80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glomerular filtration rate (GFR) (mL/min)",
"       </td>",
"       <td>",
"        106-132",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        131-166",
"       </td>",
"       <td>",
"        135-170",
"       </td>",
"       <td>",
"        117-182",
"       </td>",
"       <td>",
"        79, 80, 81",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Filtration fraction (percent)",
"       </td>",
"       <td>",
"        16.9-24.7",
"        <sup>",
"         &loz;&loz;",
"        </sup>",
"       </td>",
"       <td>",
"        14.7-21.6",
"       </td>",
"       <td>",
"        14.3-21.9",
"       </td>",
"       <td>",
"        17.1-25.1",
"       </td>",
"       <td>",
"        79, 80, 81",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Osmolarity, urine (mOsm/kg)",
"       </td>",
"       <td>",
"        500-800",
"       </td>",
"       <td>",
"        326-975",
"       </td>",
"       <td>",
"        278-1066",
"       </td>",
"       <td>",
"        238-1034",
"       </td>",
"       <td>",
"        82",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        24-h albumin excretion (mg/24 h)",
"       </td>",
"       <td>",
"        &lt;30",
"       </td>",
"       <td>",
"        5-15",
"       </td>",
"       <td>",
"        4-18",
"       </td>",
"       <td>",
"        3-22",
"       </td>",
"       <td>",
"        82, 83",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        24-h calcium excretion (mmol/24 h)",
"       </td>",
"       <td>",
"        &lt;7.5",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        1.6-5.2",
"       </td>",
"       <td>",
"        0.3-6.9",
"       </td>",
"       <td>",
"        0.8-4.2",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        24-h creatinine clearance (mL/min)",
"       </td>",
"       <td>",
"        91-130",
"       </td>",
"       <td>",
"        69-140",
"       </td>",
"       <td>",
"        55-136",
"       </td>",
"       <td>",
"        50-166",
"       </td>",
"       <td>",
"        15, 80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        24-h creatinine excretion (mmol/24 h)",
"       </td>",
"       <td>",
"        8.8-14",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        10.6-11.6",
"       </td>",
"       <td>",
"        10.3-11.5",
"       </td>",
"       <td>",
"        10.2-11.4",
"       </td>",
"       <td>",
"        82",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        24-h potassium excretion (mmol/24 h)",
"       </td>",
"       <td>",
"        25-100",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        17-33",
"       </td>",
"       <td>",
"        10-38",
"       </td>",
"       <td>",
"        11-35",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        24-h protein excretion (mg/24 h)",
"       </td>",
"       <td>",
"        &lt;150",
"       </td>",
"       <td>",
"        19-141",
"       </td>",
"       <td>",
"        47-186",
"       </td>",
"       <td>",
"        46-185",
"       </td>",
"       <td>",
"        83",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        24-h sodium excretion (mmol/24 h)",
"       </td>",
"       <td>",
"        100-260",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        53-215",
"       </td>",
"       <td>",
"        34-213",
"       </td>",
"       <td>",
"        37-149",
"       </td>",
"       <td>",
"        15, 41",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Unless otherwise specified, all normal reference values are from the seventeenth edition of",
"     <em>",
"      Harrison's Principles of Internal Medicine",
"     </em>",
"     <sup>",
"      [84]",
"     </sup>",
"     .",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Range includes references with and without iron supplementation.",
"      <br>",
"       &Delta; Normal reference range is specific range for females.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        Reference values are from Cerneca et al: Coagulation and fibrinolysis changes in normal pregnancy increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis",
"        <sup>",
"         [19]",
"        </sup>",
"        .",
"        <br>",
"         &sect; References values are from Cerneca et al and Choi et al: Tissue plasminogen activator levels change with plasma fibrinogen concentrations during pregnancy",
"         <sup>",
"          [17,19]",
"         </sup>",
"         .",
"         <br>",
"          &yen; Reference values are from Mannuci et al: Changes in health and disease of the metalloprotease that cleaves von Willebrand factor",
"          <sup>",
"           [28]",
"          </sup>",
"          .",
"          <br>",
"            Reference values are from Bacq Y et al: Liver function tests in normal pregnancy: a prospective study of 102 pregnant women and 102 matched controls",
"           <sup>",
"            [29]",
"           </sup>",
"           .",
"           <br>",
"             Reference values are from the fifteenth edition of",
"            <em>",
"             Harrison's Principles of Internal Medicine",
"            </em>",
"            <sup>",
"             [85]",
"            </sup>",
"            .",
"            <br>",
"             ** The American Thyroid Association recommends these TSH ranges if individual laboratories do not determine their own trimester-specific reference ranges.",
"             <br>",
"              <span class=\"double_bullet\">",
"               &bull;&bull;",
"              </span>",
"              Range is for premenopausal females and varies by menstrual cycle phase.",
"              <br>",
"               &Delta;&Delta; Reference values are from Leiserowitz GS et al: Creatine kinase and its MB isoenzyme in the third trimester and the peripartum period",
"               <sup>",
"                [74]",
"               </sup>",
"               .",
"               <br>",
"                <span class=\"double_lozenge\">",
"                 &loz;&loz;",
"                </span>",
"                Reference values are from Dunlop W: Serial changes in renal haemodynamics during normal human pregnancy",
"                <sup>",
"                 [79]",
"                </sup>",
"                .",
"               </br>",
"              </br>",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Beguin Y, Lipscei G, Thourmsin H, et al: Blunted erythropoietin production and decreased erythropoiesis in early pregnancy. Blood 78(1):89, 1991.",
"       </li>",
"       <li>",
"        Bianco I, Mastropietro F, D'Aseri C, et al: Serum levels of erythropoietin and soluble transferrin receptor during pregnancy in non-&beta;-thalassemic and &beta;-thalassemic women. Haematologica 85:902, 2000 [PMID: 10980626].",
"       </li>",
"       <li>",
"        Milman N, Graudal N, Nielsen OJ: Serum erythropoietin during normal pregnancy: Relationship to hemoglobin and iron status markers and impact of iron supplementation in a longitudinal, placebo-controlled study on 118 women. Int J Hematol 66:159, 1997 [PMID: 9277046].",
"       </li>",
"       <li>",
"        Larsson A, Palm M, Hansson L-O, et al: Reference values for clinical chemistry tests during normal pregnancy. BJOG 115:874, 2008 [PMID: 18485166].",
"       </li>",
"       <li>",
"        Lockitch G: Handbook of Diagnostic Biochemistry and Hematology in Normal Pregnancy. Boca Raton, FL, CRC Press, 1993.",
"       </li>",
"       <li>",
"        Milman N, Bergholt T, Byg KE, et al: Reference intervals for haematological variables during normal pregnancy and postpartum in 434 healthy Danish women. Eur J Haematol 79:39, 2007 [PMID: 17598837].",
"       </li>",
"       <li>",
"        Romslo I, Haram K, Sagen N, et al: Iron requirement in normal pregnancy as assessed by serum ferritin, serum transferring saturation and erythrocyte protoporphyrin determinations. Br J Obstet Gynaecol 90:101, 1983 [PMID: 6824608].",
"       </li>",
"       <li>",
"        Van Buul EJA, Steegers EAP, Jongsma HW, et al: Haematological and biochemical profile of uncomplicated pregnancy in nulliparous women; a longitudinal study. Neth J Med 46:73, 1995.",
"       </li>",
"       <li>",
"        Milman N, Byg KE, Hvas AM, et al: Erythrocyte folate, plasma folate and plasma homocysteine during normal pregnancy and postpartum: A longitudinal study comprising 404 Danish women. Eur J Haematol 76:200, 2006 [PMID: 16412135].",
"       </li>",
"       <li>",
"        Walker MC, Smith GN, Perkins SL, et al: Changes in homocysteine levels during normal pregnancy. Am J Obstet Gynecol 180:660, 1999 [PMID: 10076144].",
"       </li>",
"       <li>",
"        L&oacute;pez-Quesada E, Vilaseca MA, Lailla JM: Plasma total homocysteine in uncomplicated pregnancy and in preeclampsia. Eur J Obstet Gynecol Reprod Biol 108:45, 2003 [PMID: 19899161].",
"       </li>",
"       <li>",
"        &Ouml;zerol E, &Ouml;zerol I, G&ouml;kdeniz R, et al: Effect of smoking on serum concentrations of total homocysteine, folate, vitamin B12, and nitric oxide in pregnancy: A preliminary study. Fetal Diagn Ther 19:145, 2004.",
"       </li>",
"       <li>",
"        Qvist I, Abdulla M, J&auml;gerstad M, et al: Iron, zinc and folate status during pregnancy and two months after delivery. Acta Obstet Gynecol Scand 65:15, 1986 [PMID: 3716775].",
"       </li>",
"       <li>",
"        Balloch AJ, Cauchi MN: Reference ranges for haematology parameters in pregnancy derived from patient populations. Clin Lab Haemat 15:7, 1993 [PMID: 8472501].",
"       </li>",
"       <li>",
"        Singh HJ, Mohammad NH, Nila A: Serum calcium and parathormone during normal pregnancy in Malay women. J Matern Fetal Med 8:95, 1999 [PMID: 10338062].",
"       </li>",
"       <li>",
"        AzizKarim S, Khurshid M, Rizvi JH, et al: Platelets and leucocyte counts in pregnancy. J Pak Med Assoc 42:86, 1992.",
"       </li>",
"       <li>",
"        Choi JW, Pai SH: Tissue plasminogen activator levels change with plasma fibrinogen concentrations during pregnancy. Ann Hematol 81:611, 2002 [PMID: 12454697].",
"       </li>",
"       <li>",
"        Belo L, Santos-Silva A, Rocha S, et al: Fluctuations in C-reactive protein concentration and neutrophil activation during normal human pregnancy. Eur J Obstet Gynecol Reprod Biol 123:46, 2005 [PMID: 16260340].",
"       </li>",
"       <li>",
"        Cerneca F, Ricci G, Simeone R, et al: Coagulation and fibrinolysis changes in normal pregnancy increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis. Eur J Obstet Gynecol Reprod Biol 73:31, 1997 [PMID: 9175686].",
"       </li>",
"       <li>",
"        Lattuada A, Rossi E, Calzarossa C, et al: Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica 88(9):1029, 2003.",
"       </li>",
"       <li>",
"        Francalanci I, Comeglio P, Liotta AA, et al: D-Dimer concentrations during normal pregnancy, as measured by ELISA. Thromb Res 78:399, 1995 [PMID: 7660356].",
"       </li>",
"       <li>",
"        Kline JA, Williams GW, Hernandez-Nino J: D-Dimer concentrations in normal pregnancy: New diagnostic thresholds are needed. Clin Chem 51:825, 2005 [PMID: 15764641].",
"       </li>",
"       <li>",
"        Morse M: Establishing a normal range for D-dimer levels through pregnancy to aid in the diagnosis of pulmonary embolism and deep vein thrombosis. J Thromb Haemost 2:1202, 2004 [PMID: 15219216].",
"       </li>",
"       <li>",
"        Liu XH, Jiang YM, Shi H, et al: Prospective, sequential, longitudinal study of coagulation changes during pregnancy in Chinese women. Int J Gynaecol Obstet 105(3):240, 2009.",
"       </li>",
"       <li>",
"        Lefkowitz JB, Clarke SH, Barbour LA: Comparison of protein S functional and antigenic assays in normal pregnancy. Am J Obstet Gynecol 175:657, 1996 [PMID: 8828430].",
"       </li>",
"       <li>",
"        Faught W, Garner P, Jones G, et al: Changes in protein C and protein S levels in normal pregnancy. Am J Obstet Gynecol 172:147, 1995 [PMID: 7847526].",
"       </li>",
"       <li>",
"        Wickstr&ouml;m K, Edelstam G, L&ouml;wbeer CH, et al: Reference intervals for plasma levels of fibronectin, von Willebrand factor, free protein S and antithrombin during third-trimester pregnancy. Scand J Clin Lab Invest 64:31, 2004 [PMID: 13035697].",
"       </li>",
"       <li>",
"        Mannucci PM, Canciani MT, Forza I, et al: Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 98(9):2730, 2001.",
"       </li>",
"       <li>",
"        Bacq Y, Zarka O, Br&eacute;chot JF, et al: Liver function tests in normal pregnancy: A prospective study of 102 pregnant women and 102 matched controls. Hepatology 23:1030, 1996 [PMID: 8621129].",
"       </li>",
"       <li>",
"        Ardawi MSM, Nasrat HAN, BA'Aqueel HS: Calcium-regulating hormones and parathyroid hormone-related peptide in normal human pregnancy and postpartum: A longitudinal study. Eur J Endocrinol 137:402, 1997 [PMID: 9368509].",
"       </li>",
"       <li>",
"        Handwerker SM, Altura BT, Altura BM: Serum ionized magnesium and other electrolytes in the antenatal period of human pregnancy. J Am Coll Nutr 15:36, 1996 [PMID: 8632112].",
"       </li>",
"       <li>",
"        Hytten FE, Lind T: Diagnostic Indices in Pregnancy. Summit, NJ, CIBA-GEIGY Corporation, 1975.",
"       </li>",
"       <li>",
"        Karsenti D, Bacq Y, Br&eacute;chot JF, et al: Serum amylase and lipase activities in normal pregnancy: A prospective case-control study. Am J Gastroenterol 96:697, 2001 [PMID: 11280536].",
"       </li>",
"       <li>",
"        Strickland DM, Hauth JC, Widish J, et al: Amylase and isoamylase activities in serum of pregnant women. Obstet Gynecol 63:389, 1984 [PMID: 6199704].",
"       </li>",
"       <li>",
"        Carter J: Serum bile acids in normal pregnancy. BJOG 98:540, 1991 [PMID: 1873244].",
"       </li>",
"       <li>",
"        Mimouni F, Tsang RC, Hertzbert VS, et al: Parathyroid hormone and calcitriol changes in normal and insulin-dependent diabetic pregnancies. Obstet Gynecol 74:49, 1989 [PMID: 2733941].",
"       </li>",
"       <li>",
"        Pitkin RM, Gebhardt MP: Serum calcium concentrations in human pregnancy. Am J Obstet Gynecol 127:775, 1977 [PMID: 848531].",
"       </li>",
"       <li>",
"        Shakhmatova EI, Osipova NA, Natochin YV: Changes in osmolality and blood serum ion concentrations in pregnancy. Hum Physiol 26:92, 2000.",
"       </li>",
"       <li>",
"        Louro MO, Cocho JA, Tutor JC: Assessment of copper status in pregnancy by means of determining the specific oxidase activity of ceruloplasmin. Clin Chim Acta 312:123, 2001 [PMID: 11580917].",
"       </li>",
"       <li>",
"        Dux S, Yaron A, Carmel A, et al: Renin, aldosterone, and serum-converting enzyme activity during normal and hypertensive pregnancy. Gynecol Obstet Invest 17:252, 1984 [PMID: 6329926].",
"       </li>",
"       <li>",
"        Davison JB, Vallotton MB, Lindheimer MD: Plasma osmolality and urinary concentration and dilution during and after pregnancy: Evidence that lateral recumbency inhibits maximal urinary concentrating ability. BJOG 88:472, 1981 [PMID: 7236550].",
"       </li>",
"       <li>",
"        Kato T, Seki K, Matsui H, et al: Monomeric calcitonin in pregnant women and in cord blood. Obstet Gynecol 92:241, 1998 [PMID: 9699759].",
"       </li>",
"       <li>",
"        Elsheikh A, Creatsas G, Mastorakos G, et al: The renin-aldosterone system during normal and hypertensive pregnancy. Arch Gynecol Obstet 264:182, 2001 [PMID: 11205704].",
"       </li>",
"       <li>",
"        Kim EH, Lim JH, Kim YH, et al: The relationship between aldosterone to renin ratio and RI value of the uterine artery in the preeclamptic patient vs. normal pregnancy. Yonsei Med J 49(1):138, 2008.",
"       </li>",
"       <li>",
"        Suri D, Moran J, Hibbard JU, et al: Assessment of adrenal reserve in pregnancy: Defining the normal response to the adrenocorticotropin stimulation test. J Clin Endocrinol Metab 91:3866, 2006 [PMID: 16895954].",
"       </li>",
"       <li>",
"        Parente JV, Franco JG, Greene LJ, et al: Angiotensin-converting enzyme: Serum levels during normal pregnancy. Am J Obstet Gynecol 135:586, 1979 [PMID: 228554].",
"       </li>",
"       <li>",
"        Montelongo A, Lasunci&oacute;n MA, Pallardo LF, et al: Longitudinal study of plasma lipoproteins and hormones during pregnancy in normal and diabetic women. Diabetes 41:1651, 1992 [PMID: 1446807].",
"       </li>",
"       <li>",
"        Radder JK, Van Roosmalen J: HbAIC in healthy, pregnant women. Neth J Med 63:256, 2005 [PMID: 16093576].",
"       </li>",
"       <li>",
"        Price A, Obel O, Cresswell J, et al: Comparison of thyroid function in pregnant and non-pregnant Asian and western Caucasian women. Clin Chim Acta 208:91, 2001.",
"       </li>",
"       <li>",
"        &Aacute;lvarez SI, Casta&ntilde;&oacute;n SG, Ruata MLC, et al: Updating of normal levels of copper, zinc and selenium in serum of pregnant women. J Trace Elem Med Biol 21(S1):49, 2007.",
"       </li>",
"       <li>",
"        Ilhan N, Ilhan N, Simsek M: The changes of trace elements, malondialdehyde levels and superoxide dismutase activities in pregnancy with or without preeclampsia. Clin Biochem 35:393, 2002 [PMID: 12270770].",
"       </li>",
"       <li>",
"        Sharma SC, Sabra A, Molloy A, et al: Comparison of blood levels of histamine and total ascorbic acid in pre-eclampsia with normal pregnancy. Hum Nutr Clin Nutr 38C:3, 1984.",
"       </li>",
"       <li>",
"        Reiter EO, Braunstein GD, Vargas A, et al: Changes in 25-hydroxyvitamin D and 24,25-dihydroxyvitamin D during pregnancy. Am J Obstet Gynecol 135:227, 1979 [PMID: 474676].",
"       </li>",
"       <li>",
"        Hwang HS, Kwon JY, Kim MA, et al: Maternal serum highly sensitive C-reactive protein in normal pregnancy and pre-eclampsia. Int J Gynecol Obstet 98:105, 2007 [PMID: 17588579].",
"       </li>",
"       <li>",
"        van den Broek NR, Letsky EA: Pregnancy and the erythrocyte sedimentation rate. Br J Obstet Gynaecol 108:1164, 2001.",
"       </li>",
"       <li>",
"        O'Leary P, Boyne P, Flett P, et al: Longitudinal assessment of changes in reproductive hormones during normal pregnancy. Clin Chem 35(5):667, 1991.",
"       </li>",
"       <li>",
"        Carranza-Lira S, Hern&aacute;ndez F, S&aacute;nchez M, et al: Prolactin secretion in molar and normal pregnancy. Int J Gynaecol Obstet 60:137, 1998 [PMID: 9509951].",
"       </li>",
"       <li>",
"        Larrea F, M&eacute;ndez I, Parra A: Serum pattern of different molecular forms of prolactin during normal human pregnancy. Hum Reprod 8:1617, 1993 [PMID: 8300816].",
"       </li>",
"       <li>",
"        Acromite MT, Mantzoros CS, Leach RE, et al: Androgens in preeclampsia. Am J Obstet Gynecol 180:60, 1999 [PMID: 9914579].",
"       </li>",
"       <li>",
"        Belo L, Caslake M, Gaffney D, et al: Changes in LDL size and HDL concentration in normal and preeclamptic pregnancies. Atherosclerosis 162:425, 2002 [PMID: 11996963].",
"       </li>",
"       <li>",
"        Desoye G, Schweditsch MO, Pfeiffer KP, et al: Correlation of hormones with lipid and lipoprotein levels during normal pregnancy and postpartum. J Clin Endocrinol Metab 64:704, 1987 [PMID: 3546352].",
"       </li>",
"       <li>",
"        Jimenez DM, Pocovi M, Ramon-Cajal J, et al: Longitudinal study of plasma lipids and lipoprotein cholesterol in normal pregnancy and puerperium. Gynecol Obstet Invest 25:158, 1988 [PMID: 3391425].",
"       </li>",
"       <li>",
"        Piechota W, Staszewski A: Reference ranges of lipids and apolipoproteins in pregnancy. Eur J Obstet Gynecol Reprod Biol 45:27, 1992 [PMID: 1618359].",
"       </li>",
"       <li>",
"        Rang S, van Montfrans GA, Wolf H. Serial hemodynamic measurement in normal pregnancy, preeclampsia, and intrauterine growth restriction. Am J Obstet Gynecol. 198(5):519.e1-9, 2008 PMID: 18279824.",
"       </li>",
"       <li>",
"        Moertl MG, Ulrich D, Pickel K, et al: Changes in haemodynamic and autonomous nervous system parameters measured non-invasively throughout normal pregnancy. Eur J Obstet Gynecol Reprod Biol. 144 Suppl 1:S179-83. 2009 PMID: 19285779",
"       </li>",
"       <li>",
"        Pandey Ak, Das A, Srinivas C, et al: Maternal myocardial performances in various stages of pregnancy and post-partum. Research Jour of Cardiology 3(1):9-16, 2010.",
"       </li>",
"       <li>",
"        Lees M. Central circulatory responses in normotensive and hypertensive pregnancy. Postgrad Med J. 55(643): 311&ndash;314, 1979. PMCID: PMC2425449.",
"       </li>",
"       <li>",
"        Poppas A, Shroff SG, Korcarz CE, et al: Serial assessment of the cardiovascular system in normal pregnancy: Role of arterial compliance and pulsatile arterial load. Circulation 95:2407-2415, 1997.",
"       </li>",
"       <li>",
"        Katz R, Karliner JS, Resnik R: Effects of a natural volume overload state (pregnancy) on left ventricular performance in normal human subjects. Circulation 58: 434-441, 1978.",
"       </li>",
"       <li>",
"        Mesa A, Jessurun C, Hernandez A, et al: Left ventricular diastolic function in normal human pregnancy. Circulation 99:511-517, 1999.",
"       </li>",
"       <li>",
"        Resnik JL, Hong C, Resnik R, et al: Evaluation of B-type natriuetic peptide (BNP) levels in normal and preeclamptic women. Am J Obstet Gynecol 193:450-458, 2005.",
"       </li>",
"       <li>",
"        Hamid RR, Larsson A, Pernow J, et al: Assessment of left ventricular structure and function in preeclampsia by echocardiography and cardiovascular biomarkers. J Hypertens 27L2257-2264, 2009.",
"       </li>",
"       <li>",
"        Borghi CB, Esposti DD, Immordino V, et al: Relationship of systemic hemodynamics, left ventricular structure and function, and plasma natriuretic peptide concentrations during pregnancy complicated by preeclampsia. Am J Obstet Gynecol 183:140, 2000 [PMID: 10920322].",
"       </li>",
"       <li>",
"        Leiserowitz GS, Evans AT, Samuels SJ, et al: Creatine kinase and its MB isoenzyme in the third trimester and the peripartum period. J Reprod Med 37:910, 1992 [PMID: 1460608].",
"       </li>",
"       <li>",
"        Koscica KL, Bebbington M, Bernstein PS: Are maternal serum troponin I levels affected by vaginal or cesarean delivery? Am J Perinatol 21(1):31, 2004.",
"       </li>",
"       <li>",
"        Shivvers SA, Wians FH, Keffer JH, et al: Maternal cardiac troponin I levels during labor and delivery. Am J Obstet Gynecol 180:122, 1999 [PMID: 9914590].",
"       </li>",
"       <li>",
"        Fadel HE, Northrop G, Misenhimer HR, et al: Acid-base determinations in amniotic fluid and blood of normal late pregnancy. Obstet Gynecol 53:99, 1979 [PMID: 32503].",
"       </li>",
"       <li>",
"        Spiropoulos K, Prodromaki E, Tsapanos V: Effect of body position on PaO2 and PaCO2 during pregnancy. Gynecol Obstet Invest 58:22, 2004 [PMID: 15028865].",
"       </li>",
"       <li>",
"        Dunlop W: Serial changes in renal haemodynamics during normal human pregnancy. Br J Obstet Gynaecol 88:1, 1981 [PMID: 7459285].",
"       </li>",
"       <li>",
"        Ezimokhai M, Davison JM, Philips PR, et al: Non-postural serial changes in renal function during the third trimester of normal human pregnancy. Br J Obstet Gynaecol 88:465, 1981 [PMID: 7236549].",
"       </li>",
"       <li>",
"        Moran P, Baylis PH, Lindheimer, et al: Glomerular ultrafiltration in normal and preeclamptic pregnancy. J Am Soc Nephrol 14:648, 2003 [PMID: 12595500].",
"       </li>",
"       <li>",
"        Risberg A, Larsson A, Olsson K, et al: Relationship between urinary albumin and albumin/creatinine ratio during normal pregnancy and pre-eclampsia. Scand J Clin Lab Invest 64:17, 2004 [PMID: 15025425].",
"       </li>",
"       <li>",
"        Higby K, Suiter CR, Phelps JY, et al: Normal values of urinary albumin and total protein excretion during pregnancy. Am J Obstet Gynecol 171:984, 1994 [PMID: 7943114].",
"       </li>",
"       <li>",
"        Kratz A, Pesce MA, Basner RC, Einstein AJ. Appendix: Laboratory values of clinical importance. In: Longo DL,&nbsp;Fauci AS, Kasper DL, et al (Eds). Harrison's Principles of Internal Medicine, 18th ed, McGraw-Hill, New York 2012. Appendix 1, p A-1.",
"       </li>",
"       <li>",
"        Stagnaro-Green A, Abalovich M, Alexander E, et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid 2011; 21:1081.",
"       </li>",
"       <li>",
"        Leek AE, Ruoss CF, Kitau MJ, Chard T. Magernal plasma alphafetoprotein levels in the second half of normal pregnancy: Relationship to fetal weight, and maternal age and parity. BJOG 1975; 82:669.",
"       </li>",
"      </ol>",
"      Modified and reproduced with permission from: Abbassi-Ghanavati M, Greer LG. Reference Table of Normal Laboratory Values in Uncomplicated Pregnancies. In: Cunningham FG, Leveno KJ, Bloom S, Hauth JC, Rouse DJ, Spong CY. Williams Obstetrics, 23rd Edition. New York: McGraw-Hill, 2010. Copyright &copy; 2010 The McGraw-Hill Companies, Inc.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_33_38424=[""].join("\n");
var outline_f37_33_38424=null;
var title_f37_33_38425="Surgical management of advanced testicular germ cell tumors";
var content_f37_33_38425=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgical management of advanced testicular germ cell tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/33/38425/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/33/38425/contributors\">",
"     Graeme S Steele, MBBCh, FCS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/33/38425/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/33/38425/contributors\">",
"     Timothy D Gilligan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/33/38425/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/33/38425/contributors\">",
"     Philip W Kantoff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/33/38425/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/33/38425/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/33/38425/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testicular cancers, 95 percent of which are germ cell tumors (GCTs), are one of the most curable solid neoplasms because of treatment advances that began in the mid 1970s. Prior to that time, testicular cancer accounted for 11 percent of all cancer deaths in men between the ages of 25 to 34, and the five-year survival rate was 64 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/1\">",
"     1",
"    </a>",
"    ]. Over the past 30 years, testis cancer incidence has increased 50 percent while mortality has declined 60 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/2\">",
"     2",
"    </a>",
"    ]. Currently, there are about 350 deaths per year in the United States, and the five-year survival rate is over 95 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contemporary management of advanced stage nonseminomatous GCTs is based on a combined approach of chemotherapy followed by resection of all residual masses when technically feasible. In contrast, advanced stage seminomas are often managed with chemotherapy alone. Cisplatin-based regimens can cure patients with disseminated seminomas and nonseminomatous GCTs even in the context of widespread visceral metastases, highly elevated serum tumor markers, or other adverse prognostic features. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/63/24568?source=see_link\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A residual mass is present in approximately 25 to 30 percent of men with NSGCT following chemotherapy. The majority of these are in the retroperitoneum, although such masses can occur at other sites. A combined modality approach that includes surgical resection of such masses has resulted in the improved outcomes now seen in men with advanced stage nonseminomatous GCTs. The benefit of such surgery results from the removal of chemotherapy-resistant teratoma or cancer as well as the identification of residual viable cancer that may require additional chemotherapy.",
"   </p>",
"   <p>",
"    This topic will review the role of retroperitoneal lymph node dissection after chemotherapy in men with testicular GCTs, as well as the use of surgery at other sites in patients with advanced disease. A general overview of the treatment of testicular cancer is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13432?source=see_link\">",
"     \"Overview of the treatment of testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of residual masses present at the completion of chemotherapy includes",
"    <span class=\"nowrap\">",
"     necrosis/fibrosis,",
"    </span>",
"    mature or immature teratoma, and residual non-teratomatous germ cell tumor (GCT).",
"   </p>",
"   <p>",
"    When such masses are identified in the retroperitoneum, 40 to 50 percent are necrosis or fibrosis, 30 to 40 percent are teratoma, and 10 to 20 percent represent residual viable GCTs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. The percentage of patients with viable GCT may be higher in those who have received multiple chemotherapy regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Significance of teratoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple reasons to resect residual teratoma even though most teratomas are benign:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benign teratomas are relatively resistant to the chemotherapy and radiotherapy (RT) regimens for testicular GCTs.",
"     </li>",
"     <li>",
"      Viable GCT may be present and can lead to clinical recurrence if not resected [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/10,11\">",
"       10,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Malignant transformation of mature teratoma can occur [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/12\">",
"       12",
"      </a>",
"      ]. Sarcomas or adenocarcinomas arising from a teratoma are resistant to the chemotherapy regimens used for testicular GCTs and are associated with a poor prognosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/12-14\">",
"       12-14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/40/5770?source=see_link&amp;anchor=H11#H11\">",
"       \"Anatomy and pathology of testicular tumors\", section on 'Teratoma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Indolent growth of a teratoma may compromise vital organ function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RPLND AFTER CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of residual masses following chemotherapy for testicular germ cell tumors (GCTs) are identified in the retroperitoneum. A therapeutic retroperitoneal lymph node dissection (RPLND, also termed an RPLND-III) may be indicated for men with testicular GCTs who either have a residual mass following chemotherapy or have recurrent retroperitoneal disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/3/9272?source=see_link\">",
"     \"Retroperitoneal lymph node dissection in testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The indications for RPLND differ for patients with seminoma and nonseminomatous germ cell tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Seminomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial treatment for patients with seminoma is orchiectomy. Subsequent management is based upon the extent of disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with stage I disease can be managed with active surveillance, adjuvant chemotherapy, or adjuvant radiation therapy (RT). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/2/22567?source=see_link\">",
"       \"Treatment of stage I seminoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Men with stage II seminoma and nonbulky retroperitoneal disease are treated with either low-dose RT or cisplatin-based combination chemotherapy, while those with bulky disease (stage IIC) are treated with chemotherapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/45/22230?source=see_link\">",
"       \"Treatment of stage II seminoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Residual masses are commonly seen after RT or chemotherapy for pure seminoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/16-21\">",
"     16-21",
"    </a>",
"    ]. In such patients, two different radiologic patterns can be seen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one, the retroperitoneal mass has the appearance of a sheet of tissue around the great vessels, obliterating radiographic planes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/22\">",
"       22",
"      </a>",
"      ]. Such a mass merges with the great vessels, psoas muscles, and other retroperitoneal structures. It usually represents fibrosis and is often unresectable [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In other cases, lesions are well delineated and distinct from surrounding structures. Compared to the above pattern of radiographic abnormality, these masses are more likely to be resectable and often represent residual seminoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/23,24\">",
"       23,24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Historically, standard practice has been not to resect or treat residual masses &lt;3 cm in size following treatment for seminoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. These masses rarely contain viable tumor if resected and men rarely relapse during surveillance if they are not resected. In addition, at least one report suggests that approximately one-half of such masses will disappear during surveillance within one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/28\">",
"     28",
"    </a>",
"    ]. Close follow-up with serial CT imaging is recommended to detect early relapse.",
"   </p>",
"   <p>",
"    The optimal approach to residual masses &ge;3 cm is uncertain. One approach is to recommend that either all residual masses &ge;3 cm or all well-delineated residual masses &ge;3 cm be resected. However, progression of such masses is very uncommon after three or four cycles of standard platinum-based [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/27\">",
"     27",
"    </a>",
"    ]. PET imaging provides more reliable indication of whether or not viable seminoma is present. Our practice is to obtain PET scans in seminoma patients with residual masses 3 cm or larger and only to perform resection or biopsy of the residual mass if there is increased FDG uptake. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/45/22230?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of stage II seminoma\", section on 'Post therapy residual masses'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Nonseminomatous GCTs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The current standard of care for disseminated nonseminomatous GCTs is to resect all residual masses following chemotherapy unless this is technically not possible. Such operations may entail resection of retroperitoneal, pulmonary, mediastinal, supraclavicular,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hepatic masses.",
"    <br/>",
"   </p>",
"   <p>",
"    Any patient with nonseminomatous GCT with one or more residual retroperitoneal lymph nodes larger than 1 cm following chemotherapy should undergo RPLND. Centers that are not accustomed to performing RPLNDs should refer the patient to a center of excellence with extensive experience with resecting postchemotherapy residual GCT masses whenever possible. Postchemotherapy RPLNDs are associated with a higher complication rate compared to RPLND for stage I or IIA testis cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/3/9272?source=see_link\">",
"     \"Retroperitoneal lymph node dissection in testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Small residual masses or lymph nodes are usually detectable with high resolution imaging (CT or MRI) following chemotherapy, but the definition of normal can differ from one institution to another. In one series of 87 patients with residual retroperitoneal masses less than 2 cm in size after chemotherapy, post-resection pathologic results revealed teratoma in 26 men and viable malignant GCT in seven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/29\">",
"     29",
"    </a>",
"    ]. Among the 54 patients with lymph nodes smaller than 10 mm, six (11 percent) had viable malignant GCT.",
"   </p>",
"   <p>",
"    The role of RPLND in patients with nonseminomatous GCTs who had retroperitoneal adenopathy prior to chemotherapy and who have normal postchemotherapy scans (ie, no residual mass larger than 1 cm) is controversial. Some groups advocate performing an RPLND for any detectable lesion, while the majority advocate careful surveillance and salvage therapy if there is any evidence of progression in the retroperitoneum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/29-33\">",
"     29-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PET imaging has not been sufficiently sensitive to be clinically useful in deciding whether or not to resect the retroperitoneal lymph nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. PET cannot reliably differentiate teratoma from fibrosis, a distinction with important implications that affects the decision of whether or not to perform an RPLND. Furthermore, in contrast to the situation in seminoma, PET is not sufficiently sensitive in detecting nodes that contain viable tumor.",
"   </p>",
"   <p>",
"    In a multicenter study of 121 patients who underwent RPLND for residual masses greater than 1 cm after cisplatin-based chemotherapy, PET imaging was positive in only 47 of 67 cases (70 percent) with pathologically confirmed tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/34\">",
"     34",
"    </a>",
"    ]. Furthermore, PET was positive in 33 of 54 cases in which tumors were not identified. Because a negative PET scan does not indicate that a residual mass can safely be observed, there is no established role for PET scans in assessing residual masses in patients with NSGCT and their use is discouraged.",
"   </p>",
"   <p>",
"    Other factors that have been studied as potential predictors of the histology of residual retroperitoneal masses include the presence of teratomatous elements in the primary tumor, levels of serum tumor markers prior to chemotherapy, and the degree of reduction in mass size during chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/4-6,36-38\">",
"     4-6,36-38",
"    </a>",
"    ]. However, none of these factors is accurate enough to exclude the need for surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/29,30,39\">",
"     29,30,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The finding of what appears to be histopathologically viable cancer or teratoma at postchemotherapy resection does not necessarily predict that the patient would relapse without resection or other additional treatment. Studies from institutions that observe patients with residual masses smaller than 1 cm have reported excellent results.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of 276 patients with metastatic NSGCT, 161 had normal postchemotherapy scans (115 with complete resolution of all metastatic lesions and 46 with a residual mass no larger than 1 cm) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/32\">",
"       32",
"      </a>",
"      ]. These 161 patients were observed and 10 relapses were reported, eight of which were pure teratoma and limited to the retroperitoneum. Disease-specific survival was 100 percent after a median follow-up of over four years.",
"     </li>",
"     <li>",
"      Similarly, among 141 patients at Indiana University with disseminated nonseminomatous GCT who achieved a complete response to chemotherapy (87 of whom had prechemotherapy retroperitoneal adenopathy), 12 patients (9 percent) had relapsed at a median follow-up of 15.5 years, which resulted in four deaths [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/31\">",
"       31",
"      </a>",
"      ]. Six of these (4 percent) relapsed in the retroperitoneum, of whom two died. Five patients had late relapses, including two in the retroperitoneum, and these five were all in complete remission at the time the data were reported. Among the 87 patients who had prechemotherapy retroperitoneal adenopathy, there were 10 relapses (11 percent) and three deaths (3 percent). Three of the 10 relapses occurred five or more years after treatment and none of these three died.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most centers thus only perform postchemotherapy RPLND in patients with residual masses larger than 1 cm. For patients managed without RPLND, surveillance must be prolonged since recurrences ten years or more after treatment can occur. Multiple imaging procedures in relatively young patients during this time may entail a significant radiation exposure and increase the risk of second malignancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/56/2954?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment of relapsed and refractory testicular germ cell tumors\", section on 'Late relapse'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Outcome after RPLND",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcome following RPLND after chemotherapy for NSGCT has been well described in several large series.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a French series of 151 patients who underwent RPLND after first-line chemotherapy, 132 patients (87 percent) were alive and in complete remission, 15 (10 percent) relapsed in the retroperitoneum and 18 died [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/40\">",
"       40",
"      </a>",
"      ]. In 70 patients, the RPLND was judged to conform to current standards of care and there were two (3 percent) relapses. In the remaining 81 patients, there were 13 (16 percent) relapses. These data suggest that centers that do not see a large volume of these patients should not undertake a postchemotherapy RPLND. Men who are recommended for a postchemotherapy RPLND should be referred to a tertiary medical center.",
"     </li>",
"     <li>",
"      In a German study of 152 consecutive patients who underwent postchemotherapy RPLND, 84 (55 percent) had necrosis or fibrosis, 45 (30 percent) had mature teratoma, and 23 (15 percent) had viable malignancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/41\">",
"       41",
"      </a>",
"      ]. Eight relapses were observed (5 percent) after a median follow-up of 39 months. Major complications included chylous ascites, aortoduodenal fistula, pulmonary embolism, femoral nerve lesion, and rebleeding, each in approximately 1 percent of cases. Only one patient died.",
"     </li>",
"     <li>",
"      Long-term follow-up in patients with residual teratoma at RPLND was analyzed in one institutional series of 210 cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/14\">",
"       14",
"      </a>",
"      ]. Surgical findings included 178 with mature teratoma, 15 with immature teratoma, and 17 with teratoma with malignant transformation (85, 7, and 8 percent, respectively). The ten-year disease-free survival after complete resection of residual teratoma was 80 percent. At a median follow-up of 37 months, 30 patients relapsed, including 10 with teratoma, five with teratoma with malignant transformation and 15 with malignant germ cell tumor. Disease-specific survival at 5 and 10 years was 94 and 92 percent, respectively. On multivariate analysis, large size of the residual mass and intermediate or poor pretreatment International Germ Cell Cancer Collaborative Group (IGCCCG) risk status were predictors of a higher likelihood of recurrence (",
"      <a class=\"graphic graphic_table graphicRef61906 \" href=\"mobipreview.htm?41/46/42732\">",
"       table 1",
"      </a>",
"      ). Similar results were seen in series from M. D. Anderson Cancer Center and Indiana University in patients who had teratoma identified at RPLND [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/42,43\">",
"       42,43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/17/24852?source=see_link\">",
"       \"Risk stratification of metastatic testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to men with teratoma or",
"    <span class=\"nowrap\">",
"     necrosis/fibrosis",
"    </span>",
"    discovered at postchemotherapy RPLND, men with viable malignant GCT have a relatively poor prognosis. This was demonstrated in a study involving 146 patients who had viable residual disease identified at post-treatment resection, all of whom had normal tumor markers prior to surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/44\">",
"     44",
"    </a>",
"    ]. The five-year progression-free and overall survival rates were 64 and 73 percent, respectively. Adverse prognostic factors were incomplete resection of residual masses, more than 10 percent viable malignant cells in the resected residual mass, and an intermediate or poor IGCCCG prognostic classification at the start of first-line chemotherapy. A subsequent validation study testing these prognostic variables reported that overall survival rates in patients with zero, one, and two to three risk factors were 90, 86, and 52 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Complications of RPLND",
"    </span>",
"    &nbsp;&mdash;&nbsp;RPLND following chemotherapy includes both resection of residual disease and a full bilateral node dissection. Surgery can entail a combined abdominal and thoracic approach, depending upon the distribution of residual masses. In some cases, resection may require adjunctive nephrectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Masses at other sites'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the best of hands RPLND is associated with an 18 percent complication rate due to the technically demanding nature of the surgery and patient comorbidity. Depending upon the site and extent of the tumor mass, postoperative absence of ejaculation occurs in a significant percentage of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Resection of the infrarenal vena cava is necessary in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/49,50\">",
"     49,50",
"    </a>",
"    ], and aortic tube grafts may be necessary to replace aortic segments that are damaged by subadventitial dissection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Men who have received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    as part of their chemotherapy regimen may have restrictive lung disease, a greater risk of lung toxicity in response to high concentrations of inspired oxygen, and sensitivity to volume replacement both intraoperatively and postoperatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/52\">",
"     52",
"    </a>",
"    ]. Intraoperative central venous pressure monitoring and close attention to fluid volume is recommended in these patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/31/12794?source=see_link\">",
"     \"Bleomycin-induced lung injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/49/20250?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment-related toxicity in men with testicular germ cell tumors\", section on 'Pulmonary'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one review, pulmonary complications were the most frequent cause of severe morbidity after an RPLND-III [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/52\">",
"     52",
"    </a>",
"    ]. Among 125 such patients, six patients developed acute respiratory distress syndrome and five needed prolonged ventilatory support. The underlying cause was a combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -induced lung toxicity, and resection of large retroperitoneal and lung volumes in patients with both intrathoracic and retroperitoneal residual masses (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Lung lesions'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Because of the fibrosis and intense desmoplastic reaction after chemotherapy, minimally invasive RPLND has generally been associated with higher complications, up to 42 percent in some series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/53\">",
"     53",
"    </a>",
"    ]. Recent series still report minor complications in 7 of 16 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Adjuvant chemotherapy after RPLND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following resection of residual masses that contain viable GCT, at least two further cycles of chemotherapy are advised, although retrospective studies have reported conflicting results with regard to whether such chemotherapy is associated with improved outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Successful outcomes have been reported in men who refuse further chemotherapy following surgery alone, even if tumor markers are elevated preoperatively, although this is not the preferred approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/55\">",
"     55",
"    </a>",
"    ]. Among patients with viable tumor at resection following chemotherapy, factors associated with a favorable outcome include complete resection, less than 10 percent viable tumor cells, and for men who presented with advanced disease, good-risk disease according to the International Germ Cell Consensus Classification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/44,45,56\">",
"     44,45,56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/19/10550?source=see_link&amp;anchor=H2#H2\">",
"     \"Management of stage II nonseminomatous germ cell tumors\", section on 'Pathologic stage II NSGCT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     POSTTREATMENT ABNORMAL SERUM TUMOR MARKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all men treated with chemotherapy normalize their serum tumor markers by the end of primary treatment. Two issues arise in these patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Men may have persistently elevated (but not rising) serum tumor markers. (See",
"      <a class=\"local\" href=\"#H983050414\">",
"       'Men with persistently elevated tumor markers'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Men may have rising tumor markers. (See",
"      <a class=\"local\" href=\"#H983050470\">",
"       'Men with rising tumor markers'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The approach to these patients is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H983050414\">",
"    <span class=\"h2\">",
"     Men with persistently elevated tumor markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus on the best approach to manage men with persistently elevated serum tumor markers that are either stable or sluggishly declining at the end of treatment. Although they are at a high risk of relapse, we do not suggest administration of additional chemotherapy. Rather, we offer either early resection of residual masses or surveillance.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Resection &mdash; Postchemotherapy resection of residual masses or retroperitoneal lymph node dissection (RPLND) is often followed by normalization of tumor markers and durable long-term survival [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/45,57,58\">",
"       45,57,58",
"      </a>",
"      ]. As an example, of 114 patients with persistently elevated markers after first-line (n=50) or second-line (n=64) chemotherapy, postchemotherapy RPLND was associated with an overall five-year survival rate of 54 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/58\">",
"       58",
"      </a>",
"      ]. When stratified by final pathologic findings, the five-year survival rate for men with residual malignant GCT, teratoma, or fibrosis was 31, 78, and 86 percent. Preoperative variables associated with an adverse outcome included a rising HCG, a highly elevated AFP, and a prior RPLND.",
"      <br/>",
"      <br/>",
"      The risk of surgery in men who have not normalized their serum tumor markers is that the markers may rise in the immediate postoperative period while the patient is recovering. This may result in an undesirable delay to the start of second-line chemotherapy.",
"     </li>",
"     <li>",
"      Surveillance &mdash; The rationale for surveillance rather than immediate resection is that these patients are at high risk for relapse and having a better sense of what their tumor markers will do helps determine the most appropriate management.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Men with markers that rise instead of slowly normalizing have recurrent disease. These patients should be treated with systemic chemotherapy and not surgical management.",
"     </li>",
"     <li>",
"      Men who normalize their markers over time should undergo resection of any residual masses.",
"     </li>",
"     <li>",
"      We suggest not administering additional chemotherapy for men with persistently elevated markers unless the markers start to rise or there is radiologic evidence of disease progression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H983050470\">",
"    <span class=\"h2\">",
"     Men with rising tumor markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men with rising tumor markers at the end of treatment have chemorefractory disease. We recommend systemic chemotherapy rather than surgical resection for residual disease. However, in carefully selected cases, surgery may represent the patient's best chance of cure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/56/2954?source=see_link\">",
"     \"Treatment of relapsed and refractory testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MASSES AT OTHER SITES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Testicular masses",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men who present with clinically advanced disease, a radical orchiectomy is performed prior to chemotherapy whenever possible. Nonetheless, there are some men who present with life-threatening advanced disease who undergo systemic chemotherapy prior to orchiectomy. In this setting, orchiectomy should be performed upon completion of chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/63/33782?source=see_link&amp;anchor=H6#H6\">",
"     \"Radical inguinal orchiectomy for testicular germ cell tumors\", section on 'Delayed orchiectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Lung lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men with persistent intrathoracic masses following cisplatin-based chemotherapy should undergo resection of disease if technically feasible. Complete resection can be accomplished in almost all patients, and over 80 percent can be expected to achieve long-term survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/59-61\">",
"     59-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The outcomes of resection for postchemotherapy intrapulmonary residual masses were illustrated in a single institution review of 251 men with testicular NSGCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/61\">",
"     61",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among men undergoing resection after their initial chemotherapy, the histopathology was teratoma, necrosis, persistent NSGCT, and non-germ cell cancer in 49, 32, 11, and 8 percent, respectively. In contrast, teratoma was less common and persistent NSGCT more common among those who underwent surgery after salvage chemotherapy (26 and 31 percent of cases, respectively).",
"     </li>",
"     <li>",
"      The majority of men with residual NSGCT after first-line chemotherapy were given additional chemotherapy. At long-term follow-up, 88 percent were alive and 79 percent continuously disease-free. The results were worse in patients resected after salvage chemotherapy. At long-term follow-up, 54 percent were alive and 44 percent continuously disease-free.",
"     </li>",
"     <li>",
"      There were only three postoperative deaths: one each from sepsis, pneumonia, and respiratory failure with pulmonary fibrosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1146316108\">",
"    <span class=\"h3\">",
"     Preoperative considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;All men who have received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    are at risk for complications from surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anesthesia. Therefore, resection of intrathoracic residual disease following chemotherapy may be accompanied by greater morbidity and mortality. For men in whom a pulmonary resection is envisioned, we suggest limiting the total bleomycin dose to &le;300 units. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/49/20250?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment-related toxicity in men with testicular germ cell tumors\", section on 'Pulmonary'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/31/12794?source=see_link\">",
"     \"Bleomycin-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risks of pulmonary toxicity in patients who had received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    is illustrated by a series of 530 men from Indiana University who presented for resection of residual intrathoracic disease following chemotherapy for either metastatic or primary mediastinal nonseminomatous GCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/62\">",
"     62",
"    </a>",
"    ]. In a subset of 32 men who required pneumonectomy or bilobectomy, the mean total dose of prior bleomycin was 360 units or milligrams, and the mean preoperative diffusing capacity was 66 percent of predicted. Prior treatment with bleomycin was associated with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Four operative deaths (13 percent) directly attributable to respiratory complications",
"     </li>",
"     <li>",
"      Major pulmonary postoperative complications in an additional four men, including intubation for longer than 48 hours, a prolonged air leak with empyema, and need for supplemental oxygen at discharge.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, 14 of 20 long-term survivors had a satisfactory performance status at follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Mediastinal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to germ cell tumors (GCTs) that are metastatic to the mediastinum, GCTs that arise in the mediastinum carry a very poor prognosis despite chemotherapy or a multimodality approach. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/52/10058?source=see_link\">",
"     \"Extragonadal germ cell tumors involving the mediastinum and retroperitoneum\"",
"    </a>",
"    .) Nonetheless, men with a mediastinal primary nonseminomatous germ cell tumor (NSGCT) who have one or more residual masses following chemotherapy are treated like other NSGCT patients with residual masses. &nbsp;",
"   </p>",
"   <p>",
"    For men with residual disease in both the retroperitoneum and mediastinum, we prefer a combined surgical approach with RPLND and mediastinal surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. In one report of 18 patients who underwent concomitant RPLND and mediastinal surgery, the overall five-year survival rate was 92 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Neck disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although residual cervical nodal disease is an uncommon site of residual masses or late recurrence (&lt;5 percent in one report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/65\">",
"     65",
"    </a>",
"    ]), such patients should be considered for modified neck dissection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. In one series of 45 such patients, only four recurred in the treated neck, and 97 percent of those with normal preoperative serum tumor markers remained disease-free.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Liver metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resection of residual hepatic disease following chemotherapy can be performed safely and is as important as resection of residual retroperitoneal or pulmonary masses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/68-72\">",
"     68-72",
"    </a>",
"    ]. This was illustrated by a series of 52 patients with normal serum markers after chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/68\">",
"     68",
"    </a>",
"    ]. After resection of residual hepatic disease, 35 (67 percent) were recurrence-free at last follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decision to undertake hepatic resection should take into account the size of the hepatic lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/71\">",
"     71",
"    </a>",
"    ]. Lesions &le;10 mm in greatest dimension have a high probability of necrosis and can be closely monitored. In contrast, larger lesions have a higher risk of containing viable cancer and should be resected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Brain metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain metastases may be present in men with testicular germ cell tumors at the initial diagnosis, in conjunction with systemic relapse, or as an isolated relapse after control of systemic disease.",
"   </p>",
"   <p>",
"    Most men receive cisplatin-based systemic chemotherapy as a component of their initial treatment for brain metastases. However, for men presenting with multiple lesions, whole brain radiation is indicated. Chemotherapy may be given concurrently with radiation therapy in selected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Surgical excision may be useful in some patients to debulk extensive disease or to eradicate limited areas of residual disease following systemic therapy.",
"   </p>",
"   <p>",
"    The approach to patients with brain metastases is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/56/2954?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of relapsed and refractory testicular germ cell tumors\", section on 'Brain metastases'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1146316203\">",
"    <span class=\"h3\">",
"     Multi-site disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men with multiple residual masses following cisplatin-based chemotherapy, up to 33 percent can have a complete response following resection of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/75\">",
"     75",
"    </a>",
"    ]. However, 50 percent of those that undergo surgery once tumor markers have normalized will have evidence only of necrosis at final pathology and will have undertaken surgery unnecessarily.",
"   </p>",
"   <p>",
"    For men with residual retroperitoneal disease and disease at other sites, we suggest resection of retroperitoneal disease as the initial surgical treatment. A subsequent resection of residual disease should be performed only if teratoma is found in the final pathology of the retroperitoneal disease. If viable GCT is found, a decision needs to be made between salvage chemotherapy alone or salvage chemotherapy coupled with further resection.",
"   </p>",
"   <p>",
"    This approach is supported by multiple studies demonstrating that retroperitoneal necrosis is a predictor of necrosis in other sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/75-78\">",
"     75-78",
"    </a>",
"    ]. In one of the largest series, 159 men underwent simultaneous RPLND and thoracotomy following cisplatin-based chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/77\">",
"     77",
"    </a>",
"    ]. The finding of necrosis in the retroperitoneal specimen was associated with an 89 percent probability of necrosis in the lung. Despite these data, others report discordant histologies in up to 50 percent of men undergoing resections at different anatomic sites and advocate the need for resection of all areas of residual disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38425/abstract/79-81\">",
"     79-81",
"    </a>",
"    ]. Therefore, decisions about resection of other disease sites should be individualized based on patient and provider preferences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although testicular germ cell tumors (GCTs) are highly chemosensitive, surgical management is an important component of multimodality treatment for men with advanced disease. Approximately 25 to 30 percent of men with nonseminomatous GCTs will have a residual mass following cisplatin-based combination chemotherapy in the setting of normal serum tumor markers. Such residual masses may reflect viable tumor, teratoma, or",
"      <span class=\"nowrap\">",
"       necrosis/fibrosis.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of a rising tumor marker (alpha fetoprotein or human chorionic gonadotropin) is a relative contraindication to adjunctive surgery in patients following chemotherapy. For such patients, further systemic therapy is generally the preferred treatment, although surgery may have a role in very carefully selected patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/56/2954?source=see_link\">",
"       \"Treatment of relapsed and refractory testicular germ cell tumors\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H11\">",
"       'Posttreatment abnormal serum tumor markers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with stable but persistently elevated serum tumor markers should undergo resection of all residual masses or be observed until markers normalize and then undergo resection. The rationale for observing in this setting is that these patients are at high risk of relapse. If the markers start to rise or there is other evidence of disease progression, chemotherapy rather than surgery is generally preferred. Thus, very close surveillance is required in this setting for patients undergoing observation. For patients undergoing resection, labs should be checked a few days before surgery to ensure that the markers have not started to rise. Patients in whom it is not possible to resect all residual masses should undergo observation and be treated with chemotherapy in the event of progressive disease. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Posttreatment abnormal serum tumor markers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Factors influencing the optimal management of residual masses include histology, location, size, and the presence of coexisting lesions elsewhere.",
"     </li>",
"     <li>",
"      Retroperitoneal masses present following chemotherapy can be due to",
"      <span class=\"nowrap\">",
"       necrosis/fibrosis,",
"      </span>",
"      teratoma, or viable residual GCT, and it is generally not possible to distinguish these possibilities without a tissue diagnosis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Nonseminomatous GCTs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Retroperitoneal lymph node dissection (RPLND) is an important component of a multidisciplinary approach in these patients, but surgery demands a high level of expertise with respect to both the surgery itself and postoperative care. Thus these men should be managed in centers of excellence where a high volume of testicular cancer patients is seen. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/3/9272?source=see_link\">",
"       \"Retroperitoneal lymph node dissection in testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For men with seminoma, we suggest limiting immediate RPLND to those who have clearly delineated masses greater than 3 cm in diameter that show increased FDG uptake on PET scan (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Up to 80 percent of men with stage II seminoma will have radiographic residual masses following completion of their treatment. Imaging cannot definitively distinguish those who have viable tumor, although PET may provide useful information and does have reasonable sensitivity and specificity. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Seminomas'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/45/22230?source=see_link&amp;anchor=H10#H10\">",
"       \"Treatment of stage II seminoma\", section on 'Post therapy residual masses'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with nonseminomatous GCTs, normal tumor markers, and a residual retroperitoneal mass following chemotherapy, we suggest resection of the mass in conjunction with a full retroperitoneal lymph node dissection (RPLND), rather than observation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients with small lesions on imaging (ie, &lt;1 cm), careful surveillance is an appropriate alternative. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Nonseminomatous GCTs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest surgical resection rather than observation for patients who have residual lesions at supradiaphragmatic sites but without involvement of the retroperitoneum (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The most common sites of such involvement include the lungs and mediastinum; neck involvement is less common. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Lung lesions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Mediastinal disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Neck disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For men with residual lesions at both supradiaphragmatic and retroperitoneal sites, we suggest a sequential rather than concurrent surgical approach, with initial resection of the retroperitoneal lesion and an RPLND (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients with residual lesions in the liver following chemotherapy, we suggest resection of lesions that are greater than 10 mm in greatest diameter (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Smaller lesions can be carefully observed, with resection if there is any evidence of growth. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Liver metastases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with brain metastases generally are managed with cisplatin-based chemotherapy followed by resection of residual masses when feasible. The role of whole brain radiation is controversial but it should be considered for patients with unresectable residual masses that cannot be treated with stereotactic radiosurgery. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Brain metastases'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/56/2954?source=see_link&amp;anchor=H19#H19\">",
"       \"Treatment of relapsed and refractory testicular germ cell tumors\", section on 'Brain metastases'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/1\">",
"      Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol 1990; 8:1777.",
"     </a>",
"    </li>",
"    <li>",
"     SEER Cancer Statistics Review, 1975-2006, Horner MJ, Ries LA, et al (Eds), National Cancer Institute, Bethesda, MD 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/3\">",
"      Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/4\">",
"      Steyerberg EW, Keizer HJ, Foss&aring; SD, et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol 1995; 13:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/5\">",
"      Carver BS, Bianco FJ Jr, Shayegan B, et al. Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection. J Urol 2006; 176:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/6\">",
"      Spiess PE, Brown GA, Liu P, et al. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Cancer 2006; 107:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/7\">",
"      Spiess PE, Brown GA, Pisters LL, et al. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters? Cancer 2006; 107:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/8\">",
"      Eggener SE, Carver BS, Loeb S, et al. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors. Cancer 2007; 109:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/9\">",
"      Rick O, Bokemeyer C, Weinknecht S, et al. Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer. J Clin Oncol 2004; 22:3713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/10\">",
"      Bajorin DF, Herr H, Motzer RJ, Bosl GJ. Current perspectives on the role of adjunctive surgery in combined modality treatment for patients with germ cell tumors. Semin Oncol 1992; 19:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/11\">",
"      Sonneveld DJ, Sleijfer DT, Koops HS, et al. Mature teratoma identified after postchemotherapy surgery in patients with disseminated nonseminomatous testicular germ cell tumors: a plea for an aggressive surgical approach. Cancer 1998; 82:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/12\">",
"      Comiter CV, Kibel AS, Richie JP, et al. Prognostic features of teratomas with malignant transformation: a clinicopathological study of 21 cases. J Urol 1998; 159:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/13\">",
"      Donadio AC, Motzer RJ, Bajorin DF, et al. Chemotherapy for teratoma with malignant transformation. J Clin Oncol 2003; 21:4285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/14\">",
"      Carver BS, Shayegan B, Serio A, et al. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. J Clin Oncol 2007; 25:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/15\">",
"      Andr&eacute; F, Fizazi K, Culine S, et al. The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. Eur J Cancer 2000; 36:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/16\">",
"      Loehrer PJ Sr, Birch R, Williams SD, et al. Chemotherapy of metastatic seminoma: the Southeastern Cancer Study Group experience. J Clin Oncol 1987; 5:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/17\">",
"      Mencel PJ, Motzer RJ, Mazumdar M, et al. Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol 1994; 12:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/18\">",
"      Horwich A, Paluchowska B, Norman A, et al. Residual mass following chemotherapy of seminoma. Ann Oncol 1997; 8:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/19\">",
"      Culine S, Abs L, Terrier-Lacombe MJ, et al. Cisplatin-based chemotherapy in advanced seminoma: the Institut Gustave Roussy experience. Eur J Cancer 1998; 34:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/20\">",
"      Horwich A, Oliver RT, Wilkinson PM, et al. A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party. Br J Cancer 2000; 83:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/21\">",
"      Quek ML, Simma-Chiang V, Stein JP, et al. Postchemotherapy residual masses in advanced seminoma: current management and outcomes. Expert Rev Anticancer Ther 2005; 5:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/22\">",
"      Friedman EL, Garnick MB, Stomper PC, et al. Therapeutic guidelines and results in advanced seminoma. J Clin Oncol 1985; 3:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/23\">",
"      Herr HW, Sheinfeld J, Puc HS, et al. Surgery for a post-chemotherapy residual mass in seminoma. J Urol 1997; 157:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/24\">",
"      Ravi R, Ong J, Oliver RT, et al. The management of residual masses after chemotherapy in metastatic seminoma. BJU Int 1999; 83:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/25\">",
"      Duchesne GM, Stenning SP, Aass N, et al. Radiotherapy after chemotherapy for metastatic seminoma--a diminishing role. MRC Testicular Tumour Working Party. Eur J Cancer 1997; 33:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/26\">",
"      Puc HS, Heelan R, Mazumdar M, et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol 1996; 14:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/27\">",
"      Schultz SM, Einhorn LH, Conces DJ Jr, et al. Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J Clin Oncol 1989; 7:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/28\">",
"      Flechon A, Bompas E, Biron P, Droz JP. Management of post-chemotherapy residual masses in advanced seminoma. J Urol 2002; 168:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/29\">",
"      Oldenburg J, Alfsen GC, Lien HH, et al. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol 2003; 21:3310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/30\">",
"      Bosl GJ, Motzer RJ. Weighing risks and benefits of postchemotherapy retroperitoneal lymph node dissection: not so easy. J Clin Oncol 2010; 28:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/31\">",
"      Ehrlich Y, Brames MJ, Beck SD, et al. Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J Clin Oncol 2010; 28:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/32\">",
"      Kollmannsberger C, Daneshmand S, So A, et al. Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. J Clin Oncol 2010; 28:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/33\">",
"      Dash A, Carver BS, Stasi J, et al. The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor. Cancer 2008; 112:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/34\">",
"      Oechsle K, Hartmann M, Brenner W, et al. [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. J Clin Oncol 2008; 26:5930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/35\">",
"      Severin SE, Skolysheva LK, Shur SA, Vulfson PL. The pH-dependent conformational transition in glycogen phosphorylase b. The effect of carnosine and anserine on its activity. Biochem Int 1990; 20:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/36\">",
"      Foss&aring; SD, Ous S, Lien HH, Stenwig AE. Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer. J Urol 1989; 141:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/37\">",
"      Levitt MD, Reynolds PM, Sheiner HJ, Byrne MJ. Non-seminomatous germ cell testicular tumours: residual masses after chemotherapy. Br J Surg 1985; 72:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/38\">",
"      Debono DJ, Heilman DK, Einhorn LH, Donohue JP. Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol 1997; 15:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/39\">",
"      Albers PS, Weinknecht S, Krege S, et al. Prediction of necrosis after chemotherapy of advanced germ cell tumors: Results of a prospective multicenter trial of the GTCSG (abstract). J Urol 2002; 167:172a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/40\">",
"      Fl&eacute;chon A, Tavernier E, Boyle H, et al. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour. BJU Int 2010; 106:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/41\">",
"      Heidenreich A, Pfister D, Witthuhn R, et al. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. Eur Urol 2009; 55:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/42\">",
"      Svatek RS, Spiess PE, Sundi D, et al. Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection. Cancer 2009; 115:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/43\">",
"      Beck SD, Foster RS, Bihrle R, et al. Long-term outcome for patients with high volume retroperitoneal teratoma undergoing post-chemotherapy surgery. J Urol 2009; 181:2526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/44\">",
"      Fizazi K, Tjulandin S, Salvioni R, et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group. J Clin Oncol 2001; 19:2647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/45\">",
"      Fizazi K, Oldenburg J, Dunant A, et al. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann Oncol 2008; 19:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/46\">",
"      Vergouwe Y, Steyerberg EW, Foster RS, et al. Validation of a prediction model and its predictors for the histology of residual masses in nonseminomatous testicular cancer. J Urol 2001; 165:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/47\">",
"      Stephenson AJ, Tal R, Sheinfeld J. Adjunctive nephrectomy at post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer. J Urol 2006; 176:1996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/48\">",
"      Arai Y, Kawakita M, Okada Y, Yoshida O. Sexuality and fertility in long-term survivors of testicular cancer. J Clin Oncol 1997; 15:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/49\">",
"      Jacobsen KD, Ous S, Waehre H, et al. Ejaculation in testicular cancer patients after post-chemotherapy retroperitoneal lymph node dissection. Br J Cancer 1999; 80:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/50\">",
"      Spitz A, Wilson TG, Kawachi MH, et al. Vena caval resection for bulky metastatic germ cell tumors: an 18-year experience. J Urol 1997; 158:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/51\">",
"      Beck SD, Lalka SG. Long-term results after inferior vena caval resection during retroperitoneal lymphadenectomy for metastatic germ cell cancer. J Vasc Surg 1998; 28:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/52\">",
"      Donohue JP, Thornhill JA, Foster RS, Bihrle R. Vascular considerations in postchemotherapy. Retroperitoneal lymph-node dissection: Part I--Vena cava. World J Urol 1994; 12:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/53\">",
"      Palese MA, Su LM, Kavoussi LR. Laparoscopic retroperitoneal lymph node dissection after chemotherapy. Urology 2002; 60:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/54\">",
"      Permpongkosol S, Lima GC, Warlick CA, et al. Postchemotherapy laparoscopic retroperitoneal lymph node dissection: evaluation of complications. Urology 2007; 69:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/55\">",
"      Baniel J, Foster RS, Rowland RG, et al. Complications of post-chemotherapy retroperitoneal lymph node dissection. J Urol 1995; 153:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/56\">",
"      Coogan CL, Foster RS, Rowland RG, et al. Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone. Urology 1997; 50:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/57\">",
"      Beck SD, Patel MI, Sheinfeld J. Tumor marker levels in post-chemotherapy cystic masses: clinical implications for patients with germ cell tumors. J Urol 2004; 171:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/58\">",
"      Beck SD, Foster RS, Bihrle R, et al. Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol 2005; 23:6149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/59\">",
"      Albers P, Ganz A, Hannig E, et al. Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. J Urol 2000; 164:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/60\">",
"      Liu D, Abolhoda A, Burt ME, et al. Pulmonary metastasectomy for testicular germ cell tumors: a 28-year experience. Ann Thorac Surg 1998; 66:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/61\">",
"      Cagini L, Nicholson AG, Horwich A, et al. Thoracic metastasectomy for germ cell tumours: long term survival and prognostic factors. Ann Oncol 1998; 9:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/62\">",
"      Kesler KA, Wilson JL, Cosgrove JA, et al. Surgical \"salvage\" therapy for intrathoracic chemorefractory metastases from non-seminomatous germ cell cancer of testicular origin: an institutional retrospective review (abstract). Proc Am Soc Clin Oncol 2004; 23:387a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/63\">",
"      Einhorn LH. Do all germ cell tumor patients with residual masses in multiple sites require postchemotherapy resections? J Clin Oncol 1997; 15:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/64\">",
"      Fadel E, Court B, Chapelier AR, et al. One-stage approach for retroperitoneal and mediastinal metastatic testicular tumor resection. Ann Thorac Surg 2000; 69:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/65\">",
"      Hejase MJ, Donohue JP, Foster RS, et al. Post-chemotherapy resection of nonseminomatous germ cell testicular tumors metastatic to the mediastinum. J Urol 1996; 156:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/66\">",
"      See WA, Laurenzo JF, Dreicer R, Hoffman HT. Incidence and management of testicular carcinoma metastatic to the neck. J Urol 1996; 155:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/67\">",
"      van Vledder MG, van der Hage JA, Kirkels WJ, et al. Cervical lymph node dissection for metastatic testicular cancer. Ann Surg Oncol 2010; 17:1682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/68\">",
"      Weisberger EC, McBride LC. Modified neck dissection for metastatic nonseminomatous testicular carcinoma. Laryngoscope 1999; 109:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/69\">",
"      Hahn TL, Jacobson L, Einhorn LH, et al. Hepatic resection of metastatic testicular carcinoma: a further update. Ann Surg Oncol 1999; 6:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/70\">",
"      Elias D, Cavalcanti de Albuquerque A, Eggenspieler P, et al. Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients. J Am Coll Surg 1998; 187:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/71\">",
"      Goulet RJ Jr, Hardacre JM, Einhorn LH, et al. Hepatic resection for disseminated germ cell carcinoma. Ann Surg 1990; 212:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/72\">",
"      Rivoire M, Elias D, De Cian F, et al. Multimodality treatment of patients with liver metastases from germ cell tumors: the role of surgery. Cancer 2001; 92:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/73\">",
"      Bokemeyer C, Nowak P, Haupt A, et al. Treatment of brain metastases in patients with testicular cancer. J Clin Oncol 1997; 15:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/74\">",
"      Raghavan D, Mackintosh JF, Fox RM, et al. Improved survival after brain metastases in non-seminomatous germ cell tumours with combined modality treatment. Br J Urol 1987; 60:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/75\">",
"      Morelli F, Tozzi L, Setola P, et al. Postchemotherapy residual masses in germ cell tumor patients: our experience. Ann Oncol 2006; 17 Suppl 7:vii132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/76\">",
"      Stephens AW, Gonin R, Hutchins GD, Einhorn LH. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol 1996; 14:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/77\">",
"      Steyerberg EW, Keizer HJ, Messemer JE, et al. Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor. Prediction of histology. ReHiT Study Group. Cancer 1997; 79:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/78\">",
"      Steyerberg EW, Donohue JP, Gerl A, et al. Residual masses after chemotherapy for metastatic testicular cancer: the clinical implications of the association between retroperitoneal and pulmonary histology. Re-analysis of Histology in Testicular Cancer (ReHiT) Study Group. J Urol 1997; 158:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/79\">",
"      Tognoni PG, Foster RS, McGraw P, et al. Combined post-chemotherapy retroperitoneal lymph node dissection and resection of chest tumor under the same anesthetic is appropriate based on morbidity and tumor pathology. J Urol 1998; 159:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/80\">",
"      Hartmann JT, Candelaria M, Kuczyk MA, et al. Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. Eur J Cancer 1997; 33:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38425/abstract/81\">",
"      Brenner PC, Herr HW, Morse MJ, et al. Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis. J Clin Oncol 1996; 14:1765.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2952 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-8C00B56BB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_33_38425=[""].join("\n");
var outline_f37_33_38425=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Significance of teratoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RPLND AFTER CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Seminomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Nonseminomatous GCTs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Outcome after RPLND",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Complications of RPLND",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Adjuvant chemotherapy after RPLND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      POSTTREATMENT ABNORMAL SERUM TUMOR MARKERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H983050414\">",
"      Men with persistently elevated tumor markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H983050470\">",
"      Men with rising tumor markers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MASSES AT OTHER SITES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Testicular masses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Lung lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1146316108\">",
"      - Preoperative considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Mediastinal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Neck disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Liver metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Brain metastases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1146316203\">",
"      - Multi-site disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2952\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2952|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/46/42732\" title=\"table 1\">",
"      Risk strat system advancted TGCTs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/40/5770?source=related_link\">",
"      Anatomy and pathology of testicular tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/31/12794?source=related_link\">",
"      Bleomycin-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/52/10058?source=related_link\">",
"      Extragonadal germ cell tumors involving the mediastinum and retroperitoneum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/63/24568?source=related_link\">",
"      Initial risk-stratified treatment for advanced testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/19/10550?source=related_link\">",
"      Management of stage II nonseminomatous germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13432?source=related_link\">",
"      Overview of the treatment of testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/63/33782?source=related_link\">",
"      Radical inguinal orchiectomy for testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/3/9272?source=related_link\">",
"      Retroperitoneal lymph node dissection in testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/17/24852?source=related_link\">",
"      Risk stratification of metastatic testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/56/2954?source=related_link\">",
"      Treatment of relapsed and refractory testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/2/22567?source=related_link\">",
"      Treatment of stage I seminoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/45/22230?source=related_link\">",
"      Treatment of stage II seminoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/49/20250?source=related_link\">",
"      Treatment-related toxicity in men with testicular germ cell tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_33_38426="Clinical features, diagnosis, and treatment of Klebsiella pneumoniae infection";
var content_f37_33_38426=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features, diagnosis, and treatment of Klebsiella pneumoniae infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/33/38426/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/33/38426/contributors\">",
"     Wen-Liang Yu, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/33/38426/contributors\">",
"     Yin-Ching Chuang, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/33/38426/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/33/38426/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/33/38426/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/33/38426/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/33/38426/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Klebsiella pneumoniae is a member of the Klebsiella genus of Enterobacteriaceae and belongs to the normal flora of the human mouth and intestine. Of the pathogenic Klebsiella species, K. pneumoniae is the most prevalent and clinically important. Infections with K. pneumoniae are usually hospital-acquired and occur primarily in patients with impaired host defenses.",
"   </p>",
"   <p>",
"    An important exception to these general observations is a community-acquired invasive primary liver abscess syndrome, which can occur in patients without any underlying predisposing medical conditions and has primarily been described in countries in East Asia, particularly Taiwan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29176?source=see_link\">",
"     \"Invasive liver abscess syndrome caused by Klebsiella pneumoniae\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The epidemiology, clinical features, diagnosis, and treatment of infections due to K. pneumoniae will be reviewed here. The microbiology and pathogenesis of K. pneumoniae infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/18/21801?source=see_link\">",
"     \"Microbiology and pathogenesis of Klebsiella pneumoniae infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Humans are the primary reservoir for K. pneumoniae. Carrier rates of K. pneumoniae in the community range from 5 to 38 percent in stool samples and 1 to 6 percent in the nasopharynx; Klebsiella species are rarely carried on the skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/2\">",
"     2",
"    </a>",
"    ]. Higher rates of nasopharyngeal carriage have been noted in ambulatory alcoholic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Carrier rates are markedly increased in hospitalized patients in whom reported rates are 77 percent in the stool, 19 percent in the pharynx, and 42 percent on the hands [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/2\">",
"     2",
"    </a>",
"    ]. The higher rates of colonization are primarily related to the use of antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ]. This increase in prevalence is important clinically since, in one report, Klebsiella nosocomial infection was four times higher in stool carriers compared with noncarriers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    K. pneumoniae can also be found in soil and water, and organisms from coastal water can be a zoonotic pathogen of marine mammals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There may be seasonal variation in the occurrence of K. pneumoniae infections, as illustrated by a study that found a higher incidence of K. pneumoniae bloodstream infections during the warmer months across four continents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/10\">",
"     10",
"    </a>",
"    ]. This association was not seen with Enterobacter or Serratia infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Host risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of K. pneumoniae infection is increased in individuals with impaired host defenses (eg, diabetes mellitus, alcoholism, malignancy, hepatobiliary disease, chronic obstructive pulmonary disease, glucocorticoid therapy, and renal failure) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/11-21\">",
"     11-21",
"    </a>",
"    ]. In a series of 101 patients with Klebsiella bacteremia, for example, underlying diabetes was present in 36 percent and malignancy in 26 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/14\">",
"     14",
"    </a>",
"    ]. However, the relative importance of diabetes and malignancy as risk factors varies with site of acquisition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rare cases have raised the possibility of certain occupational exposures as risk factors for infection, as illustrated by a report of food handlers who developed K. pneumoniae central nervous system infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Site of acquisition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections caused by K. pneumoniae can be acquired in the hospital setting, in long-term care facilities such as nursing homes (called non-nosocomial healthcare-associated infections), and, less often, in the community [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/2,5,12,14,17-19,23\">",
"     2,5,12,14,17-19,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been estimated that Klebsiella species account for 3 to 8 percent of all nosocomial bacterial infections, with the most common manifestations being urinary tract infection, pneumonia, and primary bacteremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/2,24\">",
"     2,24",
"    </a>",
"    ]. The major risk factors for such infections are prior antibiotic use and use of invasive plastic devices, such as bladder catheters, endotracheal tubes, and intravenous catheters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/2,5,18\">",
"     2,5,18",
"    </a>",
"    ]. Widespread antibiotic use is also responsible for the development of multidrug resistance in K. pneumoniae. (See",
"    <a class=\"local\" href=\"#H6012683\">",
"     'Resistant organisms'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The predisposing diseases and site of infection appear to vary with the site of acquisition. This was illustrated in a prospective study from Taiwan of 158 consecutively hospitalized patients with K. pneumoniae bacteremia seen between 1997 and 1999 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Underlying diabetes was significantly more common with community-acquired infection (49 versus 13 percent), whereas malignancy was significantly more common with nosocomial infection (53 versus 14 percent). Among community-acquired infections, diabetes is a particular risk factor for primary liver abscess. (See",
"      <a class=\"local\" href=\"#H6013591\">",
"       'Liver abscess'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29176?source=see_link&amp;anchor=H4#H4\">",
"       \"Invasive liver abscess syndrome caused by Klebsiella pneumoniae\", section on 'Pathogenesis and risk factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      All cases of liver abscess were community acquired, and liver abscess was identified in 23 percent of community-acquired infections. An inability to identify a primary source of infection was significantly more common with nosocomial bacteremia (58 versus 16 percent of community-acquired bacteremias).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Geographic distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although nosocomial K. pneumoniae infections occur worldwide, some types of community-acquired infection are seen in only a few areas. As an example, regional differences in the primary source of K. pneumoniae bacteremia were evaluated in a review of 455 consecutive cases in seven countries (Taiwan, South Africa, United States, Australia, Belgium, Turkey, and Argentina) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/25\">",
"     25",
"    </a>",
"    ]. Community-acquired pneumonia was seen only in Taiwan and South Africa and the invasive community-acquired syndrome of liver abscess, meningitis, or endophthalmitis was only seen in Taiwan. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29176?source=see_link&amp;anchor=H3#H3\">",
"     \"Invasive liver abscess syndrome caused by Klebsiella pneumoniae\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Virulence factors in the K. pneumoniae isolates appeared to play a significant role in the geographic restriction of these syndromes. The isolates from Taiwan and South Africa compared with the other countries were much more likely to have a mucoid phenotype (100 versus 2 percent) and to be rmpA-positive (86 versus 7 percent). Other virulence factors, such as K1 capsular serotype, were common in Taiwan and South Africa but rarely seen in the other countries. Furthermore, in other studies from Taiwan, an increased number of virulence factors has been particularly associated with community-acquired primary liver abscess [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/1,26\">",
"     1,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/18/21801?source=see_link&amp;anchor=H3#H3\">",
"     \"Microbiology and pathogenesis of Klebsiella pneumoniae infection\", section on 'Pathogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29176?source=see_link&amp;anchor=H5#H5\">",
"     \"Invasive liver abscess syndrome caused by Klebsiella pneumoniae\", section on 'Virulence factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The increased virulence associated with community-acquired infections in these regions is not seen in most other countries. As an example, a report of 241 patients with Klebsiella bacteremia from Israel found significantly higher rates of both shock and mortality with nosocomial infections (65 and 42 versus 37 and 22 percent in community-acquired infections) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;K. pneumoniae is primarily a nosocomial pathogen that has been associated with urinary tract infection, pulmonary infection, bacteremia, and other infections in susceptible individuals who have the risk factors described above. Community-acquired infections are less common and include pneumonia, urinary tract infection, and, primarily in East Asia (particularly Taiwan), a liver abscess syndrome that may be associated with metastatic infections such as endophthalmitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    meningitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pulmonary infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;K. pneumoniae pulmonary infections include nosocomial (hospital-acquired) pneumonia, community-acquired pneumonia, secondary infection in patients with chronic obstructive pulmonary disease (COPD), lung abscess, and empyema (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71970 \" href=\"mobipreview.htm?10/13/10454\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H690737\">",
"    <span class=\"h3\">",
"     Nosocomial pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;K. pneumoniae is a relatively common cause of nosocomial pneumonia. This was illustrated in a review of 4543 patients with pneumonia in United States hospitals between January 2002 and December 2003 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/28\">",
"     28",
"    </a>",
"    ]. K. pneumoniae accounted for 8.4 percent of cases of ventilator-associated pneumonia (VAP), 7.1 percent of cases of non-ventilated hospital-acquired pneumonia (defined as first positive culture more than two days after admission), and 7.6 percent of cases of healthcare-associated pneumonia (eg, infections occurring in long-term care facilities, also called non-nosocomial healthcare-associated pneumonia). In other series, K. pneumoniae accounted for 2 to 3.3 percent of cases of VAP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/29,30\">",
"     29,30",
"    </a>",
"    ] and 4.8 percent of cases of non-ventilated hospital-acquired pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/57/12183?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\", section on 'Pneumonia types'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations of nosocomial pneumonia due to K. pneumoniae are similar to the typical presentation of nosocomial or ventilator-associated pneumonia in general, namely new pulmonary infiltrate with fever, cough, increased sputum production, and leukocytosis. Nosocomial colonization of the upper respiratory tract is common in hospitalized patients, particularly in patients who require ventilator support or admission to an intensive care unit. Thus, isolation of Klebsiella from the sputum of a hospitalized patient without other signs and symptoms of pneumonia may not be indicative of an infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24040?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical presentation and diagnosis of ventilator-associated pneumonia\", section on 'Presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nosocomial K. pneumoniae pulmonary infections usually present as bronchopneumonia or bronchitis. In a series of 198 cases of acute K. pneumoniae pneumonia, the majority of which were nosocomial, the most common CT findings were ground glass opacities (100 percent), alveolar consolidation (91 percent), intralobar reticular opacities (86 percent), and pleural effusions (53 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/31\">",
"     31",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    On Gram stain of the sputum, short, plump, gram-negative bacilli that are usually surrounded by a capsule that appears as a clear space can be seen in nosocomial K. pneumoniae pneumonia. However, this finding is not specific, as other organisms may also appear this way. Other pathogens, specifically Staphylococcus aureus or Pseudomonas aeruginosa, may be found in addition to K. pneumoniae in the sputum from nosocomial cases more frequently than community-acquired cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/32\">",
"     32",
"    </a>",
"    ]. Additionally, Klebsiella isolates in nosocomial cases are more likely to be multidrug resistant. (See",
"    <a class=\"local\" href=\"#H6012683\">",
"     'Resistant organisms'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Community-acquired pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;K. pneumoniae is an infrequent cause of community-acquired pneumonia (CAP) in the United States and Europe that most often occurs in alcoholics and patients with diabetes or severe chronic obstructive pulmonary disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/33\">",
"     33",
"    </a>",
"    ]. In a review of 262 patients with CAP in the Netherlands, a presumptive diagnosis of K. pneumoniae was made in only one case [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/34\">",
"     34",
"    </a>",
"    ]. Similarly, in a global review of 202 episodes of community-acquired K. pneumoniae bacteremia, only four cases of bacteremic pneumonia were noted in the United States, Europe, Argentina, and Australia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/11\">",
"     11",
"    </a>",
"    ]. On the other hand, 53 cases were noted in South Africa and Taiwan.",
"   </p>",
"   <p>",
"    In contrast to its low prevalence as a cause of CAP overall, K. pneumoniae constitutes a higher proportion of isolates in more severe infections. In a study from Taiwan, K. pneumoniae was the most common bacteria isolated from 59 patients with CAP requiring mechanical ventilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/35\">",
"     35",
"    </a>",
"    ]. Additionally, in three separate series different series, the proportion of K. pneumoniae isolates was 9.5 percent in patients with CAP requiring admission, 11 percent in patients presenting with septic shock, and 22 percent in patients with severe CAP (one-half with shock) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/28,36,37\">",
"     28,36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations of K. pneumoniae pneumonia are similar to those of other causes of bacterial pneumonia (eg, cough, fever, pleuritic chest pain, dyspnea, tachypnea, sputum production, crackles on physical examination, and leukocytosis). However, K. pneumoniae pneumonia is also associated with marked inflammation and necrosis that can lead to thick, mucoid and blood-tinged sputum, referred to as \"currant jelly\" sputum. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26026?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnostic approach to community-acquired pneumonia in adults\", section on 'Clinical evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to the radiographic findings in nosocomial cases, community-acquired K. pneumoniae often produces a lobar pneumonia that is similar radiologically to that due to Streptococcus pneumoniae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/31,38\">",
"     31,38",
"    </a>",
"    ]. There is a predilection for involvement of the posterior segment of the right upper lobe. Bowing of the fissure downward due to intense consolidation can led to the bulging fissure sign (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71970 \" href=\"mobipreview.htm?10/13/10454\">",
"     image 1",
"    </a>",
"    ). The distinction of Klebsiella as a cause of community-acquired pneumonia cannot be made on radiographic findings alone.",
"   </p>",
"   <p>",
"    On Gram stain of sputum, Klebsiella species typically appear as short, plump, gram-negative bacilli, which are usually surrounded by a capsule that appears as a clear space (",
"    <a class=\"graphic graphic_picture graphicRef71969 \" href=\"mobipreview.htm?26/45/27345\">",
"     picture 1",
"    </a>",
"    ). However, this finding is not specific, as other organisms may also appear this way.",
"   </p>",
"   <p>",
"    Even with early and appropriate antimicrobial therapy, mortality rates of K. pneumonia CAP are high, particularly in the setting of associated bacteremia. In a study of patients with CAP with bacteremia, the 49 patients with infections due to K. pneumoniae had a higher mortality rate than the 44 patients with Streptococcus pneumoniae (55 versus 27 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/39\">",
"     39",
"    </a>",
"    ]. Respiratory failure is a frequent cause of death in patients with lobar pneumonia, particularly when there is rapid dissemination to multiple lobes or progression to acute respiratory distress syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11768209\">",
"    <span class=\"h3\">",
"     COPD with secondary infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In China and Taiwan, Klebsiella and other gram-negative bacilli are relatively frequent isolates in acute exacerbations of COPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/20,21,40\">",
"     20,21,40",
"    </a>",
"    ]. In one study of 494 acute COPD exacerbations in patients hospitalized at a university-affiliated hospital in Taiwan, the predominant identifiable sputum pathogens were K. pneumoniae (20 percent), Pseudomonas aeruginosa (17 percent) and H. influenzae (8 percent); S. pneumoniae accounted for only 2.4 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/20\">",
"     20",
"    </a>",
"    ]. In the US and Europe, K. pneumoniae is less frequently isolated than Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations are similar to those of COPD exacerbations from other bacterial causes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/43/7866?source=see_link&amp;anchor=H1#H1\">",
"     \"Management of infection in acute exacerbations of chronic obstructive pulmonary disease\", section on 'Introduction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/43/7866?source=see_link&amp;anchor=H10#H10\">",
"     \"Management of infection in acute exacerbations of chronic obstructive pulmonary disease\", section on 'Sputum purulence'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Lung abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;K. pneumoniae is an uncommon cause of lung abscess, which is caused most frequently by anaerobes that make up the flora of the gingival crevice. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/9/24729?source=see_link\">",
"     \"Lung abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the bacteriology of lung abscess may be different in Taiwan, as illustrated by the findings of a retrospective evaluation of 90 adults hospitalized with lung abscess from 1995 to 2003 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/43\">",
"     43",
"    </a>",
"    ]. Gram-negative bacilli, and K. pneumoniae specifically, accounted for 36 and 25 percent of isolates, respectively; other organisms included anaerobes (34 percent), gram-positive cocci (26 percent), and gram-positive bacilli (4 percent).",
"   </p>",
"   <p>",
"    An accompanying editorial noted that the study might have been biased since 25 percent of the patients had received antibiotics prior to culture, making recovery of anaerobes less likely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/44\">",
"     44",
"    </a>",
"    ]. In addition, there may have been selection bias in terms of when transthoracic aspiration was performed, since only 90 of 336 cases of lung abscess (27 percent) had evaluable microbiologic studies.",
"   </p>",
"   <p>",
"    In the Taiwan series, K. pneumoniae lung abscess was significantly associated with underlying diabetes mellitus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/43\">",
"     43",
"    </a>",
"    ]. None of the patients with K. pneumoniae lung abscess were noted to have putrid sputum, one-third presented with a dry cough, and one-third had ongoing symptoms for greater than 30 days. Compared with anaerobic lung abscess, K. pneumoniae lung abscess was associated with significantly higher rates of concomitant bacteremia, delayed defervescence, and multiple cavities on chest x-ray (odds ratio 9.4, 9.2, and 11, respectively). This finding was consistent with the observation that invasive community-acquired K. pneumoniae infection in Taiwan is significantly associated with an unusually virulent strain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/26\">",
"     26",
"    </a>",
"    ]. Scattered cases of necrotizing pneumonia caused by these virulent K. pneumoniae strains are now being seen worldwide, including the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/18/21801?source=see_link&amp;anchor=H3#H3\">",
"     \"Microbiology and pathogenesis of Klebsiella pneumoniae infection\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to being a primary pulmonary infection, K. pneumoniae lung abscess can represent a metastatic infection in patients with the community-acquired invasive liver abscess syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/46-48\">",
"     46-48",
"    </a>",
"    ] or with pyomyositis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29176?source=see_link&amp;anchor=H8#H8\">",
"     \"Invasive liver abscess syndrome caused by Klebsiella pneumoniae\", section on 'Metastatic infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Empyema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Klebsiella pneumoniae is a relatively common isolate in patients with empyema, as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of 197 patients with empyema at two military hospitals in the United States, K. pneumoniae was isolated in 16 (8 percent), 6 as a single organism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      K. pneumoniae is a more common cause of empyema in Taiwan, as it is for lung and liver abscess as noted above. This was illustrated in a study of 171 patients with acute thoracic empyema [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/51\">",
"       51",
"      </a>",
"      ]. A total of 163 organisms were isolated from the pleural fluid of 139 patients. K. pneumoniae was the most commonly isolated pathogen (24 percent of patients) and was strongly associated with a diagnosis of diabetes mellitus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a retrospective analysis of 147 cases of empyema or complicated parapneumonic effusion in Taiwan, patients with monomicrobial pleural infection with K. pneumoniae had similar symptoms as those without K. pneumoniae infection. Fever, chest pain, cough, sputum production, and dyspnea, occurred in 46, 54, 60, 51, and 73 percent respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/52\">",
"     52",
"    </a>",
"    ]. However, those with K. pneumoniae pleural disease had higher progression to shock within 2 days (14 versus 4 percent) and in-hospital mortality (32 versus 13 percent). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28089?source=see_link&amp;anchor=H6#H6\">",
"     \"Parapneumonic effusion and empyema in adults\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Bacteremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Klebsiella pneumoniae is a relatively common cause of gram-negative bacillary bacteremia, more frequently in nosocomial than community-acquired infections, as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Data from the National Nosocomial Infections Surveillance (NNIS) System in the United States in 2003 showed that gram-negative bacilli were responsible for 24 percent of bloodstream infections in intensive care units (ICUs) in the United States [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/53\">",
"       53",
"      </a>",
"      ]. K. pneumoniae accounted for 18 percent of the gram-negative bacteremias and 4.2 percent of all bacteremias. In another NNIS report, 21 percent of K. pneumoniae isolates from patients in ICUs were not susceptible to third generation cephalosporins [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, an Italian study found that K. pneumoniae accounted for only 5.4 percent of community-acquired cases of gram-negative bacillary bacteremia, while 76 percent were due to Escherichia coli [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/55\">",
"       55",
"      </a>",
"      ]. This difference is related to the fact that the urinary tract was the most common source for these infections, and E. coli dominates in genitourinary infections [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/56\">",
"       56",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Cystitis and pyelonephritis'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13561?source=see_link\">",
"       \"Acute uncomplicated cystitis and pyelonephritis in women\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/47/10999?source=see_link\">",
"       \"Acute complicated cystitis and pyelonephritis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical findings associated with K. pneumonia bacteremia were evaluated in a retrospective analysis of 640 cases in Canada [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/57\">",
"     57",
"    </a>",
"    ]. Seventy percent of cases were nosocomial or healthcare related and 30 percent were community-acquired. The median age was 69 years old, and the most important risk factors were solid organ transplantation, chronic liver disease, dialysis dependence, and malignancy. The biliary and genitourinary tracts were the most common primary sites of infection. The overall mortality rate was 20 percent, and higher with older age, nosocomial infection, nonbiliary and nongenitourinary sources, and comorbid conditions. These findings are similar to those seen for bacteremia due to gram-negative bacilli in general. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/12/20681?source=see_link\">",
"     \"Gram-negative bacillary bacteremia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A primary source of infection is not identifiable in 30 to 47 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/12,57,58\">",
"     12,57,58",
"    </a>",
"    ]. This is more likely to occur in nosocomial compared with community-acquired infections. Given the high prevalence of primary liver abscess in patients with community-acquired bacteremia in East Asia, imaging for liver abscess, usually with ultrasonography or computed tomography, may be warranted in patients with community-acquired K. pneumoniae bacteremia of uncertain origin, particularly those who have persistent fever despite appropriate antibiotic therapy. (See",
"    <a class=\"local\" href=\"#H6013591\">",
"     'Liver abscess'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/53/29526?source=see_link\">",
"     \"Pyogenic liver abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Catheter-related bacteremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nosocomial bloodstream infections (BSIs) are frequently associated with catheters, although Klebsiella is a relatively infrequent cause of catheter-related BSIs. In a prospective analysis from the SCOPE database of 24,179 nosocomial BSIs occurring in 49 hospitals in the United States between 1995 and 2002, the majority of which had central venous catheters in place, K. pneumoniae accounted for only 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/59\">",
"     59",
"    </a>",
"    ]. The gram-positive aerobes, coagulase-negative staphylococci, Staphylococcus aureus, and Enterococcus, accounted for 60 percent of the BSIs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37464?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology, pathogenesis, and microbiology of intravascular catheter infections\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis and treatment of central venous catheter-related BSIs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/23/375?source=see_link\">",
"     \"Diagnosis of intravascular catheter-related infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7498?source=see_link\">",
"     \"Treatment of intravascular catheter-related infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Infective endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gram-negative bacilli, including K. pneumoniae, are uncommon causes of infective endocarditis (IE) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/60-63\">",
"     60-63",
"    </a>",
"    ]. As an example, gram-negative bacilli accounted for only 2.1 percent of cases in a study of 1779 patients seen between 2000 and 2003 in 39 medical centers in 16 western countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/60\">",
"     60",
"    </a>",
"    ]. Similarly, in a series of 315 definite or possible cases of IE from Taiwan, only one was due to K. pneumoniae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/62\">",
"     62",
"    </a>",
"    ]. Even patients with K. pneumoniae bacteremia are at low risk for IE (1 of 86 in one report) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The low rate of Klebsiella pneumoniae as a cause of IE may be related in part to decreased adherence of these organisms to heart valves compared with the gram-positive organisms that account for most cases of IE (viridans streptococci, coagulase-positive and coagulase-negative staphylococci, and enterococci) and to Pseudomonas aeruginosa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/31/14840?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology, risk factors and microbiology of infective endocarditis\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, among patients with K. pneumoniae bacteremia, evaluation for IE with transthoracic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    transesophageal echocardiography should be performed only when the diagnosis is suspected clinically or the patient is at high risk (eg, significant or new heart murmur, prosthetic heart valve). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41352?source=see_link\">",
"     \"Diagnostic approach to infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2812582\">",
"    <span class=\"h2\">",
"     Genitourinary tract infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Klebsiella pneumoniae can cause both lower and upper urinary tract infection, although it is a much less common urinary pathogen than Escherichia coli [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/64-66\">",
"     64-66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Cystitis and pyelonephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In two large series of over 2400 women with acute cystitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/65\">",
"     65",
"    </a>",
"    ] and over 2400 outpatients with acute pyelonephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/64\">",
"     64",
"    </a>",
"    ], K. pneumoniae was isolated in 3 to 4 percent of cases whereas E. coli accounted for approximately 80 percent. The clinical findings of urinary tract infections caused by K. pneumoniae are similar to those caused by other bacterial pathogens. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13561?source=see_link\">",
"     \"Acute uncomplicated cystitis and pyelonephritis in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    K. pneumoniae can also cause emphysematous (gas-forming) urinary tract infections, which primarily occur in patients with diabetes mellitus and may be associated with urinary tract obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/30/34278?source=see_link\">",
"     \"Emphysematous urinary tract infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Renal and perinephric abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal abscess can develop by one of two general mechanisms: hematogenous spread, which usually results in a cortical abscess; and, less often, ascending infection from the bladder, which primarily involves the medulla. The features of K. pneumoniae renal abscess were illustrated in a retrospective review of 24 patients in Taiwan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/69\">",
"     69",
"    </a>",
"    ]. The major predisposing factors were diabetes mellitus (58 percent), urolithiasis (25 percent) and immunosuppression (17 percent). Complications included bacteremia (54 percent), emphysematous pyelonephritis (21 percent), and metastatic infection (13 percent). Metastatic infection manifested as endophthalmitis has been noted in other reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6013720\">",
"     'Endophthalmitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Perinephric abscess can result from hematogenous spread or develop as a complication of pyelonephritis. Both abscess types usually present with manifestations similar to acute pyelonephritis, such as fever, chills, and flank pain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/51/14134?source=see_link\">",
"     \"Renal and perinephric abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2812917\">",
"    <span class=\"h3\">",
"     Prostatitis and prostatic abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Klebsiella pneumoniae is generally an infrequent cause of both prostatitis and prostatic abscess [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. In a review of 1442 patients with chronic prostatitis in Croatia, for example, an infectious cause was found in 1070; K. pneumoniae was responsible for only 16 (1.5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/72\">",
"     72",
"    </a>",
"    ]. An exception to this observation was noted in a study from Taiwan in which 10 of 17 cases of prostatic abscess, a severe complication of prostatitis, were due to K. pneumoniae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most severe forms of prostatic infection caused by K. pneumoniae are emphysematous (gas-forming) prostatitis and emphysematous prostatic abscess. Risk factors include diabetes mellitus and chronic alcoholism, and most reports of these rare complications come from East Asia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/75-77\">",
"     75-77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to being a local infection, K. pneumoniae prostatic abscess can represent a metastatic infection in patients with the community-acquired invasive liver abscess syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/47\">",
"     47",
"    </a>",
"    ]. On the other hand, prostatitis or prostatic abscess can lead to metastatic infections, including endophthalmitis, septic arthritis, and osteomyelitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/78-80\">",
"     78-80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29176?source=see_link&amp;anchor=H8#H8\">",
"     \"Invasive liver abscess syndrome caused by Klebsiella pneumoniae\", section on 'Metastatic infection'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H6013720\">",
"     'Endophthalmitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with acute prostatic infections often present with fever and chills, dysuria, obstructive urinary symptoms, and pelvic or perineal pain. On exam, the prostate is usually tender, warm, and edematous. In emphysematous prostatitis, imaging studies demonstrate the presence of gas in the prostate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/76\">",
"     76",
"    </a>",
"    ]. The clinical manifestations of prostatic infections are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/42/4776?source=see_link&amp;anchor=H5#H5\">",
"     \"Acute bacterial prostatitis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2814435\">",
"    <span class=\"h2\">",
"     Intraabdominal infections",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6013591\">",
"    <span class=\"h3\">",
"     Liver abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;K. pneumoniae is a frequent isolate from pyogenic liver abscesses, which are typically polymicrobial and associated with underlying hepatobiliary pathology or cholangitis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81783 \" href=\"mobipreview.htm?37/2/37921\">",
"     image 2",
"    </a>",
"    ). In case series from New York and San Diego, K. pneumoniae was the most common cause of pyogenic hepatic abscess [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/81,82\">",
"     81,82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the report from New York, the clinical features of 171 cases of pyogenic liver abscesses were reviewed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/81\">",
"     81",
"    </a>",
"    ]. The most common presenting symptoms were fever (90 percent), right upper quadrant pain (72 percent) and chills (69 percent). The triad of fever, right upper quadrant pain or tenderness, and elevated alkaline phosphatase were seen in only 43 percent, but 86 percent had at least two of those features. K. pneumoniae was isolated from 23 of 54 (41 percent) liver abscesses in which an organism was recovered, and clinical characteristics were similar to the patients with liver abscesses of other or unknown etiologies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/53/29526?source=see_link&amp;anchor=H5#H5\">",
"     \"Pyogenic liver abscess\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A distinct clinical syndrome, primary liver abscess (ie, in the absence of underlying hepatobiliary disease) due to K. pneumoniae, has been recognized as an important community-acquired infection in East Asia, particularly Taiwan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/1,46,83\">",
"     1,46,83",
"    </a>",
"    ]. This entity is seen less often in other countries but may account for the frequency of K. pneumonia isolates from liver abscesses outside of Asia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/81,82,84\">",
"     81,82,84",
"    </a>",
"    ]. In the series from New York described above, of the 23 cases of K. pneumonia liver abscess, only one occurred in a patient with underlying hepatobiliary disease, and all affected patients were Asian or Hispanic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/81\">",
"     81",
"    </a>",
"    ]. The syndrome of Klebsiella primary liver abscess is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29176?source=see_link\">",
"     \"Invasive liver abscess syndrome caused by Klebsiella pneumoniae\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2814768\">",
"    <span class=\"h3\">",
"     Splenic abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;K. pneumoniae has been reported in 10 to 16 percent of cases of splenic abscess from two series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. In studies from Taiwan, many of these patients also had concurrent liver abscess [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/86-88\">",
"     86-88",
"    </a>",
"    ]. This raises the possibility of splenic abscess representing a metastatic infection in patients with primary liver abscess, an association that has been described by others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6013591\">",
"     'Liver abscess'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29176?source=see_link&amp;anchor=H8#H8\">",
"     \"Invasive liver abscess syndrome caused by Klebsiella pneumoniae\", section on 'Metastatic infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common presenting features of splenic abscesses are fever, left upper quadrant pain, splenomegaly, and left pleural effusion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/34/34346?source=see_link&amp;anchor=H7#H7\">",
"     \"Approach to the adult patient with splenomegaly and other splenic disorders\", section on 'Splenic abscess'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2814503\">",
"    <span class=\"h3\">",
"     Spontaneous bacterial peritonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous bacterial peritonitis (SBP) is defined as an ascitic fluid infection without an evident intraabdominal surgically-treatable source [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/89\">",
"     89",
"    </a>",
"    ]. It almost always occurs in patients with cirrhosis and ascites. Patients typically present with fever and abdominal pain and have an elevated polymorphonuclear leukocyte count in the ascitic fluid. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/0/7172?source=see_link\">",
"     \"Clinical manifestations of spontaneous bacterial peritonitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with SBP and positive ascitic fluid cultures, more than 60 percent are due to gram-negative enteric flora [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/89\">",
"     89",
"    </a>",
"    ]. Escherichia coli is most common, followed by Klebsiella pneumoniae, which is present in approximately 10 to 15 percent of cases (",
"    <a class=\"graphic graphic_table graphicRef80188 \" href=\"mobipreview.htm?22/8/22667\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. This applies to both community-acquired and nosocomial infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6013720\">",
"    <span class=\"h2\">",
"     Endophthalmitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endogenous endophthalmitis caused by K. pneumoniae is an infrequent but often devastating septic metastatic infection. It has mostly been described in association with primary liver abscess in patients from East Asia, particularly Taiwan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/1,46,47,83,92-94\">",
"     1,46,47,83,92-94",
"    </a>",
"    ], but also in patients in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/82\">",
"     82",
"    </a>",
"    ]. In three series from Taiwan with a total of 524 patients with K. pneumoniae liver abscess, metastatic infection occurred in 12 percent, one-half of whom (6 percent total) had endophthalmitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/1,46,47\">",
"     1,46,47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29176?source=see_link&amp;anchor=H8#H8\">",
"     \"Invasive liver abscess syndrome caused by Klebsiella pneumoniae\", section on 'Metastatic infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Metastatic K. pneumoniae endophthalmitis is not limited to primary liver abscess and has been rarely reported with other K. pneumoniae infections including perinephric abscess [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/70,71\">",
"     70,71",
"    </a>",
"    ], pyelonephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/95\">",
"     95",
"    </a>",
"    ], prostatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/78\">",
"     78",
"    </a>",
"    ], prostatic abscess [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/79\">",
"     79",
"    </a>",
"    ], and pulmonary infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with Klebsiella endophthalmitis commonly complain of ocular pain, visual blurring, and eye redness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/97\">",
"     97",
"    </a>",
"    ]. Unilateral disease is often more common than bilateral. The infection tends to be fulminant and often rapidly progresses to permanent visual loss, particularly with a delay in diagnosis and treatment beyond 24 hours after symptom onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/1,92-94,98\">",
"     1,92-94,98",
"    </a>",
"    ]. In a retrospective review of 61 patients with endogenous K. pneumoniae endophthalmitis, 87 percent had poor visual acuity (less than",
"    <span class=\"nowrap\">",
"     4/200)",
"    </span>",
"    at presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/97\">",
"     97",
"    </a>",
"    ]. At three months postinfection, 76 percent still had poor visual acuity and 58 percent had no light perception. Hypopyon (layering of white blood cells in the anterior chamber) was common (72 percent) and a poor prognostic indicator. Good vision at presentation and early initiation of therapy have been associated with a higher likelihood of maintenance of vision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/92,93\">",
"     92,93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endophthalmitis should be considered in any patient complaining of unilateral or bilateral decreased or blurred vision or eye pain in the setting of K. pneumoniae infections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/18/24873?source=see_link&amp;anchor=H16#H16\">",
"     \"Bacterial endophthalmitis\", section on 'Endogenous bacterial endophthalmitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Conversely, the possibility of a separate focus of K. pneumoniae infection, particularly a liver abscess, should be suspected and evaluated in patients who have endogenous endophthalmitis due to K. pneumoniae. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29176?source=see_link&amp;anchor=H12#H12\">",
"     \"Invasive liver abscess syndrome caused by Klebsiella pneumoniae\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6013768\">",
"    <span class=\"h2\">",
"     Meningitis/brain abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Klebsiella pneumoniae is a relatively common cause of nosocomial meningitis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59139 \" href=\"mobipreview.htm?16/29/16854\">",
"     image 3",
"    </a>",
"    ). In a series of 151 cases from the United States, for example, K. pneumoniae accounted for 13 of them (8.6 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/99\">",
"     99",
"    </a>",
"    ]. Neurosurgery is the main risk factor for nosocomial meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/100,101\">",
"     100,101",
"    </a>",
"    ], and the likelihood of postneurosurgery meningitis due to gram-negative organisms such as K. pneumoniae was increased when prophylaxis for gram-positive pathogens was administered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/100\">",
"     100",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/38/31335?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology of bacterial meningitis in adults\", section on 'Nosocomial'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link&amp;anchor=H23#H23\">",
"     \"Overview of control measures to prevent surgical site infection\", section on 'Neurosurgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to nosocomial meningitis, K. pneumoniae is a rare cause of community-acquired bacterial meningitis in the United States and Europe as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 253 cases from the United States, all gram-negative bacilli accounted for 9 of 253 cases (3.6 percent); data were not given for specific organisms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/99\">",
"       99",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a review of 696 cases from the Netherlands, only one was due to K. pneumoniae [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/102\">",
"       102",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a small series of community-acquired K. pneumoniae meningitis, chronic alcoholism was a major risk factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/103,104\">",
"     103,104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An exception to the rarity of K. pneumoniae as a cause of community-acquired bacterial meningitis or brain abscess is the development of meningitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    brain abscess as a metastatic complication of primary K. pneumoniae liver abscess that is community-acquired and mostly seen in East Asia, particularly Taiwan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/1,46,47,105\">",
"     1,46,47,105",
"    </a>",
"    ]. In three series from Taiwan with a total of 524 patients with K. pneumoniae liver abscess, metastatic infection occurred in 12 percent, one-third of whom (4.2 percent) had meningitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    brain abscess [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/1,46,47\">",
"     1,46,47",
"    </a>",
"    ]. Meningitis is more common than brain abscess and some patients have both [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/1,47\">",
"     1,47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29176?source=see_link&amp;anchor=H8#H8\">",
"     \"Invasive liver abscess syndrome caused by Klebsiella pneumoniae\", section on 'Metastatic infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a series of nine patients with metastatic central nervous system K. pneumoniae infection, five had significant persistent neurologic deficits after therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/1\">",
"     1",
"    </a>",
"    ]. One predictor of an adverse outcome is the neurologic status at the time of initiation of therapy with an appropriate antibiotic. In a series of 29 patients with K. pneumoniae meningitis treated with an appropriate antibiotic, the main predictor of an adverse outcome was a Glasgow coma scale of 7 points or less (",
"    <a class=\"graphic graphic_table graphicRef81854 \" href=\"mobipreview.htm?28/62/29676\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/106\">",
"     106",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/9/28825?source=see_link&amp;anchor=H28#H28\">",
"     \"Stupor and coma in adults\", section on 'Glasgow coma scale'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fever and signs of central nervous system infection such as altered mental status, seizures, or nuchal rigidity are present in most patients with meningitis due to a gram-negative organism, including K. pneumoniae. In a series from Taiwan, patients with community-acquired and nosocomial K. pneumonia meningitis had similar presenting features, with the exception of less frequent nuchal rigidity in patients with nosocomial meningitis (50 versus 94 percent in community-acquired cases) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/106\">",
"     106",
"    </a>",
"    ]. The CSF findings of high leukocytes, high protein, and low glucose were reported with similar high frequency in both groups. Gram stain demonstrated visible gram-negative rods in less than one-third of cases. The clinical features of gram-negative bacillary meningitis are discussed in further detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/13/16600?source=see_link\">",
"     \"Epidemiology and clinical features of gram-negative bacillary meningitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Deep neck abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Taiwan, K. pneumoniae is an important etiology of deep neck space infections, which elsewhere are caused mainly by anaerobes and Streptococci. In a Taiwanese review of 100 community-acquired fascial space infections of the head and neck, K. pneumoniae was the most common pathogen in the 65 monomicrobial infections (48 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/107\">",
"     107",
"    </a>",
"    ]. Similar findings were noted in another report, with K. pneumoniae being the most common pathogen with parotid infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/108\">",
"     108",
"    </a>",
"    ]. In both series, K. pneumoniae infection was more prevalent in patients with diabetes.",
"   </p>",
"   <p>",
"    The clinical manifestations of deep neck abscess depend on the primary source of infection and the extent of tissue involvement. The clinical features of deep neck space infections are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36569?source=see_link&amp;anchor=H11#H11\">",
"     \"Deep neck space infections\", section on 'General clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to being a primary infection, K. pneumoniae neck abscess can represent a metastatic infection in patients with the community-acquired invasive liver abscess syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/48\">",
"     48",
"    </a>",
"    ]. In addition, deep neck abscess may be the source of metastatic infection to other sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/109\">",
"     109",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29176?source=see_link&amp;anchor=H8#H8\">",
"     \"Invasive liver abscess syndrome caused by Klebsiella pneumoniae\", section on 'Metastatic infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Skin and soft tissue infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Klebsiella pneumoniae can cause severe cellulitis with or without crepitation that may progress to potentially fatal necrotizing fasciitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/110-113\">",
"     110-113",
"    </a>",
"    ] or necrotizing myositis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/114,115\">",
"     114,115",
"    </a>",
"    ]. K. pneumoniae is an infrequent cause of these infections in western countries but is a more common cause in Taiwan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/110,111,113\">",
"     110,111,113",
"    </a>",
"    ] and, in one series, was the most commonly isolated pathogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/110\">",
"     110",
"    </a>",
"    ]. Patients with necrotizing soft tissue infections can present with pain, swelling, and erythema of the affected site and with systemic toxicity, although in some patients, excruciating pain in the absence of any cutaneous findings is the only initial sign or symptom. In a small series of 15 cases of monomicrobial K. pneumoniae necrotizing fasciitis from Taiwan, concomitant bacteremia (80 percent) and distant abscesses (27 percent) were common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/113\">",
"     113",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/362?source=see_link\">",
"     \"Necrotizing soft tissue infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to occurring as a primary infection, K. pneumoniae necrotizing fasciitis can represent a metastatic infection in patients with the invasive liver abscess syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/1,116\">",
"     1,116",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29176?source=see_link&amp;anchor=H8#H8\">",
"     \"Invasive liver abscess syndrome caused by Klebsiella pneumoniae\", section on 'Metastatic infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Other infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Klebsiella pneumoniae has infrequently been associated with several other infections:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Psoas muscle abscess &ndash; K. pneumoniae psoas abscess is a rare infection that has been described in case reports and small institutional series, mostly from Taiwan [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/109,117,118\">",
"       109,117,118",
"      </a>",
"      ]. Fever and pain in the flank, back, and hip are the usual manifestations, and diabetes mellitus is the most common underlying disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/117\">",
"       117",
"      </a>",
"      ]. Many of these infections reflect seeding from a distal site, such as liver abscess [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/46,47\">",
"       46,47",
"      </a>",
"      ], urinary tract [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/117\">",
"       117",
"      </a>",
"      ], or deep neck abscess [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/109\">",
"       109",
"      </a>",
"      ]. Another source of infection is ruptured iliac artery mycotic aneurysm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/118\">",
"       118",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/19/22839?source=see_link\">",
"       \"Psoas abscess\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Spinal infection &ndash; Sporadic cases of K. pneumoniae spondylodiscitis, vertebral osteomyelitis, and spinal epidural abscess have been reported, and are usually due to primary infection or contiguous involvement from surrounding infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/119-122\">",
"       119-122",
"      </a>",
"      ]. In addition, spinal infection may represent a metastatic site in patients with K. pneumoniae primary liver abscess [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/1,123\">",
"       1,123",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/28/22985?source=see_link\">",
"       \"Vertebral osteomyelitis and discitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/40/17033?source=see_link&amp;anchor=H2#H2\">",
"       \"Epidural abscess\", section on 'Spinal epidural abscess'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Septic arthritis &ndash; Klebsiella pneumoniae in a rare cause of septic (bacterial) arthritis that has involved the knee or hip in isolated case reports [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/124-127\">",
"       124-127",
"      </a>",
"      ]. The infection may be accompanied by gas formation in the joint space and in the surrounding soft tissue [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/124\">",
"       124",
"      </a>",
"      ]. Septic arthritis most often arises from hematogenous spread to the joint. K. pneumoniae septic arthritis may represent a metastatic infection from liver abscess [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/47\">",
"       47",
"      </a>",
"      ], prostatitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/80\">",
"       80",
"      </a>",
"      ], or pyomyositis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/49\">",
"       49",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/50/11049?source=see_link\">",
"       \"Septic arthritis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Purulent pericarditis &ndash; A virulent strain with hypermucoviscosity phenotype was described in a case of purulent pericarditis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/128\">",
"       128",
"      </a>",
"      ]. Cardiac tamponade can also be a complication of pyogenic liver abscess [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/129\">",
"       129",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35303?source=see_link\">",
"       \"Purulent pericarditis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pyomyositis &ndash; The presumed mechanism of muscle infection with K. pneumoniae is transient bacteremia, leading to seeding of a site of prior muscle injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/49,130\">",
"       49,130",
"      </a>",
"      ]. Other foci of metastatic infection may be present, including liver abscess, septic arthritis, endophthalmitis, lung abscess, and subcutaneous abscesses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/49\">",
"       49",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32950?source=see_link\">",
"       \"Pyomyositis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mycotic aneurysm (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/17/35098?source=see_link\">",
"       \"Overview of infected (mycotic) arterial aneurysm\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6012612\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of K. pneumoniae infection is confirmed by culture of blood, sputum, urine, or aspirated body fluid, including pleural effusion, pericardial effusion, synovial fluid, cerebrospinal fluid, and abscess material.",
"   </p>",
"   <p>",
"    In the setting of bacterial pneumonia, sputum Gram stain may provide a presumptive identification for an etiologic agent, but the sensitivity is only about 50 percent. Klebsiella spp typically appear as short, plump, gram-negative bacilli, which are usually surrounded by a capsule that appears as a clear space (",
"    <a class=\"graphic graphic_picture graphicRef71969 \" href=\"mobipreview.htm?26/45/27345\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Imaging often plays an important role in the diagnosis of infection (not specifically K. pneumoniae infection) at a variety of sites. This includes chest radiograph for suspected pneumonia and imaging for suspected abscess formation in the liver, spleen, kidney, or prostate, mycotic aneurysm, epidural abscess, and vertebral osteomyelitis. The choice of imaging tests is discussed elsewhere in the topic reviews on each of these infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6012644\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of K. pneumoniae infection is established, the antibiotic regimen is usually determined by the results of susceptibility testing. Drainage may be warranted in patients with tissue abscesses. Patients with Klebsiella endophthalmitis should receive intravitreal antibiotics and vitrectomy in addition to systemic antibiotics. Additional issues that must be addressed include whether the isolate produces an extended-spectrum beta-lactamase (ESBL) or carbapenemase and the severity of infection.",
"   </p>",
"   <p>",
"    Treatment of the various clinical syndromes is discussed in detail in separate topic reviews. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/63/36858?source=see_link&amp;anchor=H249925653#H249925653\">",
"       \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\", section on 'Approach to therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40986?source=see_link\">",
"       \"Treatment of community-acquired pneumonia in adults who require hospitalization\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/43/7866?source=see_link&amp;anchor=H11#H11\">",
"       \"Management of infection in acute exacerbations of chronic obstructive pulmonary disease\", section on 'Antibiotic therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/9/24729?source=see_link&amp;anchor=H16#H16\">",
"       \"Lung abscess\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28089?source=see_link&amp;anchor=H15#H15\">",
"       \"Parapneumonic effusion and empyema in adults\", section on 'Empyema'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7498?source=see_link\">",
"       \"Treatment of intravascular catheter-related infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/47/10999?source=see_link&amp;anchor=H12414288#H12414288\">",
"       \"Acute complicated cystitis and pyelonephritis\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/51/14134?source=see_link&amp;anchor=H7#H7\">",
"       \"Renal and perinephric abscess\", section on 'Management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/53/29526?source=see_link&amp;anchor=H10#H10\">",
"       \"Pyogenic liver abscess\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/18/24873?source=see_link&amp;anchor=H16#H16\">",
"       \"Bacterial endophthalmitis\", section on 'Endogenous bacterial endophthalmitis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6012683\">",
"    <span class=\"h2\">",
"     Resistant organisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing resistance to a broad array of antibiotics is an alarming trend with clinical strains of K. pneumoniae. The possibility of production of ESBL or carbapenemases should be taken into account when choosing an antibiotic regimen for K. pneumoniae infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2267521\">",
"    <span class=\"h3\">",
"     Extended-spectrum beta-lactamases",
"    </span>",
"    &nbsp;&mdash;&nbsp;ESBL confer resistance to most beta-lactam antibiotics, including penicillins, cephalosporins, and the monobactam",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/53/30553?source=see_link\">",
"     \"Extended-spectrum beta-lactamases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/2/26663?source=see_link\">",
"     \"Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dissemination or outbreaks of ESBL-producing K. pneumoniae strains have been reported worldwide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/13,131-135\">",
"     13,131-135",
"    </a>",
"    ]. In a prospective study of 455 consecutive episodes of nosocomial K. pneumoniae bacteremia from 12 hospitals around the world in 1996 and 1997, ESBL-producing organisms accounted for 31 percent of all episodes and 44 percent of episodes acquired in an intensive care unit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/131\">",
"     131",
"    </a>",
"    ]. Most hospitals with more than one ESBL-producing isolate had multiple strains with the same genotypic pattern, indicating patient-to-patient spread. ESBL production is associated with higher mortality in K. pneumoniae infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior broad-spectrum antibiotic therapy is the major risk factor for the development of multidrug (not limited to ESBL) resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/13,131,135,136\">",
"     13,131,135,136",
"    </a>",
"    ]. In the above prospective study of nosocomial K. pneumoniae bacteremia, for example, prior administration of beta-lactam antibiotics with an oxyimino group (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    ) was the major independent risk factor for ESBL infection (risk ratio 3.9) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/131\">",
"     131",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of such K. pneumoniae isolates is not different from that of other ESBL-producing species. An important clinical observation is that use of an oxyimino-beta-lactam (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    ) to treat severe infections caused by ESBL-producing K. pneumoniae is associated with a high rate of treatment failure even if the organism tests susceptible to the antibiotic in vitro (eg, MIC &le;8",
"    <span class=\"nowrap\">",
"     mcg/mL).",
"    </span>",
"    However, in the Unites States and Europe, laboratory guidelines have lowered MIC breakpoints for susceptibility of gram-negative rods (eg, MIC &lt;1",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    for cefotaxime) so that such organisms would no longer be reported as susceptible in vitro.",
"   </p>",
"   <p>",
"    Treatment recommendations and other issues related to ESBL-producing organisms are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/53/30553?source=see_link&amp;anchor=H14#H14\">",
"     \"Extended-spectrum beta-lactamases\", section on 'Treatment options'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2267914\">",
"    <span class=\"h3\">",
"     Carbapenemases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carbapenem-hydrolyzing beta-lactamases have also emerged in K. pneumoniae worldwide. K. pneumoniae is the most common species to harbor the K. pneumoniae carbapenemase (KPC) and New Delhi metallo-beta-lactamase (NDM-1), both of which cleave all beta-lactams and substantially reduce clinical efficacy of carbapenems and beta-lactamase inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/33/9754?source=see_link\">",
"     \"Carbapenemases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/47/44789?source=see_link\">",
"     \"Combination beta-lactamase inhibitors, carbapenems, and monobactams\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of broad spectrum cephalosporins",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    carbapenems is an important risk factor for the development of colonization or infection with such pathogens, although prior receipt of carbapenems is not essential for acquisition of these strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/137-139\">",
"     137-139",
"    </a>",
"    ]. Infections with carbapenemase-producing K. pneumoniae are associated with mortality rates as high as 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/140\">",
"     140",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to decreased susceptibility to beta-lactams and carbapenems, resistance genes for other antibiotics, including aminoglycosides and fluoroquinolones, are frequently present in carbapenemase-producing strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/141,142\">",
"     141,142",
"    </a>",
"    ]. For KPC-carrying K. pneumoniae, resistance rates of 98 percent have been reported for the fluoroquinolones, and approximately 50 percent are resistant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/143\">",
"     143",
"    </a>",
"    ]. Thus, treatment options for carbapenemase-producing K. pneumoniae are limited and antibiotic selection should be tailored to susceptibility testing results for agents beyond the beta-lactam and carbapenem classes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/33/9754?source=see_link&amp;anchor=H8#H8\">",
"     \"Carbapenemases\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6012742\">",
"    <span class=\"h2\">",
"     Severe infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virulent strains are prone to cause a destructive tissue abscess syndrome (eg, primary liver abscess) with possible metastatic infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/33/38426/abstract/1,46,47,83\">",
"     1,46,47,83",
"    </a>",
"    ]. These strains are almost always susceptible in vitro to all generations of cephalosporins. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29176?source=see_link&amp;anchor=H5#H5\">",
"     \"Invasive liver abscess syndrome caused by Klebsiella pneumoniae\", section on 'Virulence factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29176?source=see_link&amp;anchor=H13#H13\">",
"     \"Invasive liver abscess syndrome caused by Klebsiella pneumoniae\", section on 'Antibiotic choice'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16016802\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Klebsiella pneumoniae, a gram-negative bacillus, most frequently causes infection in hospitalized patients and in those with impaired host defenses, including patients with diabetes mellitus, alcoholism, malignancy, hepatobiliary disease, chronic obstructive pulmonary disease, renal failure, and glucocorticoid therapy. The frequency, distribution, and expression of virulence factors may differ between community-acquired and nosocomial strains. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      K. pneumoniae is a common cause of nosocomial pulmonary infections in both ventilated and unventilated patients. It is an uncommon cause of community-acquired pneumonia, but in such cases, infection is typically severe and often requires hospitalization. K. pneumoniae is also a relatively common isolate in patients with empyema. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Pulmonary infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      K. pneumoniae is a relatively common cause of nosocomial bacteremia. However, infective endocarditis due to K. pneumoniae is rare and may be related to decreased adherence of these organisms to heart valves. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Bacteremia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Infective endocarditis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other clinical K. pneumoniae infections include pyogenic liver abscess (either primary or in the setting of hepatobiliary disease), lower and upper genito-urinary tract infections, and both superficial and deep-skin and soft-tissue infections. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis of K. pneumoniae is generally made by isolation of the organism from culture of the relevant specimen. On Gram stain, Klebsiella species typically appear as short, plump, gram-negative bacilli, which are usually surrounded by a capsule that appears as a clear space (",
"      <a class=\"graphic graphic_picture graphicRef71969 \" href=\"mobipreview.htm?26/45/27345\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6012612\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The antibiotic regimen for infections with K. pneumoniae is usually determined by the results of susceptibility testing. Outbreaks of strains that produce an extended-spectrum beta-lactamase or a carbapenemase have been reported worldwide. (See",
"      <a class=\"local\" href=\"#H6012644\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6012683\">",
"       'Resistant organisms'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/1\">",
"      Fang CT, Lai SY, Yi WC, et al. Klebsiella pneumoniae genotype K1: an emerging pathogen that causes septic ocular or central nervous system complications from pyogenic liver abscess. Clin Infect Dis 2007; 45:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/2\">",
"      Podschun R, Ullmann U. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev 1998; 11:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/3\">",
"      Fuxench-L&oacute;pez Z, Ram&iacute;rez-Ronda CH. Pharyngeal flora in ambulatory alcoholic patients: prevalence of gram-negative bacilli. Arch Intern Med 1978; 138:1815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/4\">",
"      Pollack M, Charache P, Nieman RE, et al. Factors influencing colonisation and antibiotic-resistance patterns of gram-negative bacteria in hospital patients. Lancet 1972; 2:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/5\">",
"      Asensio A, Oliver A, Gonz&aacute;lez-Diego P, et al. Outbreak of a multiresistant Klebsiella pneumoniae strain in an intensive care unit: antibiotic use as risk factor for colonization and infection. Clin Infect Dis 2000; 30:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/6\">",
"      Selden R, Lee S, Wang WL, et al. Nosocomial klebsiella infections: intestinal colonization as a reservoir. Ann Intern Med 1971; 74:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/7\">",
"      Akoachere JF, Bughe RN, Oben BO, et al. Phenotypic characterization of human pathogenic bacteria in fish from the coastal waters of South West Cameroon: public health implications. Rev Environ Health 2009; 24:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/8\">",
"      Jang S, Wheeler L, Carey RB, et al. Pleuritis and suppurative pneumonia associated with a hypermucoviscosity phenotype of Klebsiella pneumoniae in California sea lions (Zalophus californianus). Vet Microbiol 2010; 141:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/9\">",
"      Castinel A, Grinberg A, Pattison R, et al. Characterization of Klebsiella pneumoniae isolates from New Zealand sea lion (Phocarctos hookeri) pups during and after the epidemics on Enderby Island, Auckland Islands. Vet Microbiol 2007; 122:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/10\">",
"      Anderson DJ, Richet H, Chen LF, et al. Seasonal variation in Klebsiella pneumoniae bloodstream infection on 4 continents. J Infect Dis 2008; 197:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/11\">",
"      Ko WC, Paterson DL, Sagnimeni AJ, et al. Community-acquired Klebsiella pneumoniae bacteremia: global differences in clinical patterns. Emerg Infect Dis 2002; 8:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/12\">",
"      Tsay RW, Siu LK, Fung CP, Chang FY. Characteristics of bacteremia between community-acquired and nosocomial Klebsiella pneumoniae infection: risk factor for mortality and the impact of capsular serotypes as a herald for community-acquired infection. Arch Intern Med 2002; 162:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/13\">",
"      Kang CI, Kim SH, Bang JW, et al. Community-acquired versus nosocomial Klebsiella pneumoniae bacteremia: clinical features, treatment outcomes, and clinical implication of antimicrobial resistance. J Korean Med Sci 2006; 21:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/14\">",
"      Lee KH, Hui KP, Tan WC, Lim TK. Klebsiella bacteraemia: a report of 101 cases from National University Hospital, Singapore. J Hosp Infect 1994; 27:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/15\">",
"      Feldman C, Smith C, Levy H, et al. Klebsiella pneumoniae bacteraemia at an urban general hospital. J Infect 1990; 20:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/16\">",
"      Lu CH, Chang WN, Wu HS. Klebsiella pneumoniae meningitis: analysis on clinical features of thirty-two adult patients. Zhonghua Yi Xue Za Zhi (Taipei) 1997; 60:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/17\">",
"      Watanakunakorn C, Jura J. Klebsiella bacteremia: a review of 196 episodes during a decade (1980-1989). Scand J Infect Dis 1991; 23:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/18\">",
"      Hansen DS, Gottschau A, Kolmos HJ. Epidemiology of Klebsiella bacteraemia: a case control study using Escherichia coli bacteraemia as control. J Hosp Infect 1998; 38:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/19\">",
"      Haddy RI, Lee M 3rd, Sangal SP, et al. Klebsiella pneumoniae bacteremia in the community hospital. J Fam Pract 1989; 28:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/20\">",
"      Lin SH, Kuo PH, Hsueh PR, et al. Sputum bacteriology in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease in Taiwan with an emphasis on Klebsiella pneumoniae and Pseudomonas aeruginosa. Respirology 2007; 12:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/21\">",
"      Yi ZM, Yang H, Xiang XD. [Characteristics of bacteriology and drug sensitivity in patients with COPD combined with pneumonia]. Hunan Yi Ke Da Xue Xue Bao 2003; 28:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/22\">",
"      Habib AG, Tambyah PA. Community-acquired Klebsiella pneumoniae central nervous system infections in adults in Singapore. Eur J Clin Microbiol Infect Dis 2003; 22:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/23\">",
"      Yang PY, Huang CC, Leu HS, et al. Klebsiella pneumoniae bacteremia: community-acquired vs. nosocomial infections. Chang Gung Med J 2001; 24:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/24\">",
"      Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med 1991; 91:72S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/25\">",
"      Yu VL, Hansen DS, Ko WC, et al. Virulence characteristics of Klebsiella and clinical manifestations of K. pneumoniae bloodstream infections. Emerg Infect Dis 2007; 13:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/26\">",
"      Yu WL, Ko WC, Cheng KC, et al. Association between rmpA and magA genes and clinical syndromes caused by Klebsiella pneumoniae in Taiwan. Clin Infect Dis 2006; 42:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/27\">",
"      Yinnon AM, Butnaru A, Raveh D, et al. Klebsiella bacteraemia: community versus nosocomial infection. QJM 1996; 89:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/28\">",
"      Kollef MH, Shorr A, Tabak YP, et al. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005; 128:3854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/29\">",
"      Weber DJ, Rutala WA, Sickbert-Bennett EE, et al. Microbiology of ventilator-associated pneumonia compared with that of hospital-acquired pneumonia. Infect Control Hosp Epidemiol 2007; 28:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/30\">",
"      Kollef MH, Morrow LE, Niederman MS, et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest 2006; 129:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/31\">",
"      Okada F, Ando Y, Honda K, et al. Clinical and pulmonary thin-section CT findings in acute Klebsiella pneumoniae pneumonia. Eur Radiol 2009; 19:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/32\">",
"      Okada F, Ando Y, Honda K, et al. Acute Klebsiella pneumoniae pneumonia alone and with concurrent infection: comparison of clinical and thin-section CT findings. Br J Radiol 2010; 83:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/33\">",
"      Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/34\">",
"      van der Eerden MM, Vlaspolder F, de Graaff CS, et al. Value of intensive diagnostic microbiological investigation in low- and high-risk patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2005; 24:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/35\">",
"      Hu HC, Huang CC, Tsai YH, et al. Outcome analysis of patients requiring mechanical ventilation with severe community-acquired pneumonia and identified bacterial pathogens. Chang Gung Med J 2005; 28:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/36\">",
"      Marik PE. The clinical features of severe community-acquired pneumonia presenting as septic shock. Norasept II Study Investigators. J Crit Care 2000; 15:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/37\">",
"      Paganin F, Lilienthal F, Bourdin A, et al. Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor. Eur Respir J 2004; 24:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/38\">",
"      Fiberesima FP, Onwuchekwa AC. Community acquired pneumonia in Port Harcourt Rivers State of Nigeria. Cent Afr J Med 2008; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/39\">",
"      Lin YT, Jeng YY, Chen TL, Fung CP. Bacteremic community-acquired pneumonia due to Klebsiella pneumoniae: clinical and microbiological characteristics in Taiwan, 2001-2008. BMC Infect Dis 2010; 10:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/40\">",
"      Li XJ, Li Q, Si LY, Yuan QY. Bacteriological differences between COPD exacerbation and community-acquired pneumonia. Respir Care 2011; 56:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/41\">",
"      Rosell A, Mons&oacute; E, Soler N, et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med 2005; 165:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/42\">",
"      Nseir S, Cavestri B, Di Pompeo C, et al. Factors predicting bacterial involvement in severe acute exacerbations of chronic obstructive pulmonary disease. Respiration 2008; 76:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/43\">",
"      Wang JL, Chen KY, Fang CT, et al. Changing bacteriology of adult community-acquired lung abscess in Taiwan: Klebsiella pneumoniae versus anaerobes. Clin Infect Dis 2005; 40:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/44\">",
"      Bartlett JG. The role of anaerobic bacteria in lung abscess. Clin Infect Dis 2005; 40:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/45\">",
"      Yu VL, Chang FY. The role of Klebsiella pneumoniae in lung abscesses: a geographic phenomenon (for now!). Clin Infect Dis 2006; 42:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/46\">",
"      Wang JH, Liu YC, Lee SS, et al. Primary liver abscess due to Klebsiella pneumoniae in Taiwan. Clin Infect Dis 1998; 26:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/47\">",
"      Cheng DL, Liu YC, Yen MY, et al. Septic metastatic lesions of pyogenic liver abscess. Their association with Klebsiella pneumoniae bacteremia in diabetic patients. Arch Intern Med 1991; 151:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/48\">",
"      Nadasy KA, Domiati-Saad R, Tribble MA. Invasive Klebsiella pneumoniae syndrome in North America. Clin Infect Dis 2007; 45:e25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/49\">",
"      Wang TK, Wong SS, Woo PC. Two cases of pyomyositis caused by Klebsiella pneumoniae and review of the literature. Eur J Clin Microbiol Infect Dis 2001; 20:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/50\">",
"      Brook I, Frazier EH. Aerobic and anaerobic microbiology of empyema. A retrospective review in two military hospitals. Chest 1993; 103:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/51\">",
"      Chen KY, Hsueh PR, Liaw YS, et al. A 10-year experience with bacteriology of acute thoracic empyema: emphasis on Klebsiella pneumoniae in patients with diabetes mellitus. Chest 2000; 117:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/52\">",
"      Lin YT, Chen TL, Siu LK, et al. Clinical and microbiological characteristics of community-acquired thoracic empyema or complicated parapneumonic effusion caused by Klebsiella pneumoniae in Taiwan. Eur J Clin Microbiol Infect Dis 2010; 29:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/53\">",
"      Gaynes R, Edwards JR, National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 2005; 41:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/54\">",
"      National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/55\">",
"      Luzzaro F, Vigan&ograve; EF, Fossati D, et al. Prevalence and drug susceptibility of pathogens causing bloodstream infections in northern Italy: a two-year study in 16 hospitals. Eur J Clin Microbiol Infect Dis 2002; 21:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/56\">",
"      Friedman ND, Kaye KS, Stout JE, et al. Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002; 137:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/57\">",
"      Meatherall BL, Gregson D, Ross T, et al. Incidence, risk factors, and outcomes of Klebsiella pneumoniae bacteremia. Am J Med 2009; 122:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/58\">",
"      Tumbarello M, Spanu T, Sanguinetti M, et al. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 2006; 50:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/59\">",
"      Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/60\">",
"      Fowler VG Jr, Miro JM, Hoen B, et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 2005; 293:3012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/61\">",
"      Anderson MJ, Janoff EN. Klebsiella endocarditis: report of two cases and review. Clin Infect Dis 1998; 26:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/62\">",
"      Hsu CN, Wang JY, Tseng CD, et al. Clinical features and predictors for mortality in patients with infective endocarditis at a university hospital in Taiwan from 1995 to 2003. Epidemiol Infect 2006; 134:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/63\">",
"      Gould K, Ramirez-Ronda CH, Holmes RK, Sanford JP. Adherence of bacteria to heart valves in vitro. J Clin Invest 1975; 56:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/64\">",
"      Czaja CA, Scholes D, Hooton TM, Stamm WE. Population-based epidemiologic analysis of acute pyelonephritis. Clin Infect Dis 2007; 45:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/65\">",
"      Echols RM, Tosiello RL, Haverstock DC, Tice AD. Demographic, clinical, and treatment parameters influencing the outcome of acute cystitis. Clin Infect Dis 1999; 29:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/66\">",
"      Lorente Gar&iacute;n JA, Placer Santos J, Salvad&oacute; Costa M, et al. [Antibiotic resistance transformation in community-acquired urinary infections]. Rev Clin Esp 2005; 205:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/67\">",
"      Grupper M, Kravtsov A, Potasman I. Emphysematous cystitis: illustrative case report and review of the literature. Medicine (Baltimore) 2007; 86:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/68\">",
"      Huang JJ, Tseng CC. Emphysematous pyelonephritis: clinicoradiological classification, management, prognosis, and pathogenesis. Arch Intern Med 2000; 160:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/69\">",
"      Chang SW, Yen DH, Fung CP, et al. Klebsiella pneumoniae renal abscess. Zhonghua Yi Xue Za Zhi (Taipei) 2000; 63:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/70\">",
"      Takebayashi K, Matsumoto S, Nakagawa Y, et al. Endogenous endophthalmitis and disseminated intravascular coagulation complicating a Klebsiella pneumoniae perirenal abscess in a patient with type 2 diabetes. Am J Med Sci 2005; 329:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/71\">",
"      Stotka JL, Rupp ME. Klebsiella pneumoniae urinary tract infection complicated by endophthalmitis, perinephric abscess, and ecthyma gangrenosum. South Med J 1991; 84:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/72\">",
"      Skerk V, Krhen I, Schonwald S, et al. The role of unusual pathogens in prostatitis syndrome. Int J Antimicrob Agents 2004; 24 Suppl 1:S53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/73\">",
"      Krieger JN, McGonagle LA. Diagnostic considerations and interpretation of microbiological findings for evaluation of chronic prostatitis. J Clin Microbiol 1989; 27:2240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/74\">",
"      Liu KH, Lee HC, Chuang YC, et al. Prostatic abscess in southern Taiwan: another invasive infection caused predominantly by Klebsiella pneumoniae. J Microbiol Immunol Infect 2003; 36:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/75\">",
"      Kuo PH, Huang KH, Lee CW, et al. Emphysematous prostatitis caused by Klebsiella pneumoniae. J Formos Med Assoc 2007; 106:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/76\">",
"      Tai HC. Emphysematous prostatic abscess: a case report and review of literature. J Infect 2007; 54:e51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/77\">",
"      Bae GB, Kim SW, Shin BC, et al. Emphysematous prostatic abscess due to Klebsiella pneumoniae: report of a case and review of the literature. J Korean Med Sci 2003; 18:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/78\">",
"      Ebisuno S, Miyai M. A case of Klebsiella pneumoniae endophthalmitis metastasized from prostatitis. Hinyokika Kiyo 1994; 40:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/79\">",
"      Chuang LH, Song HS, Lee SC, et al. Endogenous Klebsiella pneumoniae endophthalmitis associated with prostate abscess: case report. Chang Gung Med J 2000; 23:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/80\">",
"      Chew LC. Septic monoarthritis and osteomyelitis in an elderly man following Klebsiella pneumoniae genitourinary infection: case report. Ann Acad Med Singapore 2006; 35:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/81\">",
"      Rahimian J, Wilson T, Oram V, Holzman RS. Pyogenic liver abscess: recent trends in etiology and mortality. Clin Infect Dis 2004; 39:1654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/82\">",
"      Lederman ER, Crum NF. Pyogenic liver abscess with a focus on Klebsiella pneumoniae as a primary pathogen: an emerging disease with unique clinical characteristics. Am J Gastroenterol 2005; 100:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/83\">",
"      Fung CP, Chang FY, Lee SC, et al. A global emerging disease of Klebsiella pneumoniae liver abscess: is serotype K1 an important factor for complicated endophthalmitis? Gut 2002; 50:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/84\">",
"      Frazee BW, Hansen S, Lambert L. Invasive infection with hypermucoviscous Klebsiella pneumoniae: multiple cases presenting to a single emergency department in the United States. Ann Emerg Med 2009; 53:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/85\">",
"      Brook I, Frazier EH. Microbiology of liver and spleen abscesses. J Med Microbiol 1998; 47:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/86\">",
"      Lee CH, Leu HS, Hu TH, Liu JW. Splenic abscess in southern Taiwan. J Microbiol Immunol Infect 2004; 37:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/87\">",
"      Lee CH, Hu TH, Liu JW. Splenic abscess caused by Klebsiella pneumoniae and non-Klebsiella pneumoniae in Taiwan: emphasizing risk factors for acquisition of Klebsiella pneumoniae splenic abscess. Scand J Infect Dis 2005; 37:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/88\">",
"      Chang KC, Chuah SK, Changchien CS, et al. Clinical characteristics and prognostic factors of splenic abscess: a review of 67 cases in a single medical center of Taiwan. World J Gastroenterol 2006; 12:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/89\">",
"      Such J, Runyon BA. Spontaneous bacterial peritonitis. Clin Infect Dis 1998; 27:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/90\">",
"      Park YH, Lee HC, Song HG, et al. Recent increase in antibiotic-resistant microorganisms in patients with spontaneous bacterial peritonitis adversely affects the clinical outcome in Korea. J Gastroenterol Hepatol 2003; 18:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/91\">",
"      Song JY, Jung SJ, Park CW, et al. Prognostic significance of infection acquisition sites in spontaneous bacterial peritonitis: nosocomial versus community acquired. J Korean Med Sci 2006; 21:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/92\">",
"      Chen YJ, Kuo HK, Wu PC, et al. A 10-year comparison of endogenous endophthalmitis outcomes: an east Asian experience with Klebsiella pneumoniae infection. Retina 2004; 24:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/93\">",
"      Tan YM, Chee SP, Soo KC, Chow P. Ocular manifestations and complications of pyogenic liver abscess. World J Surg 2004; 28:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/94\">",
"      Wong JS, Chan TK, Lee HM, Chee SP. Endogenous bacterial endophthalmitis: an east Asian experience and a reappraisal of a severe ocular affliction. Ophthalmology 2000; 107:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/95\">",
"      Lin HH, Chien CC, Fang JT, et al. Unusual clinical presentation of Klebsiella pneumoniae induced endogenous endophthalmitis and xanthogranulomatous pyelonephritis in a non-nephrolithiasis and non-obstructive urinary tract. Ren Fail 2002; 24:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/96\">",
"      Ang LP, Lee HM, Au Eong KG, et al. Endogenous Klebsiella endophthalmitis. Eye (Lond) 2000; 14:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/97\">",
"      Ang M, Jap A, Chee SP. Prognostic factors and outcomes in endogenous Klebsiella pneumoniae endophthalmitis. Am J Ophthalmol 2011; 151:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/98\">",
"      Yoon YH, Lee SU, Sohn JH, Lee SE. Result of early vitrectomy for endogenous Klebsiella pneumoniae endophthalmitis. Retina 2003; 23:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/99\">",
"      Durand ML, Calderwood SB, Weber DJ, et al. Acute bacterial meningitis in adults. A review of 493 episodes. N Engl J Med 1993; 328:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/100\">",
"      Korinek AM, Baugnon T, Golmard JL, et al. Risk factors for adult nosocomial meningitis after craniotomy: role of antibiotic prophylaxis. Neurosurgery 2006; 59:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/101\">",
"      Tang LM, Chen ST. Klebsiella pneumoniae meningitis: prognostic factors. Scand J Infect Dis 1994; 26:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/102\">",
"      van de Beek D, de Gans J, Spanjaard L, et al. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 2004; 351:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/103\">",
"      Chang WN, Lu CH, Chang CS, Huang CR. Community-acquired spontaneous bacterial meningitis in patients with alcoholic liver disease. J Formos Med Assoc 2003; 102:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/104\">",
"      Bouadma L, Schortgen F, Thomas R, et al. Adults with spontaneous aerobic Gram-negative bacillary meningitis admitted to the intensive care unit. Clin Microbiol Infect 2006; 12:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/105\">",
"      Ni YH, Yeh KM, Peng MY, et al. Community-acquired brain abscess in Taiwan: etiology and probable source of infection. J Microbiol Immunol Infect 2004; 37:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/106\">",
"      Fang CT, Chen YC, Chang SC, et al. Klebsiella pneumoniae meningitis: timing of antimicrobial therapy and prognosis. QJM 2000; 93:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/107\">",
"      Chang CM, Lu FH, Guo HR, Ko WC. Klebsiella pneumoniae fascial space infections of the head and neck in Taiwan: emphasis on diabetic patients and repetitive infections. J Infect 2005; 50:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/108\">",
"      Huang TT, Tseng FY, Yeh TH, et al. Factors affecting the bacteriology of deep neck infection: a retrospective study of 128 patients. Acta Otolaryngol 2006; 126:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/109\">",
"      Jang TN, Juang GD, Fung CP. Fulminating gas-forming psoas muscle abscess due to Klebsiella pneumoniae following a deep neck infection. J Formos Med Assoc 1997; 96:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/110\">",
"      Liu YM, Chi CY, Ho MW, et al. Microbiology and factors affecting mortality in necrotizing fasciitis. J Microbiol Immunol Infect 2005; 38:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/111\">",
"      Ou LF, Yeh FL, Fang RH, Yu KW. Bacteriology of necrotizing fasciitis: a review of 58 cases. Zhonghua Yi Xue Za Zhi (Taipei) 1993; 51:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/112\">",
"      Corredoira JM, Ariza J, Pallar&eacute;s R, et al. Gram-negative bacillary cellulitis in patients with hepatic cirrhosis. Eur J Clin Microbiol Infect Dis 1994; 13:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/113\">",
"      Cheng NC, Yu YC, Tai HC, et al. Recent trend of necrotizing fasciitis in Taiwan: focus on monomicrobial Klebsiella pneumoniae necrotizing fasciitis. Clin Infect Dis 2012; 55:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/114\">",
"      DiGioia RA, Kane JG, Parker RH. Crepitant cellulitis and myonecrosis caused by Klebsiella. JAMA 1977; 237:2097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/115\">",
"      Bruno-Murtha LA, Sedghivaziri MA, Arbeit RD. Crepitant myonecrosis caused by Klebsiella pneumoniae in an immunocompromised diabetic patient. J Infect Dis 1990; 162:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/116\">",
"      Lau YJ, Hu BS, Wu WL, et al. Identification of a major cluster of Klebsiella pneumoniae isolates from patients with liver abscess in Taiwan. J Clin Microbiol 2000; 38:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/117\">",
"      Chang CM, Ko WC, Lee HC, et al. Klebsiella pneumoniae psoas abscess: predominance in diabetic patients and grave prognosis in gas-forming cases. J Microbiol Immunol Infect 2001; 34:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/118\">",
"      Chen CW, Ko WC, Sung JM, Huang JJ. Ruptured mycotic aneurysm of the iliac artery complicated by emphysematous psoas muscle abscess: report of two cases. J Formos Med Assoc 2002; 101:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/119\">",
"      Sugawa M, Tanaka R, Nakamura M, et al. A case of infectious pseudoaneurysm of the abdominal aorta associated with infectious spondylitis due to Klebsiella pneumoniae. Jpn J Med 1989; 28:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/120\">",
"      MacKinnon S, Kane JG, Parker RH. False-positive cryptococcal antigen test and cervical prevertebral abscess. JAMA 1978; 240:1982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/121\">",
"      Kouroussis C, Georgoulias V, Souglakos J, et al. Spontaneous spondylodiscitis caused by Klebsiella pneumoniae. Infection 1999; 27:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/122\">",
"      Kangwanprasert M, Young RS. Case report: spinal epidural abscess from Klebsiella pneumoniae. Hawaii Med J 2005; 64:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/123\">",
"      Kuramochi G, Takei SI, Sato M, et al. Klebsiella pneumoniae liver abscess associated with septic spinal epidural abscess. Hepatol Res 2005; 31:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/124\">",
"      Broom MJ, Beebe RD. Emphysematous septic arthritis due to Klebsiella pneumoniae. Clin Orthop Relat Res 1988; :219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/125\">",
"      Ritter MS, Mroch H, Burns MJ. Soaring suppurative sea shells from the sea shore: Pseudomonas aeruginosa and Klebsiella pneumoniae septic arthritis after a marine sea shell injury. Pediatr Emerg Care 1993; 9:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/126\">",
"      Park CH, Joo YE, Choi SK, et al. Klebsiella pneumoniae septic arthritis in a cirrhotic patient with hepatocellular carcinoma. J Korean Med Sci 2004; 19:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/127\">",
"      Apple JS, Halvorsen RA, Chapman TM, Martinez S. Klebsiella pneumoniae arthritis of the hip in a diabetic patient. South Med J 1984; 77:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/128\">",
"      Yu WL, Cheng CC, Chuang YC. First report of acute purulent pericarditis by capsule genotype K1 Klebsiella pneumoniae in an alcoholic patient. Diagn Microbiol Infect Dis 2009; 63:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/129\">",
"      Hara N, Kato M, Fuse K, et al. A rare case of pyogenic liver abscess complicated with cardiac tamponade. Intern Med 2008; 47:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/130\">",
"      Yahalom G, Guranda L, Meltzer E. Internal obturator muscle abscess caused by Klebsiella pneumoniae. J Infect 2007; 54:e157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/131\">",
"      Paterson DL, Ko WC, Von Gottberg A, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med 2004; 140:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/132\">",
"      Cartelle M, del Mar Tomas M, Pertega S, et al. Risk factors for colonization and infection in a hospital outbreak caused by a strain of Klebsiella pneumoniae with reduced susceptibility to expanded-spectrum cephalosporins. J Clin Microbiol 2004; 42:4242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/133\">",
"      DiPersio JR, Deshpande LM, Biedenbach DJ, et al. Evolution and dissemination of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae: epidemiology and molecular report from the SENTRY Antimicrobial Surveillance Program (1997-2003). Diagn Microbiol Infect Dis 2005; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/134\">",
"      Wiener J, Quinn JP, Bradford PA, et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999; 281:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/135\">",
"      Dinubile MJ, Friedland I, Chan CY, et al. Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy. Eur J Clin Microbiol Infect Dis 2005; 24:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/136\">",
"      Garc&iacute;a San Miguel L, Cobo J, Valverde A, et al. Clinical variables associated with the isolation of Klebsiella pneumoniae expressing different extended-spectrum beta-lactamases. Clin Microbiol Infect 2007; 13:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/137\">",
"      Herbert S, Halvorsen DS, Leong T, et al. Large outbreak of infection and colonization with gram-negative pathogens carrying the metallo- beta -lactamase gene blaIMP-4 at a 320-bed tertiary hospital in Australia. Infect Control Hosp Epidemiol 2007; 28:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/138\">",
"      Nou&eacute;r SA, Nucci M, de-Oliveira MP, et al. Risk factors for acquisition of multidrug-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase. Antimicrob Agents Chemother 2005; 49:3663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/139\">",
"      Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, et al. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008; 52:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/140\">",
"      Zarkotou O, Pournaras S, Tselioti P, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 2011; 17:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/141\">",
"      Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-beta-lactamases: the quiet before the storm? Clin Microbiol Rev 2005; 18:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/142\">",
"      Hirakata Y, Izumikawa K, Yamaguchi T, et al. Rapid detection and evaluation of clinical characteristics of emerging multiple-drug-resistant gram-negative rods carrying the metallo-beta-lactamase gene blaIMP. Antimicrob Agents Chemother 1998; 42:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/33/38426/abstract/143\">",
"      Bratu S, Tolaney P, Karumudi U, et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother 2005; 56:128.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3122 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-6C4A3AC97D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_33_38426=[""].join("\n");
var outline_f37_33_38426=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16016802\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Host risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Site of acquisition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Geographic distribution",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pulmonary infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H690737\">",
"      - Nosocomial pneumonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Community-acquired pneumonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11768209\">",
"      - COPD with secondary infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Lung abscess",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Empyema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Bacteremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Catheter-related bacteremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2812582\">",
"      Genitourinary tract infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Cystitis and pyelonephritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Renal and perinephric abscess",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2812917\">",
"      - Prostatitis and prostatic abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2814435\">",
"      Intraabdominal infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6013591\">",
"      - Liver abscess",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2814768\">",
"      - Splenic abscess",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2814503\">",
"      - Spontaneous bacterial peritonitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6013720\">",
"      Endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6013768\">",
"      Meningitis/brain abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Deep neck abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Skin and soft tissue infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Other infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6012612\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6012644\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6012683\">",
"      Resistant organisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2267521\">",
"      - Extended-spectrum beta-lactamases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2267914\">",
"      - Carbapenemases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6012742\">",
"      Severe infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16016802\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3122\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3122|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?10/13/10454\" title=\"diagnostic image 1\">",
"      Chest x-rays of K pneumoniae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?37/2/37921\" title=\"diagnostic image 2\">",
"      K pneum liver abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?16/29/16854\" title=\"diagnostic image 3\">",
"      Brain images of K pneumoniae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3122|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/45/27345\" title=\"picture 1\">",
"      Gram stain sputum 6 with answer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3122|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/8/22667\" title=\"table 1\">",
"      Bacteriology of SBP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/62/29676\" title=\"table 2\">",
"      Glasgow coma scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/42/4776?source=related_link\">",
"      Acute bacterial prostatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/47/10999?source=related_link\">",
"      Acute complicated cystitis and pyelonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13561?source=related_link\">",
"      Acute uncomplicated cystitis and pyelonephritis in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/34/34346?source=related_link\">",
"      Approach to the adult patient with splenomegaly and other splenic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/18/24873?source=related_link\">",
"      Bacterial endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/2/26663?source=related_link\">",
"      Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/33/9754?source=related_link\">",
"      Carbapenemases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/0/7172?source=related_link\">",
"      Clinical manifestations of spontaneous bacterial peritonitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24040?source=related_link\">",
"      Clinical presentation and diagnosis of ventilator-associated pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/47/44789?source=related_link\">",
"      Combination beta-lactamase inhibitors, carbapenems, and monobactams",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36569?source=related_link\">",
"      Deep neck space infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/23/375?source=related_link\">",
"      Diagnosis of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26026?source=related_link\">",
"      Diagnostic approach to community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/30/34278?source=related_link\">",
"      Emphysematous urinary tract infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/13/16600?source=related_link\">",
"      Epidemiology and clinical features of gram-negative bacillary meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/38/31335?source=related_link\">",
"      Epidemiology of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37464?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of intravascular catheter infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/57/12183?source=related_link\">",
"      Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/31/14840?source=related_link\">",
"      Epidemiology, risk factors and microbiology of infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/40/17033?source=related_link\">",
"      Epidural abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/53/30553?source=related_link\">",
"      Extended-spectrum beta-lactamases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/12/20681?source=related_link\">",
"      Gram-negative bacillary bacteremia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29176?source=related_link\">",
"      Invasive liver abscess syndrome caused by Klebsiella pneumoniae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/9/24729?source=related_link\">",
"      Lung abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/43/7866?source=related_link\">",
"      Management of infection in acute exacerbations of chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/18/21801?source=related_link\">",
"      Microbiology and pathogenesis of Klebsiella pneumoniae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/362?source=related_link\">",
"      Necrotizing soft tissue infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/17/35098?source=related_link\">",
"      Overview of infected (mycotic) arterial aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28089?source=related_link\">",
"      Parapneumonic effusion and empyema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/19/22839?source=related_link\">",
"      Psoas abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35303?source=related_link\">",
"      Purulent pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/53/29526?source=related_link\">",
"      Pyogenic liver abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32950?source=related_link\">",
"      Pyomyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/51/14134?source=related_link\">",
"      Renal and perinephric abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/50/11049?source=related_link\">",
"      Septic arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/9/28825?source=related_link\">",
"      Stupor and coma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40986?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults who require hospitalization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/63/36858?source=related_link\">",
"      Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7498?source=related_link\">",
"      Treatment of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/28/22985?source=related_link\">",
"      Vertebral osteomyelitis and discitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_33_38427="Normal salivary cortisol";
var content_f37_33_38427=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F57112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F57112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Salivary cortisol concentrations in normal subjects, according to analytic method",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mean (SE), ng/mL",
"       </td>",
"       <td class=\"subtitle1\">",
"        Range, ng/mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Radioimmunoassay of",
"unextracted saliva",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Men (7 AM)",
"       </td>",
"       <td>",
"        5.0 &plusmn; 0.4",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Women (7 AM)",
"       </td>",
"       <td>",
"        5.8 &plusmn; 0.5",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Men and women (11 PM)",
"       </td>",
"       <td>",
"        0.4 &plusmn; 0.1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Radioimmunoassay of",
"unextracted saliva",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Men and women (9 AM)",
"       </td>",
"       <td>",
"        6.0 &plusmn; 0.4",
"       </td>",
"       <td>",
"        1.9-10.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Men and women (11 PM)",
"       </td>",
"       <td>",
"        1.0 &plusmn; 0.1",
"       </td>",
"       <td>",
"        0.6-2.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Obese men and women (9 AM)",
"       </td>",
"       <td>",
"        5.3 &plusmn; 1.0",
"       </td>",
"       <td>",
"        0.9-16.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Obese men and women (11 PM)",
"       </td>",
"       <td>",
"        1.3 &plusmn; 0.2",
"       </td>",
"       <td>",
"        0.6-3.9",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     To convert salivary cortisol values to nmol/L multiply by 2.76.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Raff, H, Raff, JL, Findling, JW, J Clin Endocrinol Metab 1998; 83:2681 and Castro, M, Elias, PC, Quidute, AR, et al, J Clin Endocrinol Metab 1999; 84:878.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_33_38427=[""].join("\n");
var outline_f37_33_38427=null;
var title_f37_33_38428="Candida spp susceptibility";
var content_f37_33_38428=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F61023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F61023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    General patterns of susceptibility of",
"    <em>",
"     Candida",
"    </em>",
"    species",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Species",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fluconazole",
"       </td>",
"       <td class=\"subtitle1\">",
"        Itraconazole",
"       </td>",
"       <td class=\"subtitle1\">",
"        Voriconazole",
"       </td>",
"       <td class=\"subtitle1\">",
"        Posaconazole",
"       </td>",
"       <td class=\"subtitle1\">",
"        Flucytosine",
"       </td>",
"       <td class=\"subtitle1\">",
"        Amphotericin B",
"       </td>",
"       <td class=\"subtitle1\">",
"        Echinocandins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Candida albicans",
"        </em>",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        S",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Candida tropicalis",
"        </em>",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        S",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Candida parapsilosis",
"        </em>",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        S to R*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Candida glabrata",
"        </em>",
"       </td>",
"       <td>",
"        S-DD to R",
"       </td>",
"       <td>",
"        S-DD to R",
"       </td>",
"       <td>",
"        S to R",
"       </td>",
"       <td>",
"        S to R",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        S to I",
"       </td>",
"       <td>",
"        S to R*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Candida krusei",
"        </em>",
"       </td>",
"       <td>",
"        R",
"       </td>",
"       <td>",
"        S-DD to R",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        I to R",
"       </td>",
"       <td>",
"        S to I",
"       </td>",
"       <td>",
"        S",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Candida lusitaniae",
"        </em>",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        S to R",
"       </td>",
"       <td>",
"        S",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     I: intermediately susceptible; NS: nonsusceptible; R: resistant; S: susceptible; S-DD: susceptible dose-dependent.",
"     <br>",
"      * Echinocandin resistance among",
"      <em>",
"       C. parapsilosis",
"      </em>",
"      and",
"      <em>",
"       C. glabrata",
"      </em>",
"      isolates is uncommon.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Pappas, PG, Kauffman, CA, Andes, D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infections Diseases Society of America. Clin Infect Dis 2009; 48:503. Copyright &copy; 2009 University of Chicago Press.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.journals.uchicago.edu/\">",
"      file://www.journals.uchicago.edu/",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_33_38428=[""].join("\n");
var outline_f37_33_38428=null;
var title_f37_33_38429="Diet stages LAGB";
var content_f37_33_38429=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F50516&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F50516&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diet stages of laparoscopic adjustable gastric band",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       LAGB diet stage*",
"      </td>",
"      <td class=\"subtitle1\">",
"       Begin",
"      </td>",
"      <td class=\"subtitle1\">",
"       Fluids/Food",
"      </td>",
"      <td class=\"subtitle1\">",
"       Guidelines",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Stage I",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &nbsp;",
"      </td>",
"      <td>",
"       Post-op day 1 and 2",
"      </td>",
"      <td>",
"       <p>",
"        <strong>",
"         LAGB clear liquids:",
"        </strong>",
"       </p>",
"       <p>",
"        Non-carbonated; no calories",
"       </p>",
"       <p>",
"        No sugar; no caffeine",
"       </p>",
"      </td>",
"      <td>",
"       Post-op LAGB day 1, patients may begin sips of water, ice chips and no sugar liquids, avoid carbonation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Stage II",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"6\">",
"       <p>",
"        <strong>",
"         Begin supplementation:",
"        </strong>",
"       </p>",
"       <p>",
"        <strong>",
"         Chewable",
"        </strong>",
"        multivitamin with minerals, x 2/day",
"       </p>",
"       <p>",
"        <strong>",
"         Chewable or liquid",
"        </strong>",
"        Calcium citrate with vitamin D",
"       </p>",
"      </td>",
"      <td rowspan=\"6\">",
"       Post-op day 2-3 (discharge diet)",
"      </td>",
"      <td rowspan=\"6\">",
"       <p>",
"        <strong>",
"         LAGB clear liquids:",
"        </strong>",
"       </p>",
"       <p>",
"        Variety of no sugar liquids or artificially sweetened liquids",
"       </p>",
"       <p>",
"        <strong>",
"         Plus LAGB full liquids:",
"        </strong>",
"       </p>",
"       <p>",
"        No more than 3 g fat per serving protein-rich liquids",
"       </p>",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Patients should consume a minimum of 48-64 ounces of total fluids per day; 24-32 ounces or more ounces LAGB clear liquids; plus 24-32 ounces of any combination of full liquids:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - 1 percent or skim milk mixed with:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Whey or soy protein powder if lactose intolerant",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Lactaid milk or soy milk mix with soy protein powder",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Light yogurt, blended",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Plain yogurt",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Stage III",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"4\">",
"       Week I",
"      </td>",
"      <td rowspan=\"4\">",
"       Post-op day 10-14*",
"      </td>",
"      <td rowspan=\"4\">",
"       <p>",
"        Increase LAGB clear liquids (total liquids 48-64 plus ounces per day) and replace full liquids with soft, moist, diced, ground or pureed protein sources as tolerated - as evidenced by the absence of excessive fullness or bloating, nausea or vomiting.",
"       </p>",
"       <p>",
"        <strong>",
"         Stage III week one:",
"        </strong>",
"        Eggs, ground meats, poultry, soft, moist fish, added gravy, bouillon, light mayo to moisten, cooked bean, hearty bean soups, cottage cheese, low fat cheese, yogurt",
"       </p>",
"      </td>",
"      <td class=\"sublist1_start\">",
"       <strong>",
"        NOTE:",
"       </strong>",
"       Patients should be reassured that hunger is common and normal after LAGB",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Protein food (moist, ground) choices are encouraged for 3-6 small meals per day, to help with satiety, since hunger is common within a week or so of LAGB",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Mindful, slow, eating is essential",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Encourage patients not to drink with meals and to wait &sim;30 minutes after each meal before resuming fluids",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Week 2",
"      </td>",
"      <td>",
"       4-weeks post-op",
"      </td>",
"      <td>",
"       <p>",
"        Advance diet as tolerated",
"       </p>",
"       <p>",
"        Tofu is a good choice as it is soft.",
"       </p>",
"       <p>",
"        Dense, chewy foods such as tough meats and doughy breads should be avoided as they may cause obstruction.",
"       </p>",
"       <p>",
"        Avoid high calorie soft foods such as ice cream.",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Adequate hydration is essential and a priority for all patients during the rapid weight loss phase",
"       </p>",
"       <p>",
"        Protein at every meal and snack, especially if increased hunger noted prior to initial fill or adjustment. Very well-cooked vegetables may also help to increase satiety.",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Week 3",
"      </td>",
"      <td>",
"       5 weeks post-op",
"      </td>",
"      <td>",
"       Continue to consume protein with some fruit or vegetable at each meal",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Stage IV",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Vitamin and mineral supplementation daily&bull;",
"      </td>",
"      <td>",
"       As hunger increases and more food is tolerated",
"      </td>",
"      <td>",
"       Healthy solid food diet",
"      </td>",
"      <td>",
"       Healthy, balanced diet consisting of adequate protein, fruits, vegetables and whole grains; calorie needs based on height, weight, age",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Post-LAGB fill/adjustment",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &sim;6 weeks post-op LAGB, and possibly every 6 weeks until satiety reached",
"      </td>",
"      <td>",
"       Full liquids x 2 days post-fill; advance to Stage III, week 1 guidelines above, as tolerated. = x 4-5 days, then advance as above.",
"      </td>",
"      <td>",
"       <p>",
"        Same as Stage II liquids above x 48 hours (and/or as otherwise advised by surgeon)",
"       </p>",
"       <p>",
"        <strong>",
"         NOTE:",
"        </strong>",
"        When diet advanced to soft solids, special attention to mindful eating and chewing until liquid key, since more restriction may increase risk for food getting stuck above stoma of band if not properly chewed (eg, if not chewed until liquid)",
"       </p>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     LAGB: Laparoscopic Adjustable Gastric Band.",
"     <br>",
"      * There is no standardization of diet stages, there are a wide variety of diet protocols varying from how long patients stay on each stage and what types of fluids/foods are recommended.",
"      <br>",
"       &bull; Nutritional labs should be drawn 2, 6, 12 months and yearly indefinitely; bone density test at baseline and every 2 years.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Table provided with permission: Sue Cummings, MS, RD, LDN; MGH Weight Center, Boston, MA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_33_38429=[""].join("\n");
var outline_f37_33_38429=null;
var title_f37_33_38430="Linear morphea - limb abnormalities";
var content_f37_33_38430=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F55660&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F55660&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Limb length discrepancy in linear morphea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 182px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lesions began on the right leg at age five in this patient. Note muscle atrophy, limb length discrepancy and pes planus foot deformity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_33_38430=[""].join("\n");
var outline_f37_33_38430=null;
var title_f37_33_38431="Superficial burn of the forearm";
var content_f37_33_38431=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Superficial burn of the forearm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 383px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Superficial, or epidermal, burns involve only the epidermal layer of skin. They do not blister but are painful, dry, red, and blanch with pressure. Note the absence of hair and areas of redness in the exposed portion of the forearm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Simon G Talbot, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_33_38431=[""].join("\n");
var outline_f37_33_38431=null;
